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Introduction
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“All our knowledge begins with the senses...
Pathophysiology of migraine
Migraine is a highly disabling neurovascular disorder1 and several theories have arisen regarding 
its pathophysiology2. Currently, migraine is considered a neurovascular disorder that involves 
activation of the trigeminovascular system3. This system comprises both peripheral and central 
projections, the former via the trigeminal ganglion that sends sensory fibers to the dura mater 
and the cranial vasculature4 and the latter via the trigeminocervical complex that consists of the 
trigeminal nucleus caudalis and the upper two cervical divisions5. The activation of this system is 
considered to result in the release of calcitonin gene-related peptide (CGRP) from the sensory fibers, 
causing vasodilation of the cranial vasculature and nociceptive transmission6. In accordance with 
this, studies have shown that during a migraine attack, there is an increase in CGRP levels in plasma 
in the jugular vein7,8, while treatment with triptans normalizes these levels9. Also, intravenous 
infusions of CGRP are known to provoke migraine-like attacks in migraine patients10.
Treatment of migraine
Before the discovery of the fundamental role of CGRP in the pathophysiology and treatment of 
migraine, the main target for selective acutely acting antimigraine drugs was the serotoninergic 
signaling, with the triptans being the gold standard since the beginning of the 1990’s11. The 
prophylactic treatment, however, consisted of medication not developed originally for migraine, 
but for other diseases, such as hypertension (HT), epilepsy and depression. 
 A decade later, and due to the important role of CGRP in migraine pathophysiology, CGRP 
receptor antagonists (gepants) were developed for the acute treatment of migraine and proved to 
be effective12,13. Unfortunately, pharmacokinetic limitations and hepatotoxicity cases did not allow 
the initial gepants to reach the market14. New gepants are currently in Phase II trials for the acute 
and prophylactic treatment of migraine, with no hepatotoxicity reported15,16, nevertheless, the 
concerns about the hepatotoxicity reports led to the development of CGRP (receptor) antibodies 
for the prophylactic treatment of migraine17-19, and so far, all clinical trials with these antibodies have 
shown promising results20,21. 
Migraine, CGRP  and cardiovascular risk  
CGRP is widely expressed throughout the body, participating not only in migraine pathophysiology, 
but also in several physiological processes and homeostatic responses during pathophysiological 
events. Therefore it is important to consider the possible side effects especially after long-term 
blockade of the CGRP pathway. 
 To begin with, sensory CGRPergic fibers have been described to innervate the coronary blood 
vessels as well as the myocardium22-24. Several studies have shown that CGRP plays an important role 
in the regulation of blood pressure and in the homeostatic responses during ischemic events, and 
it seems to act as a protective/compensatory mechanism during HT25-31. Moreover, CGRP is not only 
involved in peripheral mechanisms, but it also participates in the maintenance of cerebrovascular 
reactivity during chronic HT by increasing cerebral blood flow32-35. 
 CGRP also seems to be involved in the vascular adaptations during pregnancy, as plasma levels 
increase through the gestation period, reaching their maximum during the last trimester and 
normalizing after delivery. However, in pre-eclampsia, a pregnancy disorder characterized by high 
blood pressure and proteinuria, CGRP levels are lower36. 
 The role of CGRP as compensatory mechanism in ischemic events and blood pressure regulation 
poses a concern, especially as numerous studies have shown that migraine patients present 
an increased risk of hemorrhagic and ischemic stroke, with the risk being higher for women37-42. 
Moreover, a higher risk of myocardial infarction, coronary artery disease and altered arterial function 
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have also been described43,44. Unfortunately, the mechanisms behind these increases are not clear, 
but they are thought to involve genetic aspects and vascular dysfunction, amongst other factors.  
 One strategy to understand migraine pathophysiology and its relation with the increase in 
cardiovascular risk is the use of animal models of migraine, but current animal models, although 
useful, only represent certain features of this rather complex disorder. Another alternative is the use 
of models of monogenic disorders that are comorbid with migraine, such as “Autosomal dominant 
Retinal Vasculopathy with Cerebral Leukodystrophy” (RVCL)45,46. Interestingly, this vasculopathy, 
caused by a mutation in the TREX1 gene, is associated with endothelial dysfunction46, and almost 
two thirds of the patients present migraine without aura45, providing an unique opportunity to 
study both the genetic and the vascular interactions in migraine pathophysiology. 
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Based on the questions posed in Chapters I, III and VI, the objective of this thesis was to investigate 
the vascular effects of current and novel antimigraine drugs. For this purpose, the following 
objectives were defined:
1. The gold standard for the acute treatment of migraine are the triptans. It has been shown 
that triptans cause vasoconstriction of the middle meningeal artery and, unfortunately, of the 
coronary arteries, due to their affinity for the 5-HT1B receptors present in vascular smooth muscle 
cells. Therefore, novel serotonergic antimigraine drugs without vasoconstrictive properties 
and devoid of affinity for the 5-HT1B receptor are needed. In Chapter IV we investigated the 
binding, functional activity and contractile responses of the selective 5-HT1F receptor agonist 
lasmiditan, a novel antimigraine drug that is effective for the acute treatment of migraine. 
                                                                                                                                                                                                                                                                                                                                                  
2. Studies have shown that CGRP plays an important role in migraine pathophysiology. This has led 
to the development of antagonists (ubrogepant and atogepant) and an antibody (erenumab) 
against the CGRP receptor. We characterized the effect of ubrogepant, atogepant (Chapter V) 
and erenumab (Chapter VIII) in human cranial and coronary arteries to investigate the possible 
mechanism of their therapeutic effect, as well as their potential coronary side effects.
3. Before the arrival of the antibodies against CGRP or its receptor, prophylactic migraine 
treatment was not developed specifically for this disorder, but for hypertension, epilepsy or 
depression. Although these treatments are effective, their mechanism of action in migraine 
treatment unfortunately has not been studied in detail. Propranolol is one of the most widely 
prescribed drugs for prophylactic treatment of migraine, therefore we set out to investigate the 
effect of propranolol in the modulation of the trigeminovascular system in our human model 
of trigeminal nerve-mediated vasodilation (Chapter IX). Since most of migraine patients are 
females and we have previously shown that trigeminovascular responses can be modulated by 
sex hormones, we stratified our data to see whether the responses between males and females 
were comparable. 
4. Not all patients respond to treatments based on current targets. Based on the current knowledge 
of migraine pathophysiology, new drugs could act at receptors that are also activated by CGRP 
or that inhibit CGRP release. In Chapter XI, we investigated the role of imidazoline receptors in 
the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic 
outflow in pithed rats.
5. Migraine pathophysiology remains largely unknown. Current animal models, although 
useful, only represent certain features of this rather complex disorder. “Autosomal dominant 
Retinal Vasculopathy with Cerebral Leukodystrophy” (RVCL), caused by a mutation in the 
TREX1 gene, is a vasculopathy that presents migraine as its earliest manifestation. Monogenic 
diseases such as RVCL provide an opportunity to study the genetic and vascular mechanisms 
involved in migraine pathophysiology. In Chapter XII we assessed whether RVCL-KI mice have 
features in line with the pathology seen in patients, such as a reduced life expectancy and a 
vascular phenotype (as assessed by functional vascular measurements and the induction of 
experimental stroke). 
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Aims
...proceeds then to the understanding...
PART II:
Acute treatment of migraine

Chapter III.  
Is selective 5-HT1F receptor agonism 
an entity apart from that of the triptans 
in antimigraine therapy?
Based on: E Rubio-Beltrán*, A Labastida-Ramírez*, CM Villalón, A MaassenVanDenBrink 
(2018) Pharmacology & Therapeutics; 186:88-97.
*Both authors contributed equally
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Abstract
Migraine is a neurovascular disorder that involves activation of the trigeminovascular system and 
cranial vasodilation mediated by release of calcitonin gene-related peptide (CGRP).
 The gold standard for acute migraine treatment are the triptans, 5-HT1B/1D/(1F) receptor agonists. Their 
actions are thought to be mediated through activation of: (i) 5-HT1B receptors in cranial blood vessels 
with subsequent cranial vasoconstriction; (ii) prejunctional 5-HT1D receptors on trigeminal fibres that 
inhibit trigeminal CGRP release; and (iii) 5-HT1B/1D/1F receptors in central nervous system involved in 
(anti)nociceptive modulation. Unfortunately, coronary arteries also express 5-HT1B receptors whose 
activation would produce coronary vasoconstriction; hence, triptans are contraindicated in patients 
with cardiovascular disease. In addition, since migraineurs have an increased cardiovascular risk, it is 
important to develop antimigraine drugs devoid of vascular (side) effects.
 Ditans, here defined as selective 5-HT1F receptor agonists, were developed on the basis that 
most of the triptans activate trigeminal 5-HT1F receptors, which may explain part of the triptans’ 
antimigraine action. Amongst the ditans, lasmiditan: (i) fails to constrict human coronary arteries; 
and (ii) is effective for the acute treatment of migraine in preliminary Phase III clinical trials. 
Admittedly, the exact site of action is still unknown, but lasmiditan possess a high lipophilicity, 
which suggests a direct action on the central descending antinociceptive pathways. Furthermore, 
since 5-HT1F receptors are located on trigeminal fibres, they could modulate CGRP release. 
 This review will be focussed on the similarities and differences between the triptans and the 
ditans, their proposed sites of action, side effects and their cardiovascular risk profile.
Introduction
Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating 
headaches of moderate to severe intensity, associated with nausea, photophobia and/or 
phonophobia, lasting from 4 to 72 hours1. In the Global Burden of Disease Study, migraine was 
ranked as the third disabler in women, sixth disabler when taking both genders into account, and the 
most disabling of all neurological disorders, affecting approximately 15% of the world population2, 
with a profound negative effect on the patient’s quality of life3. Furthermore, this neurovascular 
disorder represents an economic loss of €20 billion in Europe every year4. Thus, migraine is a public 
health problem that affects both the individual and society.
Pathophysiology of migraine
Throughout the years, several theories regarding the pathophysiology of migraine have emerged5. 
In the late 1930’s and early 1940’s, Wolff’s group described migraine as a disorder of vascular origin, 
with an intense extracranial vasodilation as the cause of migraine pain6,7. Decades later, Moskowitz 
introduced the neurogenic theory, where trigeminovascular axons from blood vessels of the dura 
mater released vasoactive peptides producing an sterile inflammatory response followed by pain8. 
Nowadays, migraine is considered as a neurovascular disorder that involves activation of the 
trigeminovascular system9,10, presumably followed by vasodilation mainly mediated by the release 
of calcitonin gene-related peptide (CGRP), a neuropeptide present in perivascular sensory fibres11,12. 
Treatment of migraine
Despite the long history of migraine treatment, effective antimigraine drugs have been, until very 
recently, limited in number (for references see13). Basically, pharmacological treatment of migraine 
can be divided into prophylactic drugs, designed to reduce the frequency and severity of migraine 
attacks, and acutely acting drugs, aimed to reverse the attack once it has begun, including the 
Chapter III
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associated symptoms. The majority of migraine patients only need acute treatment, nevertheless, 
migraineurs that suffer from frequent attacks or have contraindications for the use of acutely acting 
drugs, are also prescribed prophylactic drugs14. The prophylactic treatment will not be discussed 
here as it is falls beyond the scope of the present review.
 The acute treatment can be further subdivided in specific (ergot derivatives, triptans, gepants, 
“ditans”), and non-specific (nonsteroidal anti-inflammatory drugs, analgesics) antimigraine drugs14,15. 
While non-specific drugs aim to treat migraine as a general headache or other pain, specific 
treatment is developed based on the neurovascular basis of migraine. Thus, these drugs target 
the modulation of the trigeminovascular system, the CGRP-mediated vasodilation (i.e. extracranial 
vasoconstriction, inhibition of CGRP release, CGRP receptor antagonism) and/or the pain perception 
pathway, amongst others. On this basis, CGRP receptor antagonists (gepants) are a likely candidate 
for the acute treatment of migraine, and indeed, they were effective in clinical trials12,16,17; however, 
due to pharmacokinetic and/or hepatotoxic limitations none of the gepants have yet reached the 
market18. Currently, a potential concern with gepants includes the cardiovascular side effects when 
used chronically, considering the physiological protective role of CGRP in maintaining cardiovascular 
homeostasis in ischemic events (for further references see19).  Several drugs targeting the CGRP 
receptor are presently under development for the acute and prophylactic treatment of migraine19,20.
 During the last 40 years, the target for selective antimigraine drugs has been the serotoninergic 
signalling. Long before the discovery of CGRP and its fundamental role in migraine, increased 
urinary and plasma levels of serotonin (5-hydroxytryptamine, 5-HT) and its metabolites were 
described21,22. Further studies showed that intravenous infusion of 5-HT was capable of aborting 
migraine attacks23 and that antimigraine drugs like methysergide and ergotamine were acting on, 
amongst other receptors, 5-HT1 receptors
24,25. In this review, the main focus will be on the triptans, 
5-HT1B/1D/(1F) receptor agonists, that are currently considered the gold standard for acute migraine 
treatment, and on the novel “ditans” (in this review defined as selective 5-HT1F receptor agonists), not 
only developed based on the neurovascular origin of migraine, but also in view of the cardiovascular 
risk profile of migraine patients26-34 .
Triptans
As mentioned in the above section, the role of serotoninergic neurotransmission in migraine  led 
to the design of antimigraine drugs that targeted the 5-HT receptors21-23; however, the exact 5-HT 
receptors involved in the relief of migraine attacks were unknown. Indeed, intravenous infusion of 
5-HT was able to abort migraine attacks, but considering that there are fourteen 5-HT receptors35, 
and they were all activated, numerous side effects were observed23. After several studies using 
selective agonists and antagonists it was demonstrated that the therapeutic action of 5-HT was 
mediated by “5-HT1-like receptors” that constricted cranial blood vessels
24,25,36, and the first triptan 
was developed: sumatriptan37. In the early 1990s, sumatriptan was officially introduced to the 
market38. In view of the low oral bioavailability and lipophilicity of sumatriptan39, as well as the vast 
market potential, “second generation” triptans (zolmitriptan, naratriptan, rizatriptan, almotriptan, 
eletriptan, frovatriptan, donitriptan and avitriptan) were developed, with a chemical structure 
similar to sumatriptan (see Fig. 1), but with higher oral availability and lipophilicity (see Table 1), as 
well as a longer plasma half-life35,40,41. 
Mechanism of action
Initially, it was described that the therapeutic action of 5-HT on migraine was mediated by activation 
of “5-HT1-like” receptors
36. Years later, based on structural, transductional and operational criteria, 
these receptors were classified into 5-HT1B and 5-HT1D receptors (for further references see
42,43).
III
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans
 Triptans are 5-HT1B/1D receptor agonists, and a grand majority of them are also 5 HT1F receptor 
agonists (see Table 2, Fig. 2). Sumatriptan, as previously mentioned, has low lipophilicity (see Table 
1) and cannot cross the blood brain barrier (BBB). For a drug to be considered able to cross the BBB, 
it should have a distribution coefficient at physiological pH (logDpH7.4) higher than -1
44,45. Notably, 
second generation triptans were developed with higher lipophilicity39 but their ability to cross the 
BBB is in controversy, since their reported logDpH7.4 values are not consistent amongst studies (see 
Table 1). Furthermore, it is important to consider the possible interactions between triptans and 
BBB efflux transporters (e.g. P-glycoprotein) that limit the central actions of triptans, as it has been 
reported for eletriptan46. 
Fig. 1. Chemical structures of the triptans, alniditan and the selective 5-HT1F receptor agonists. It is worth 
remarking the presence of the indole group in all the structures, with exception of lasmiditan and alniditan35.
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Table 1. Reported LogDpH7.4 values for triptans. Compounds with values higher than -1 are considered to be able 
to cross the BBB. 
Sumatriptan Zolmitriptan Naratriptan Rizatriptan Almotriptan Eletriptan Frovatriptan
Fox58 -1.5 -1 -0.2 -0.7 ND ND -1
Ferrari, et al59 -1.3 -0.7 -0.2 -0.7 +0.35 +0.5 ND
Glennon and Dukat60 -1.7 -0.8 -1.2 -1.4 -0.5 +0.2 -2.1
Milton, et al61 ND ND ND ND ND +1.1 ND
Pascual and Muñoz62 -1.3 -0.7 -0.2 -0.7 -2.1 +0.5 ND
Cheng, et al63 -1.4 -1.5 ND -0.8 +0.4 +0.2 -1.9
ND. Not defined
Table 2. Summary of pEC50 values of cAMP (5-HT1 and 5-HT7) and IP (5-HT2) assays of individual antimigraine 
drugs at 5-HT receptors64. These values represent the negative logarithm of the molar concentration of these 
compounds at which 50% of their maximal response is exerted. *pEC50 values correspond to [
35S]GTPγS assay.
5-HT1A 5-HT1B 5-HT1D* 5-ht1E 5-HT1F 5-HT2A 5-HT2B 5-HT7
Ergotamine tartrate 9.78 9.94 9.43 5.95 5.97 9.25 8.72 7.09
Sumatriptan succinate <5 7.32 8.30 5.99 8.03 <5 <5 5.22
Zolmitriptan <5 7.87 9.51 8.18 8.00 <5 <5 6.28
Naratriptan hydrochloride <5 8.05 8.80 7.75 8.38 <5 <5 <5
Rizatriptan benzoate <5 7.08 8.11 7.34 6.54 <5 5.49 <5
Almotriptan malate <5 7.08 7.75 <5 7.79 <5 5.20 <5
Eletriptan hydrobromide <5 8.00 9.04 7.53 8.13 6.07 6.81 6.45
Frovatriptan racemate <5 7.98 8.36 5.04 7.10 <5 <5 7.42
Donitriptan hydrochloride 5.94 9.96 9.51 <5 <5 8.10 7.61 5.23
Avitriptan fumarate <5 8.57 9.27 5.52 7.09 6.91 6.41 5.38
Alniditan dihydrochloride 7.00 8.87 8.20 5.68 5.92 <5 7.15 6.32
Lasmiditan hemisuccinate <5 <5 6.64 6.17 8.43 <5 <5 <5
LY334370 hydrochloride 5.84 6.52 6.92 7.53 9.08 <5 <5 <5
LY344864 hydrochloride <5 <5 6.93 6.22 8.72 <5 <5 <5
Cardiovascular (side) effects
The initially proposed therapeutic action of triptans is through the selective vasoconstriction 
of cranial blood vessels due to the high expression of 5-HT1B receptors in this vasculature
36,47 in 
comparison with peripheral blood vessels48. In agreement with this, in vitro studies have shown that 
at therapeutic concentrations triptans contract the middle meningeal artery (MMA)48. Furthermore, 
magnetic resonance angiography studies demonstrated that migraine attacks are associated with 
dilation of the extra- and intracerebral arteries, ipsilateral to the headache side; and that contraction 
of dural (but not intracranial) arteries by triptans, is associated with headache relief49, although it is 
worth mentioning that further results of the same group have been inconsistent50-52 and it is still a 
matter of debate to what extent the vascular action of the triptans contributes to their therapeutic 
efficacy. Unfortunately, studies have consistently shown that triptans induce an increase in blood 
pressure53 and contraction of coronary arteries48,54-56, which is more pronounced in the distal than in 
the proximal portion of the human coronary artery57.
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 Currently, although there is still a debate on whether the therapeutic action of triptans relays on 
their vasoconstrictive properties, it is clear that coronary vasoconstriction is a drug class effect of the 
triptans as 5-HT1B receptor agonists
65. Therefore, triptans are contraindicated in migraine patients 
with cardiovascular disease66. Additionally, it is important to consider that migraineurs are known 
to have an increased risk of haemorrhagic29 and ischemic26-28,30,31 stroke, with women presenting 
a higher risk34. Also, an altered arterial function32, and a higher risk of myocardial infarction and 
coronary heart disease33 have been described. Nonetheless, the use of triptans does not seem 
to increase the risk of stroke, myocardial infarction, cardiovascular death, ischemic heart disease 
or mortality67-69. However, taken together, their coronary vasoconstrictor potential justifies the 
contraindication of the triptans in patients with cardiovascular risk factors.
Neuronal effects
Although sumatriptan does not cross the BBB59, it has long been speculated that during a migraine 
attack there would be a disruption of the BBB, which would enable the triptans, even those with a 
low lipophilicity, to exert a central effect. However, it has recently been demonstrated that there 
is no disruption of the BBB during a migraine attack70,71, thus excluding a central action for the 
triptans, except for those with a high lipophilicity. Besides the potential role for blood vessels in 
the pathophysiology of migraines, this suggests that actions of the triptans can well be mediated 
through neuronal structures that are not protected by the BBB, as it is the case for the pituitary 
gland, choroid plexus and, most importantly, the trigeminal ganglion (TG)72, a key structure in 
migraine pathophysiology. Accordingly, treatment with sumatriptan reduces CGRP plasma levels 
as migraine lessens73. More recently, sumatriptan was also shown to inhibit capsaicin-induced 
trigeminal CGRP release in healthy volunteers74. Furthermore, expression of prejunctional 5-HT1D 
receptors has been described in trigeminovascular nociceptive neurons47,75,76 which could suggest 
a role in the modulation of CGRP release, as well as plasma protein extravasation77. Remarkably, 
based on the prejunctional location of 5-HT1D receptors in the TG, PNU-142633, a selective 5-HT1D 
receptor agonist, was developed for the acute treatment of migraine, and showed a superior 
potency over sumatriptan for blocking plasma protein extravasation. Unfortunately, it was not 
effective in the acute treatment of migraine78. It is worth mentioning that PNU-142633 was 
developed based on the gorilla 5 HT1D receptor, which could explain its lack of efficacy, and thus 
a role for the 5-HT1D receptor in the treatment of migraine cannot categorically be ruled out. 
Besides, it has been shown that activation of 5-HT1B, but not 5-HT1D receptors inhibits CGRP release 
in the pithed rat model79, indicating that, while 5-HT1D receptor activation may contribute to the 
therapeutic actions of triptans, it may not be their main site of action. Further studies are needed 
to completely elucidate the role of 5-HT1D receptor activation in migraine treatment. 
 As discussed earlier, second generation triptans were developed with higher lipophilicity 
than sumatriptan40,41. Therefore, some of them may be able to cross the BBB59,80. Although the 
lipophilicity of triptans correlates with central side effects, it does not seem to be related to 
their efficacy62, and there is no consistency in the lipophilicity reported in literature (see Table 
2). Nevertheless, we cannot categorically exclude additional therapeutic actions mediated via 
activation of 5-HT1B/1D/(1F) receptors in the central nervous system by highly lipophilic triptans
818181. 
In accordance with this, it has been shown that vasodilation of the canine external carotid artery 
induced by intracarotid administration of capsaicin, is inhibited by spinal (but not intravenous) 
administration of sumatriptan via activation of 5-HT1B receptors; in contrast, intravenous 
administration of the highly lipophilic donitriptan inhibits the capsaicin-induced vasodilation, 
also mediated by activation of 5-HT1B receptors
80,82. 
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Fig. 2. Summary of agonist profiles of triptans, ditans (here considered as selective 5-HT1F receptor agonists) 
and other 5-HT receptor ligands, for 5-HT1B, 5-HT1D and 5-HT1F receptors (pEC50>7). *In view of the high affinity of 
alniditan for the 5-HT1B/1D receptors (pEC50 cAMP 8.87 and 8.20, respectively), we classified it as a triptan, despite 
its generic name64.
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 Several studies have described 5-HT1B and (presynaptic) 5-HT1D receptors in the dorsal horn 
of the spinal cord (DHSC)83, substantia nigra, globus pallidus83,84, nucleus tractus solitarius (NTS), 
trigeminal nucleus caudalis (TNC)47,83, periaqueductal grey area (PAG)83,85, the ventroposteromedial 
nucleus of the thalamus86, hypothalamic paraventricular nucleus (PVN)87 and the rostral 
ventromedial medulla88, structures previously associated with nociceptive and anti-nociceptive 
pathways89-97. Furthermore, it has been shown that spinal 5-HT1B/1D/1F receptors are involved 
in the serotonergic descending inhibitory pain system98-102. Of special interest, intravenous 
administration of naratriptan103,104 results in inhibition of the spinal TNC. Also, the PAG, more 
specifically the ventrolateral division, is activated by afferents from the TG105-107, and microinjection 
of naratriptan in this structure inhibits nociceptive dural responses85. Moreover, the PVN, that 
has been previously shown to participate in the endogenous modulation of pain97,108 sends 
projections to the PAG109 and the spinal trigeminal nucleus87, and microinjection of naratriptan 
in this structure, attenuates dural-evoked trigeminovascular responses87. Thus, indeed highly 
lipophilic triptans could not only act through the vasoconstriction of extracranial vasculature and 
inhibition of the release of CGRP, but also through the activation of the descending inhibitory 
pain system and/or the inhibition of nociceptive transmission (see Fig. 3). Interestingly, most of 
these studies were performed using naratriptan, a highly lipophilic triptan that has a high affinity 
for the 5-HT1F receptor (see Table 2). Furthermore, although antagonists were used to confirm the 
role of 5-HT1B/1D receptors, there is no selective antagonist commercially available for the 5-HT1F 
receptor yet. Therefore, the involvement of this receptor in the neuronal actions of triptans can 
neither be confirmed nor excluded and requires further studies. 
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Ditans and the 5-HT1F receptor
Triptan monotherapy is ineffective for approximately 25% of migraineurs and in 40% of acute 
migraine attacks110. Several studies have tried to elucidate the lack of efficacy in some migraineurs, 
but were unable to explain why some patients are responders to the triptans while others are 
nonresponders. Whereas a difference in efficacy could be due to pharmacokinetic factors for some 
of the oral triptans, pharmacokinetics did not seem to be responsible for differences in efficacy in 
response to subcutaneous sumatriptan111, nor  polymorphisms in the 5-HT1B and 5-HT1F receptor 
genes were able to explain differences in clinical responses to sumatriptan112-114. Moreover, as 
previously discussed, migraine patients are known to have an increased cardiovascular risk; therefore, 
it is important to develop novel effective antimigraine drugs that are devoid of cardiovascular side 
effects. 
 Several triptans bind to the 5-HT1F receptor (see Table 2). Also, as will be discussed later, 5 HT1F 
receptors are expressed in several structures associated with migraine pathophysiology and with 
the (neuronal) therapeutic actions of triptans. This led to the development of selective 5-HT1F 
receptor agonists as possible option for migraine treatment. Several selective 5-HT1F receptor 
agonists have been developed (see Fig. 1), including LY344864, an aminocarbazole, LY334370, a 
4-(3-indolyl)piperidine60 and lasmiditan (COL-144, LY573144), a piridinoyl-piperidine115. While the 
selective 5-HT1F receptor agonists were referred to as SSOFRAs (Selective Serotonin One F Receptor 
Agonists) for some time, in the last years the term “ditan” has been accepted as a synonymous of 
selective 5-HT1F receptor agonist
116. In this context, it is important to consider alniditan, a 5-HT1A/1B/1D 
receptor agonist with only low 5-HT1F receptor affinity (see Table 2), suggesting that the suffix 
“ditan” is merely to distinguish novel acutely acting (5-HT1 receptor agonists) antimigraine drugs 
from triptans, without any structural (see Fig. 2) and/or pharmacological criteria (see Table 2). As 
the following paragraph is only focused on 5-HT1F receptor agonists, alniditan will not be further 
discussed when ditans are mentioned.
Location
The human 5-HT1F receptor was first identified and cloned in 1993
117. It has been described in the 
TG75,118,119, globus pallidus, NTS, substantia nigra, PAG, DHSC83, caudate nucleus120, caudate putamen, 
nucleus accumbens121, and the TNC83,120,122,123. Interestingly, it has also been shown to be expressed 
on cerebrovascular tissues118 as well as peripheral arteries54. 
Preclinical studies
Selective 5-HT1F receptor agonists were developed as a novel therapeutic option for migraineurs, 
including those with increased cardiovascular risk. Therefore, the main concern was to study the 
(lack of) vascular effects, as well as their efficacy on predictive models of migraine treatment. 
Cardiovascular (side) effects
An established in vitro model used to analyze potential contraction of human arteries is the 
contraction of the rabbit saphenous vein124. LY334370125,126, LY344864126,127 and lasmiditan115 lacked 
vasoconstrictor effects in this model. Furthermore, in two in vivo studies in dogs, intracarotid 
administration of LY344864 did not affect carotid blood flow128, and responses to continuous 
intravenous infusions of lasmiditan, in escalating cumulative doses, failed to constrict the coronary 
and carotid arteries; sumatriptan, on the other hand, constricted both arteries at clinically relevant 
doses129. Furthermore, in in vitro studies in human mammary and coronary arteries, lasmiditan 
was also devoid of vasoconstrictor properties, while sumatriptan was shown to contract already 
at subtherapeutic concentrations64,129. It is worth mentioning that in this study, also a threshold 
stimulation with the thromboxane A2 analogue U46619 was performed to potentially “unmask” 
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vasoconstrictor responses in the internal mammary artery; notably, sumatriptan contracted at even 
lower concentrations, while lasmiditan failed to produce vasoconstriction. Similarly, pharmacological 
activation of 5-HT1F receptors failed to produce vasoconstriction in human cerebral and MMA
130,131.
Neuronal effects
A number of studies have shown that intravenous administration of the selective 5-HT1F receptor 
agonists LY334370125, LY344864132 and lasmiditan115 inhibits protein plasma extravasation in the 
dura mater. However, it is important to consider that the selective 5 HT1D receptor agonist PNU-
142633 also showed a high potency for inhibiting protein plasma extravasation, but was not 
effective in the acute treatment of  migraine78. Similar failures in the acute treatment of migraine 
were observed with endothelin receptor antagonists133 and the highly potent inhibitor of protein 
plasma extravasation CP 122,288134. Therefore, it seems likely that 5-HT1F receptor agonists act 
through additional pathways, for instance, modulation of the trigeminovascular system, inhibition 
of the CGRP-mediated vasodilation and/or modulation of the pain perception pathway (see Fig. 
3). In accordance with these potential mechanisms, activation of 5-HT1F receptors has been shown 
to inhibit the activation of second order neurons in the TNC in mice135, rats115,136-138 and cats139, 
suggesting a modulation of the trigeminovascular system. Moreover, an in vitro study with LY344864 
showed an inhibition of CGRP release in rat dura mater, but not in TNC or TG122. In contrast, a recent 
study showed that lasmiditan inhibits CGRP release in mouse dura mater, TG and TNC140, although 
only supratherapeutic concentrations were studied. Therefore, more in vitro and in vivo studies (e.g. 
closed cranial window model) are required to confirm 5-HT1F receptor involvement in the inhibition 
of CGRP release. Nonetheless, in the pithed rat model it has been shown that activation of 5-HT1F 
receptors inhibits the release of CGRP from perivascular nerve fibres141. 
 Furthermore, the expression of 5-HT1F receptors in the globus pallidus, NTS, the DHSC
83, caudate 
nucleus120, putamen and the nucleus accumbens121, structures associated with (anti)nociceptive 
pathways89,91,93,94,142,143, suggests a possible role for 5-HT1F receptor activation in the modulation of 
nociceptive impulses.
Clinical studies
Twenty years have passed since the development of LY334370136; nowadays, two more 5-HT1F 
receptor agonists have been synthesized, namely, LY344864132 and lasmiditan115. Only LY334370 and 
lasmiditan have reached clinical trials.
LY334370
The prototype for the 5-HT1F receptor agonists reached phase II of clinical trials
144, and the results 
were favourable for the acute treatment of migraine, as sustained headache response rates were 
higher on 60 mg (37%) and 200 mg (52%) compared to placebo (8%; p<0.001). However, further 
trials were halted due to observed liver damage in beagle dogs after treatment for longer than one 
month145. It is worth mentioning that liver damage was not reported in other species, discarding 
hepatotoxicity as a drug class effect.
Lasmiditan
Considered as the most promising of the 5-HT1F receptor agonists, lasmiditan differs from LY334370 
and LY344864, as it does not possess the indole group (see Fig. 1). 
 Five phase I trials have been completed146-148 for intravenous and oral formulations for safety, 
bioavailability, tolerability and pharmacokinetic studies. In 2007, a phase II study for the intravenous 
formulation was conducted149, and later on, in 2009 for the oral formulation150. In both cases, 
lasmiditan was shown to be safe and effective in the acute treatment of migraine. Phase III trials 
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are ongoing, with preliminary statements showing positive results as the percentage of patients 
pain free at two hours was higher for 100 mg (28%) and 200 mg (32%), compared to placebo (15%; 
p<0.001151). It is worth mentioning, that the first phase III trial (“SAMURAI”, NCT02439320) included 
a majority of migraineurs (80%) that had cardiovascular conditions or cardiovascular risk factors (i.e. 
obesity, hypertension, hyperlipidemia), the main group of patients that would benefit from the lack 
of vasoconstrictive properties. Two more phase III trials (“SPARTAN”, NCT02605174: “GLADIATOR”, 
NCT02565186) are under way and are aimed to compare different doses of lasmiditan, and to 
evaluate the safety and efficacy of long term use, respectively. Recently, preliminary results from 
SPARTAN have been released and showed that at two hours following the first dose of lasmiditan, 
the percentage of pain-free patients was statistically significantly higher for 50 mg (28%, p=0.003); 
100 mg (31%, p<0.001) and 200 mg (38%, p<0.001) compared to placebo (21%)152. Only patients 
that received lasmiditan in previous trials are allowed to be included in the GLADIATOR trial. It is 
worth mentioning that no direct comparison has been performed between triptans and lasmiditan 
in clinical studies. Future phase III trials with a triptan as an active comparator would allow a better 
evaluation of their efficacy.
Conclusions
Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine 
treatment that have been proven effective.  Unfortunately, they are contraindicated in patients with 
cardiovascular diseases due to their vasoconstrictor (side) effects55,65. Furthermore, triptans are not 
effective in 25% of migraine patients110; thus, it is important to develop new antimigraine drugs that 
are cardiovascularly completely safe and at least equally effective. The vasoconstrictor properties of 
triptans are thought to be mediated via activation of 5-HT1B receptors in blood vessels; this has led, 
in view of the contraindications in patients with cardiovascular pathologies, to the development of 
antimigraine drugs targeting the 5-HT1D and 5-HT1F receptors. While 5-HT1D receptor activation was 
not effective in the acute treatment of migraine78, the 5 HT1F receptor agonists have shown to be 
effective149,150. Furthermore, predictive preclinical models of migraine have shown that lasmiditan 
does not cause vasoconstriction and that its antimigraine effects are likely mediated via neural 
modulation115,129,138,140. Thus, 5-HT1F receptor agonists may provide migraine patients with another 
type of specific acutely acting antimigraine drug, with a cardiovascular safety advantage over the 
triptans, and with a mechanism of action that is likely to be, at least partly, different from that of the 
triptans. 
 Based on the lack of vasoconstrictive properties and its presumably neuronal mode of action, 
5-HT1F receptor agonists can be considered as an entity apart from that of the triptans in antimigraine 
therapy.
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Fig. 3. Structures associated with migraine pathophysiology and/or treatment. The proposed therapeutic action 
of triptans is through the selective vasoconstriction of the MMA (green), as well as the inhibition of CGRP release 
from the sensory fibres and the modulation of the TG, since they are not protected by the BBB, where also 5-HT1F 
receptors have been described (orange). Highly lipophilic triptans could also act on the ventroposteromedial 
nucleus of the thalamus, PVN, PAG, LC, NTS, TNC, RVM and the (DH) SC, where 5-HT1B and 5-HT1D receptors have 
been described and whose activation could also modulate the activity of the TG and/or the (anti)nociception 
pathways (purple). Furthermore, 5-HT1F receptors have also been reported in PAG, TG, TNC and the (DH)SC, which 
suggests a role in the modulation of the trigeminal responses as well as possible action on the (anti)nociceptive 
pathways (BOLD letters). BBB: blood brain barrier; CGRP: calcitonin-like related peptide; DHSC: dorsal horn of the 
spinal cord; MMA: middle meningeal artery; NTS: nucleus tractus solitarius; PAG: periaqueductal grey area; PVN: 
paraventricular nucleus of the hypothalamus;  RVM: rostral ventromedial medulla; TG: trigeminal ganglion; TNC: 
trigeminal nucleus caudalis.
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Abstract
Background and purpose. Triptans are 5-HT1B/1D receptor agonists (that also display 5-HT1F receptor 
affinity) with antimigraine action, contraindicated in patients with coronary artery disease due to 
their vasoconstrictor properties. Conversely, lasmiditan was developed as an antimigraine 5-HT1F 
receptor agonist. To assess the selectivity and cardiovascular effects of lasmiditan, we investigated 
the binding, functional activity and in vitro/in vivo vascular effects of lasmiditan, and compared it to 
sumatriptan.
Experimental approach. Binding and second messenger activity assays of lasmiditan and other 
serotoninergic agonists were performed for human 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E, 5-HT1F, 5-HT2A, 5-HT2B 
and 5-HT7 receptors, and the results were correlated with their potency to constrict human isolated 
coronary arteries (HCA). Furthermore, concentration-response curves to lasmiditan and sumatriptan 
were performed in proximal and distal HCA, internal mammary and middle meningeal arteries. 
Finally, anesthetized female Beagle dogs received intravenous infusions of lasmiditan or sumatriptan 
in escalating cumulative doses, and carotid and coronary artery diameters were measured.
Key results. Lasmiditan showed high selectivity for 5-HT1F receptors. Moreover, the functional potency 
of the analyzed compounds to inhibit cAMP increase through 5-HT1B receptor activation positively 
correlated with their potency to contract HCA. In human isolated arteries, sumatriptan, but not 
lasmiditan, induced contractions. Likewise, in vivo, sumatriptan decreased coronary and carotid 
artery diameters at clinically relevant doses, while lasmiditan was devoid of vasoconstrictor activity 
at all doses tested.
Conclusions and implications. Lasmiditan is a selective 5-HT1F receptor agonist devoid of vasoconstrictor 
activity. This may represent a cardiovascular safety advantage when compared to the triptans.
Introduction
Migraine is a neurologic disease characterized by throbbing unilateral headaches of moderate to 
severe intensity, accompanied by nausea, vomiting, photophopbia and/or phonophobia (Headache 
Classification Committee of the International Headache Society, 2018). It has an estimated prevalence 
of 15% in the global population, with women being three times more affected than men1,2. 
 Currently, the specific therapies for acute antimigraine treatment are the triptans, selective 
5-HT1B/1D receptor agonists that also display varying levels of 5-HT1F receptor affinity. Unfortunately, 
not all patients respond to triptans 3 and they are contraindicated in patients with cardiovascular 
disease, due to their contractile properties via activation of 5-HT1B receptors in coronary arteries
4-7. 
Therefore, there is a need for novel antimigraine drugs for the patients that are not respondent to 
the current available treatments, but also, for those patients with cardiovascular disease.
 Based on results from preclinical studies, the 5-HT1F receptor agonist, lasmiditan, was developed 
for acute antimigraine treatment8,9 and Phase III trials showed positive results10. Considering the 
increased cardiovascular risk of migraine patients1,11-13, and the presence of 5-HT1F receptors in the 
vasculature14-16, it is important to determine whether lasmiditan lacks affinity for human 5-HT1B 
receptors and whether activation of 5-HT1F receptors will result in vasoconstrictive responses. On 
this basis, the aim of this study was to investigate the pharmacological properties of lasmiditan, 
and in particular: (i) to assess the selectivity and functional activity of lasmiditan, triptans and 
other 5-HT receptor ligands on various human 5-HT receptors; (ii) to analyze its potential to induce 
vasoconstriction in in vitro (human isolated proximal and distal coronary, internal mammary and 
middle meningeal arteries) and in vivo (carotid and coronary artery diameters in anesthetized 
dogs) preclinical models; and (iii) to compare our findings with lasmiditan to those obtained with 
sumatriptan, one of the most prescribed triptans to treat acute migraine.
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 We hypothesise that, unlike sumatriptan, lasmiditan selectively activates the human 5-HT1F 
receptor and does not induce vasoconstriction in the above in vitro (including human coronary 
arteries) and in vivo vascular models.
Materials and methods
Cell membrane preparation
CHO-K1 cells expressing the human recombinant 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E, 5-HT1F, 5-HT2A, 5-HT2B 
or 5-HT7 receptors, were grown prior to the test in media without antibiotic at Ogeda S.A (Gosselies, 
Belgium). Cells were prepared using a protocol from Ogeda. In brief, cells were harvested by scraping 
from the culture vessels in ice-cold Ca2+- and Mg2+-free Phosphate-buffered saline (PBS).  The cells 
were then centrifuged for 10 min at 5,000 x g and 4°C and the pellets were suspended in buffer A 
(15 mM Tris-HCl pH 7.5; 2 mM MgCl2; 0.3 mM EDTA; 1 mM EGTA) and homogenized in a glass-glass 
homogenizer.  The crude membrane fraction was collected by 2 consecutive centrifugation steps 
at 35,000 x g and 4°C for 30 min separated by a washing step in buffer A.  The final membrane 
pellet was suspended in buffer B (75 mM Tris-HCl pH 7.5; 12.5 mM MgCl2; 0.3 mM EDTA; 1 mM EGTA; 
250 mM sucrose) and flash-frozen in liquid nitrogen.  Protein content was determined by the BCA 
method (Interchim, UP40840A).
Radioligand binding competition assay 
Competition binding was performed in duplicate in the wells of a 96-well plate containing 
binding buffer (optimized for each receptor), cells membrane extracts (approximately 20,000 cells 
distributed in the 96-well plate), radiotracer and test agonist. Nonspecific binding was determined 
by co-incubation with 200-fold excess of competitor. Cells were incubated and exposed to 
varying concentrations (1 pM to 10 µM) of a range of displacer agonists (see below). The samples 
were incubated in a final volume of 0.1 mL and then filtered over Unifilter plates (Perkin Elmer, 
Massachusetts, United States) pre-treated for 2 hours to limit tracer nonspecific binding. Filters were 
washed five times with 0.5 mL of ice-cold washing buffer (tris 50 mM pH 7.4) and 50µL of Microscint 
20 (Perkin Elmer, Massachusetts, United States) were added to each filter. The plates were incubated 
15 min at room temperature on an orbital shaker and the counted with a TopCountTM (Perkin Elmer, 
Massachusetts, United States) for 1 min per well.  
cAMP HTRF assay for Gi coupled receptors 
Concentration-response curves were performed in parallel with the agonists. For agonist tests, 
12  µl of cells were mixed with 6 µl of the test compound (at increasing concentrations) and 6µl 
of forskolin, then incubated 30 min at room temperature. After addition of the lysis buffer and 1 h 
incubation, cAMP concentrations were estimated according to the manufacturer specification 
with the HTRF kit (Cisbio International, Codelet, France). In brief, increasing concentrations of 
agonists were added to stably transfected cells in buffer in an Optiplate (PerkinElmer Life Sciences, 
Massachusetts, United States). The plates were incubated, and cells were then lysed by the addition 
of HTRF reagents (cAMP-Cryptate and anti-cAMP-d2 reagents) and diluted in lysis buffer, followed by 
incubation at room temperature. As 5-HT1B receptors have been reported in naïve CHO cells
18, we 
also tested 5-carboxamidotryptamine (5-CT, the reference agonist for the 5-HT1B receptor), in CHO 
cells transfected with a non-5-HT, G protein-coupled receptor.
cAMP HTRF assay for Gs coupled receptors 
Concentration-response curves were performed in parallel. For agonist tests, 12 µl of cells were 
mixed with 12 µl of the test compound at increasing concentrations and then incubated 30 min at 
room temperature. After addition of the lysis buffer and 60 min incubation, cAMP concentrations 
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were estimated, according to the manufacturer specification, with the HTRF kit (Cisbio International, 
Codelet, France). Briefly, increasing concentrations of agonists were added to stably transfected 
cells in buffer in an Optiplate (PerkinElmer Life Sciences, Massachusetts, United States). The plates 
were incubated, and cells were then lysed by the addition of HTRF reagents (cAMP-Cryptate and 
anti-cAMP-d2 reagents) and diluted in lysis buffer, followed by incubation at room temperature. 
IPOne HTRF assay 
The assay was performed on adherent cells. For agonist testing, the medium was removed and 20 
µl of assay buffer plus 20 µl of the studied agonist or the reference agonist were added in each 
well. The plate was incubated for 60 min at 37°C with 5% CO2. IP1-D2 reagent and anti-IP1 cryptate 
reagents were dispensed in the wells and IP1 concentrations were then measured following the 
manufacturer instructions (IPOne HTRF assay kit; Cisbio International, Codolet, France). In brief, 
increasing concentrations of agonists were added to stably transfected cells in buffer in an Optiplate 
(PerkinElmer Life Sciences, Massachusetts, United States). The plates were incubated, and cells were 
then lysed by the addition of HTRF reagents (IP1-D2 reagent and anti-IP1 cryptate reagents) and diluted 
in lysis buffer, followed by incubation at room temperature. 
GTPγ35[S] assay 
For agonist testing, membrane extracts expressing the receptor of interest was mixed with GDP. 
In parallel, GTPγ[
35S] was mixed with the beads just before starting the reaction. The following 
reagents were successively added in the wells of an Optiplate (Perkin Elmer, Massachusetts, United 
States): 50 µl of reference ligand, 10 µl of assay buffer, 20 µl of the cells:GDP mix, and 20 µl of the 
GTPγ[
35S]:beads mix.  The plate was incubated for 60 min, then centrifuged and counted with a 
PerkinElmer TopCountTM reader.
Agonists tested 
Serotonin (5-hydroxytryptamine; 5-HT), 5-CT, ergotamine, sumatriptan, zolmitriptan, naratriptan, 
rizatriptan, almotriptan, eletriptan, frovatriptan, donitriptan, avitriptan, alniditan, lasmiditan, 
LY334370 and LY344864 were tested. The radioligands and reference compounds used for the 
radioligand and second messenger studies are specified in Suppl. Tables 1 and 2. 
Human isolated arteries collection
Coronary arteries
Coronary arteries were obtained from six “heart beating” organ donors (three males and three 
females; 48-62 years), who died of non-cardiac disorders less than 24 h before the tissue was taken 
to the laboratory. The hearts were provided by the Heart Valve Bank Beverwijk Bank (nowadays 
ETB-BISLIFE Tissue Bank) at that time still located in Rotterdam, from Dutch post-mortem donors, 
after donor mediation via Bio Implant Services/Eurotransplant Foundation (Leiden, The Netherlands), 
following removal of the aortic and pulmonary valves for homograft valve transplantation. 
Immediately after circulatory arrest, the hearts were stored at 4°C in a sterile organ protecting 
solution and were brought to the laboratory within the first 24 hours of death. After arrival at the 
laboratory, the right proximal (internal diameter 3–5 mm) and distal (internal diameter 0.5–1 mm) 
portions of the coronary artery were dissected and placed in a cold, oxygenated (95% O2/5% CO2) 
Krebs buffer solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3 and 8.3 mM glucose; pH 7.4. 
Internal mammary arteries
Internal mammary arteries (internal diameter 2–3 mm) were obtained peri-operatively from 
eighteen patients (sixteen males and two females; 51–80 years) undergoing coronary bypass 
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surgery. The tissue was immediately placed in a sterile organ-protecting solution and was brought 
to the laboratory within 15 min. Subsequently, the artery was cleaned of connective tissue and 
placed in a cold, oxygenated Krebs buffer solution (for composition, see above).
Middle meningeal arteries
Middle meningeal arteries (internal diameter 0.5–1.5 mm) were obtained from the dura mater of six 
patients (two males and four females; 12-68 years) who underwent neurosurgery. The dura mater, 
together with a small piece of the meningeal artery, was collected in a sterile organ-protecting 
solution and immediately transported to the laboratory. The dura mater and connective tissue 
were dissected and the artery was placed in a cold, oxygenated Krebs solution of the following 
composition: 119 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM 
NaHCO2 and 11.1 mM glucose; pH 7.4.
 All arteries were used on the same day or stored overnight and used the following day for 
functional experiments. The studies on coronary arteries were approved by the Scientific Advisory 
Board of the Rotterdam Heart Valve Bank. The Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam, approved the study protocols with regard to mammary arteries and middle 
meningeal arteries.
Isometric tension measurements
Proximal coronary arteries were cut into segments of 2–4 mm length, excluding distinct, 
macroscopically visible atherosclerotic lesions. The segments were mounted on stainless steel 
hooks in 15 mL organ baths filled with oxygenated Krebs buffer solution at 37°C. After equilibration 
for at least 30 min and a wash every 15 min, the vessel segments were stretched to a stable tension 
of about 15 mN, with the optimal pretension as determined earlier5. Changes in tissue tension were 
measured with an isometric force transducer (Harvard, South Natick, MA, U.S.A.) and recorded on a 
flatbed recorder (Servogor 124, Goerz, Neudorf, Austria).
 The distal coronary, internal mammary and middle meningeal arteries were cut into circular 1-2 
mm long segments and mounted in Mulvany myographs (Danish Myo Technology, Aarhus, Denmark) 
between two parallel small stainless-steel wires (40 µm). All the baths were filled with warm Krebs 
buffer and aerated with carbogen. The tension was normalized to 90% of l100 for all segments, the 
diameter when transmural pressure equals 100 mm Hg19. Data were recorded using a LabChart data 
acquisition system (AD Instruments Ltd, Oxford, UK).
Experimental protocols
A paired parallel set up (i.e. all compounds were tested in different segments obtained from the 
same artery) was used. Initially, all segments were exposed to 30 mM KCl to ‘prime’ the tissue for 
stable contractions. After washout, the tissue was exposed to 100 mM KCl to determine the maximal 
contractile response. After further washout, a concentration-response curve to vehicle, sumatriptan 
or lasmiditan was constructed, using whole logarithmic steps from 1 nM up to 10 μM. After finishing 
the curve and washing several times until reaching equilibrium, the functional integrity of the 
endothelium was verified by observing relaxation to substance P (10 nM; coronary and meningeal 
arteries) or bradykinin (1 μM; mammary arteries), after precontraction with thromboxane A2 
analogue U46619 (10-100 nM)4,5.
 Furthermore, in the internal mammary arteries, a concentration-response curve to lasmiditan 
and sumatriptan was also constructed after adding threshold concentrations of U46619 (i.e. 
concentrations eliciting a contraction of ~10% of 100 mM KCl response, determined in quarter 
logarithmic steps), used to unmask contractile properties of some agonists in the presence of an 
increased tension, as previously described20. These contractile responses were evaluated post-hoc 
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in the absence (relaxation to bradykinin <18%) or presence (relaxation to bradykinin >18%) of 
functional endothelium; for this, endothelial function data was divided in percentiles, where values 
below the 50th percentile were considered without endothelium, and above the 50th percentile 
were considered with endothelium. Also, segments were preincubated with clinically relevant 
concentrations of sumatriptan (0.3 μM) or lasmiditan (1 μM), and followed by a concentration-
response curve to lasmiditan or sumatriptan, respectively, to evaluate the possible interactions 
(i.e. augmented vasoconstriction) between agonists. The clinically relevant concentration of 
sumatriptan was calculated as previously described5; in the case of lasmiditan, it was estimated 
based on the Cmax observed in humans following a 100 mg dose (0.25 μM)
21.
Correlation between binding (pKi) and the contractile potency of lasmiditan and other triptans 
We related previous6,22-24 and current data obtained (see Results) to the potency of these compounds 
to contract the human isolated coronary artery. In case a compound failed to contract human 
coronary artery, a fixed pEC50 value of 5 was set. Our pKi values used for this correlation are in 
agreement with those previously published in the literature (Suppl. Table 4, Suppl. Fig. 1). 
Animal preparations
Although in vitro experiments with human isolated arteries provide invaluable information on 
vasoconstrictive responses in specific vascular beds, to discard hemodynamic changes after 
systemic administration of novel experimental therapeutic compounds an in vivo model is 
necessary. The beagle dog is a well-accepted species that has been in use for several years to predict 
human cardiovascular responses to novel experimental therapeutic compounds25. Therefore, a total 
of eighteen adult female Beagle dogs (Canis familiaris) were selected from the CorDynamics, Inc. 
animal colony. These animals were obtained from Marshall BioResources (North Rose, N.Y., U.S.A.). 
Upon receipt at the Biologic Resources Laboratory (BRL) of the University of Illinois-Chicago, dogs 
were examined by a BRL veterinary personnel to ensure acceptable health status. Veterinary care 
was provided by the veterinarians and staff employed by the BRL. Dogs were acclimatized for at 
least 7 days prior to use, and were pair-housed in runs (meeting the size requirement set forth by 
the USDA Animal Welfare Act) with various cage-enrichment devices. Room temperature set at 18-
27°C, humidity at 30–70%, and fluorescent lights timed to give a 12 hour-light and 12 hour-dark 
cycle. Harlan Certified Canine food (25% Protein Diet #2025C, Harlan Teklad, Madison, WI) was fed 
daily (500 grams per day) and water was freely available in their runs. At the day of their terminal 
experiment, the animals were 10.0 to 11.5 months old, and their body weights ranged from 5.4 to 
7.9 kg. Body weights were measured twice (approximately one week between measurements) prior 
to each animal’s terminal procedure. Dogs were fasted for 16-18 hours prior to dosing.
 All experimental protocols were approved and conducted by CorDynamics in compliance 
with the US FDA Good Laboratory Practice guidelines (21 CFR Part 58), the Animal Welfare Act, the 
Guide for the Care and Use of Laboratory Animals, the Office of Laboratory Animal Welfare, ARRIVE 
guidelines for reporting experiments involving animals26; and the current guidance on experimental 
design and analysis for the British Journal of Pharmacology27. For more specific details on design 
and statistical analysis, see below the sections entitled: sample size calculation, randomization and 
blinding; and data presentation and statistical evaluation.
General methods 
Dogs were dosed with morphine subcutaneously (s.c., 1 mg·kg-1) approximately 10-20 min prior 
to administration of propofol anaesthesia i.v. (5-6 mg·kg-1) to allow tracheal intubation. They 
were placed on a ventilator with isoflurane delivered at 1-2% in oxygen to maintain anaesthesia 
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throughout the experiment and s.c. morphine (0.5 mg·kg-1) was administered approximately every 
two hours while under anaesthesia. The local anaesthetic bupivacaine was infiltrated into the 
incision sites. A continuous 0.9% NaCl solution for injection drip (approximately 10 mL·kg-1·hour-1) 
was maintained until the start of dosing at which time it was discontinued. Dogs were placed on 
a heating pad set to maintain the animal’s body temperature at approximately 37ºC and their 
body temperature was monitored throughout the experiment by placing a rectal temperature 
probe. Additionally, surface ECG leads were placed for anaesthesia monitoring throughout the 
experimental protocol.
 A mid-lateral neck incision was made and the left common carotid artery was exposed. A 
Transonic Systems Inc. (Ithaca, N.Y., U.S.A.) blood flow probe and two Sonometric Corporation 
(London, Ontario, Canada) crystals for arterial dimensional analysis were affixed to the artery. A left 
lateral thoracotomy (6th intercostal space) was performed and the left circumflex coronary (LCX) 
artery was exposed. A Transonic Systems Inc. blood flow probe and two Sonometric Corporation 
crystals for arterial dimensional analysis were affixed to the artery. A solid-state high-fidelity pressure 
catheter (Millar Inc., Houston, TX, U.S.A.) for measurement of arterial pressure (mean, MAP; systolic, 
SAP; and diastolic, DAP) and heart rate was inserted into a femoral artery and secured in place with 
silk suture. An indwelling catheter was placed into the femoral vein for collecting blood (2 mL) prior 
to the start of dosing and at the end of each 20 min infusion period (see experimental protocol) for 
bioanalytical analysis. 
Experimental protocol
Upon completion of the general instrumentation, a 15 min equilibrium period was allowed for a 
stable hemodynamic condition. Baseline values (defined as the average of the three 5 min values 
at the aforementioned 15 min) of MAP, heart rate, and carotid and left circumflex coronary artery 
diameter and flow were determined. Subsequently, the 18 dogs were randomly assigned into 
three groups (n=6 each), which received vehicle (saline), lasmiditan (0.03, 0.13, 1.13, 4.13 and 
11.13 mg·kg-1) or sumatriptan (0.03-11.3 mg·kg-1), respectively. All treatments were filtered through 
a 0.2 µM membrane and administered i.v. in the escalating cumulative doses mentioned above. 
Dose-intervals amongst different treatments were administered each 20 min. At the end of the 
experiment, dogs were euthanized while under anaesthesia via a barbiturate overdose.  
Sample size calculation, randomization and blinding  
Sample size calculation. The animal sample size (n=6 each group) was calculated by CorDynamics 
based on their previous studies28. For the in vitro studies, we based the experimental number (n=5-7 
each group) on previous studies from our group5,29.
Randomization. For the in vitro experiments, all artery segments were cut into rings and randomly 
assigned to a bath, then the treatment group was designed by using a table of random numbers. 
For the in vivo experiments, the animals initially divided in sets (n=6 each group as described 
above), were randomly assigned to study groups by CorDynamics staff.
Blinding. For the radioligand and second messenger assays, the analyst was not blinded to the 
compounds but to the research hypothesis. For the vascular in vitro experiments, values were 
calculated using the dose-response auto-analyze selection feature of LabChart. During the analysis, 
the investigator was unaware of which concentration response curve was being analyzed. The in 
vivo experimental values (i.e. the changes in MAP or artery diameter) in each group of animals were 
simultaneously obtained by at least two different CorDynamics investigators, with at least one of 
the investigators blinded. 
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Data presentation and statistical analysis
All data in the text and Fig.s are presented as the mean±SEM from (n) experiments, as shown in the Fig. 
legends. Data and statistical analysis comply with the recommendations on analysis and experimental 
design in pharmacology27. 
Radioligand binding and second messenger activity
Reference compounds were tested at several concentrations in duplicate to obtain a concentration-
response curve, and an estimated pEC50 (negative logarithm of the concentration eliciting 50% of the 
maximal contractile response, i.e. Emax) or pIC50 value (negative logarithm of the concentration that 
displaced 50% of the radioligand) was calculated using XLFit (IDBS, Guildford, United Kingdom). 
Additionally, the reference values obtained were compared to historical values obtained from the 
same receptor and used to validate the experimental session. A session was considered as valid 
only if the reference value was found to be within a 0.5 log interval from the historical value, for 
assays where historical values (determined in at least 5 experiments) were available30-32. For the new 
assays developed in this study (i.e. 5-ht1E receptor), the two independent pIC50 determined must be 
concordant with a 1 log unit interval for the assays to be validated. When less than 50% inhibition of 
binding or second messenger activation was obtained at 10 µM a pIC50/pEC50 of "<5" was set. 
Human isolated arteries experiments
For the human vessels in vitro studies, concentration-response curves were analyzed using GraphPad 
software (GraphPad Software Inc., San Diego, CA, U.S.A.) to determine pEC50  values as previously 
reported5. When a plateau in the concentration-response curve was not reached, the response 
observed with the highest concentration used (i.e. 100 μM) was considered as Emax. Differences 
between pEC50 and Emax values of the compounds were evaluated with Tukey's test, once an analysis 
of variance (ANOVA) for paired data had revealed that the samples represented different populations. 
Values of P<0.05 were considered to indicate significant differences.
In vivo studies
In the in vivo studies, each hemodynamic parameter was analyzed with a repeated measure analysis 
of covariance (RANCOVA) for changes from baseline at time intervals of 5, 10, 15, and 20 min for 
each of the 5 dose levels. The model factored the treatment (TRT), the time after dose (TIME), and the 
interaction of time after dose with treatment (TRT*TIME). The SAS® procedure PROC MIXED was used 
for analysis with TIME as the repeated effect and ANIMAL as the subject. The covariance between 
errors from the same animal at different time points was selected based on the corrected Akaike’s 
Information Criterion from selected covariance structures of VC, AR(1), UN, and CS. Non-monotonic 
dose-responses were evaluated. Within the framework of the RANCOVA, comparisons were made for 
vehicle vs. lasmiditan-treated animals and for vehicle vs. sumatriptan-treated animals. If TRT*TIME was 
significant, the comparisons were conducted for each time interval using an analysis of covariance 
(ANCOVA) model with an effect for treatment and baseline as a covariate. If only the TRT effect was 
significant, the comparison was conducted across the pooled time intervals for the overall phase 
only. These non-monotonic treatment group comparisons were conducted at the p=0.01 significance 
level. Baseline data was analyzed with an ANOVA for each time interval. Factors in the model included 
treatment (TRT). All statistical analyses were conducted with SAS® version 9.2. After the database lock, 
post-hoc analyses for coronary artery diameter and carotid artery diameter (primary endpoints) at the 
clinically relevant time interval 20 min (completion of dose administration) for each cumulated dose 
(0.03-11.13 mg·kg-1) were performed for comparisons between sumatriptan and vehicle. A significance 
level of p≤0.025 was used for the RANCOVA using Bonferroni correction of two tests. 
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Compounds
The compounds used in the present study (obtained from the sources indicated) were: 5-HT hydrochloride, 
naratriptan hydrochloride, almotriptan malate, avitriptan fumarate and sumatriptan succinate (Sigma 
Chemical Co., St. Louis, MO, U.S.A.); lasmiditan hemisuccinate (Eli Lilly & Co., Indianapolis, IN, U.S.A.); 5-CT 
maleate, sumatriptan succinate, zolmitriptan, rizatriptan benzoate, eletriptan hydrobromide, donitriptan 
hydrochloride, LY334370 hydrochloride and LY344864 hydrochloride (Tocris Bioscience Co., Park Ellisville, 
MO, U.S.A.); ergotamine tartrate (TEVA Pharmaceutical Industries Ltd., Petach Tivka, Israel) and alniditan 
salt (kind gift of Janssen Pharmaceutica, Beerse, Belgium).
 All compounds were dissolved in distilled water or physiological saline for the in vitro and in vivo 
studies, respectively. These vehicles had no effect on the baseline MAP values or artery diameter (not 
shown). Fresh solutions were prepared for each experiment. The doses mentioned in this text refer to 
the free base of substances.
Results
Pharmacological characterization of lasmiditan
As shown in Table 1, radioligand studies revealed that lasmiditan selectively binds to the human 5-HT1F 
receptor. On the other hand, the triptans almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, 
sumatriptan and zolmitriptan showed affinity for 5-HT1B, 5-HT1D and 5-HT1F receptors; while alniditan, 
donitriptan, ergotamine and rizatriptan had affinity for 5-HT1B and 5-HT1D receptors. Most importantly, 
when analyzing their second messenger activity, we observed that ergotamine is an agonist of the 
5-HT1A/B/D, 5-HT2A/B and 5-HT7 receptors (but not 5-HT1F receptor). Similar as above, sumatriptan, 
zolmitriptan, naratriptan, almotriptan, eletriptan, frovatriptan and avitriptan are agonists of the 
5-HT1B/1D/1F receptors. Lasmiditan, as well as LY344864, displayed a high potency only for the 5-HT1F 
receptor (Table 2). In Fig.1, the agonistic profile of the different antimigraine drugs tested on the 5-HT1B/
D/F receptors (i.e. relevant for migraine therapy), are represented. When comparing our results with those 
previously published, our values are in agreement with those in the literature (see Suppl. Tables 4-5, 
Suppl. Fig. 1). Moreover, no functional responses to 5-CT were observed in the CHO cells transfected 
with an unrelated G protein-coupled receptor (Suppl. Fig. 2).
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Fig. 1. Summary of the agonist profiles (pEC50 >7) of the antimigraine drugs tested on the 5-HT1B, 5-HT1D and 
5-HT1F receptors. Redrawn from
37.
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Table 2. Summary of pEC50 values of cAMP (5-HT1A/1B/1E/1F and 5-HT7), GTPγS (5-HT1A/1B/1D/1E/1F) and IP (5-HT2) assays 
of individual antimigraine drugs at 5-HT receptors. These values represent the negative logarithm of the molar 
concentration of these compounds at which 50% of their maximal response is exerted. The lesser than symbol 
(<) indicates that less than 50% response was obtained at 10 µM. The reference compounds used and their 
concentrations are described in Suppl. Table 2. 
Agonist
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-HT1F 5-HT2A 5-HT2B 5-HT7
cAMP GTPγS cAMP GTPγS GTPγS cAMP GTPγS cAMP GTPγS IP IP cAMP
Ergotamine tartrate 9.78 9.63 9.94 9.52 9.43 5.95 5.74 5.97 6.30 9.25 8.72 7.09
Sumatriptan succinate <5 <5 7.32 7.91 8.30 5.99 5.79 8.03 6.80 <5 <5 5.22
Zolmitriptan <5 5.52 7.87 8.42 9.51 8.18 7.81 8.00 6.67 <5 <5 6.28
Naratriptan hydrochloride <5 6.52 8.05 8.86 8.80 7.75 8.17 8.38 8.05 <5 <5 <5
Rizatriptan benzoate <5 <5 7.08 7.56 8.11 7.34 6.90 6.54 5.91 <5 5.49 <5
Almotriptan malate <5 5.48 7.08 7.85 7.75 <5 <5 7.79 6.90 <5 5.20 <5
Eletriptan hydrobromide 5.74 6.38 8.00 8.09 9.04 7.53 6.90 8.13 6.88 6.07 6.81 6.45
Frovatriptan racemate <5 6.12 7.98 8.14 8.36 5.04 <5 7.10 6.35 <5 <5 7.42
Donitriptan hydrochloride 5.94 6.74 9.96 9.52 9.51 <5 <5 <5 <5 8.10 7.61 5.23
Avitriptan fumarate <5 6.19 8.57 8.68 9.27 5.52 <5 7.09 6.05 6.91 6.41 5.38
Alniditan dihydrochloride 7.00 7.29 8.87 8.90 8.20 5.68 5.21 5.92 5.17 <5 7.15 6.32
Lasmiditan hemisuccinate <5 <5 <5 <5 6.64 6.17 5.34 8.43 7.80 <5 <5 <5
LY334370 hydrochloride 5.84 6.96 6.52 5.80 6.92 7.53 6.95 9.08 9.38 <5 <5 <5
LY344864 hydrochloride <5 <5 <5 5.82 6.93 6.22 6.12 8.72 7.85 <5 <5 <5
Table 1. Summary of pIC50 (negative logarithm of the molar concentration of these compounds at which 50% 
of the radioligand is displaced) and pKi (negative logarithm of the molar concentration of the dissociation 
constant) values of individual antimigraine drugs at 5-HT receptors. The lesser than symbol (<) indicates that 
less than 50% inhibition of binding was obtained at 10 µM. The radioligands used and their concentrations are 
described in Suppl. Table 1. 
Agonist
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-HT1F 5-HT2A 5-HT2B 5-HT7
pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi pIC50 pKi
Ergotamine tartrate 9.19 9.70 8.87 9.34 8.63 9.31 6.08 6.39 6.71 7.13 7.62 8.14 7.73 7.94 7.13 7.23
Sumatriptan succinate 6.63 7.14 7.81 8.29 8.31 9.00 5.42 5.72 7.13 7.55 <5 <5 <5 <5 6.10 6.19
Zolmitriptan 7.28 7.79 8.85 9.33 9.28 9.97 7.51 7.81 7.13 7.55 <5 <5 <5 <5 6.97 7.06
Naratriptan hydrochloride 7.31 7.82 8.75 9.22 8.62 9.30 7.83 8.13 8.33 8.75 <5 <5 <5 5.08 5.84 5.93
Rizatriptan benzoate 6.81 7.32 7.51 7.99 8.15 8.83 6.48 6.78 6.4 6.82 <5 <5 5.30 5.51 <5 <5
Almotriptan malate 6.23 6.73 7.97 8.45 7.57 8.26 <5 <5 7.15 7.57 <5 <5 <5 <5 6.36 6.46
Eletriptan hydrobromide 8.20 8.71 8.80 9.28 9.31 9.99 6.91 7.21 7.35 7.77 5.42 5.94 6.14 6.35 6.61 6.70
Frovatriptan racemate 6.83 7.34 8.09 8.57 8.10 8.78 <5 5.18 6.50 6.92 <5 <5 <5 <5 6.88 6.97
Donitriptan hydrochloride 7.42 7.93 9.29 9.77 9.18 9.86 5.47 5.77 <5 5.18 5.83 6.35 5.88 6.09 6.12 6.21
Avitriptan fumarate 7.20 7.71 8.32 8.80 8.42 9.11 5.15 5.45 6.69 7.11 5.11 5.63 5.73 5.94 6.03 6.12
Alniditan dihydrochloride 8.81 9.32 8.93 9.41 8.66 9.35 5.98 6.28 6.02 6.44 <5 5.43 6.67 6.88 7.16 7.26
Lasmiditan hemisuccinate 5.88 6.39 5.54 6.02 5.62 6.31 5.54 5.84 8.09 8.51 <5 <5 5.01 5.22 <5 <5
LY334370 hydrochloride 7.98 8.49 6.74 7.21 6.24 6.92 6.83 7.13 9.03 9.45 5.11 5.63 5.98 6.19 5.66 5.75
LY344864 hydrochloride 6.12 6.63 6.13 6.61 5.83 6.52 6.05 6.35 8.38 8.80 5.11 5.63 5.31 5.52 5.69 5.78
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Human isolated arteries 
In the human isolated coronary arteries, sumatriptan induced significant contractions in a concentration 
dependent manner in the proximal (Emax 39±12%, pEC50 6.4±0.2; n=6) and distal (Emax  59±41%, 
pEC50 6.02±0.2; n=6) coronary portions, even at clinically relevant concentrations (Fig. 2). In contrast, 
lasmiditan was devoid of any significant contractile effects in both coronary portions, even at its 
highest concentration. Moreover, Fig. 3 shows the effects of lasmiditan and sumatriptan on internal 
mammary arteries in the absence and presence of endothelium. Sumatriptan induced concentration-
dependent contractions in segments with (Emax 46±18%, pEC50 6.07±0.07; n=5) and without functional 
endothelium (Emax 31±12%, pEC50 5.6±0.94; n=7). After precontraction with threshold concentrations 
of U46619, sumatriptan also produced concentration-dependent contractions in the presence 
(Emax 63±19%, pEC50 6.83±0.05, n=5) and absence (Emax 59±16%, pEC50 6.02±0.59; n=7) of functional 
endothelium. In contrast, lasmiditan was devoid of any significant contractile effects in internal 
mammary arteries, even after a modest precontraction with U46619. 
Fig. 2. Contractile responses to lasmiditan and sumatriptan (1 nM – 100 μM) in the human isolated proximal (left) 
and distal (right) coronary arteries; *P<0.05; n=6 each. 
Fig. 3. Contractile responses to sumatriptan and lasmiditan (1 nM–100 μM) in the absence (left) and presence 
(right) of a threshold precontraction with U46619 (1–10 nM) in human isolated internal mammary arteries with 
(upper panel, n=5) and without (lower panel, n=7) functional endothelium; *P<0.05. 
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Fig. 4. Contractile responses to sumatriptan and lasmiditan (1 nM – 100 μM) in the human isolated middle 
meningeal arteries; *P<0.05; n=6 each. 
 In middle meningeal arteries, sumatriptan induced significant concentration-dependent 
contractions (Emax 73±13%, pEC50 6.32±0.15; n=6), whereas lasmiditan did not induce any 
significant contraction at all concentrations tested (Emax 0±0%, Fig. 4). 
Interaction experiments
As shown in Fig. 5, in human isolated internal mammary arteries, after preincubation with 
lasmiditan (1 μM), no changes in the contractile responses to sumatriptan were observed when 
compared to the concentration-response curve to sumatriptan alone (Emax 59±16%, pEC50 5.34±0.1 
vs. Emax  51±19%, pEC50 5.71±0.7; n=5 each).  In addition, the highest concentration of lasmiditan 
produced a non-significant vasodilation when preincubated with sumatriptan’s clinically relevant 
concentration (0.3 μM) when compared to the concentration-response curve to lasmiditan without 
sumatriptan (Emax -4.8±5.95% vs. Emax 0±0% respectively; n=5 each). 
Fig. 5. Contractile responses to sumatriptan and lasmiditan (1 nM – 100 μM) in the internal mammary artery, 
after preincubation with the clinically relevant concentration of sumatriptan (0.3 μM) or lasmiditan (1 μM), and 
followed by a concentration-response curve to lasmiditan or sumatriptan, respectively (n=6 each).
Correlation between binding (pKi) and the contractile potency of lasmiditan and other triptans 
As shown in Fig. 6, the potency of the compounds tested to contract the human isolated coronary 
artery was positively correlated with their potency to bind the 5-HT1B receptor, whereas it was 
negatively correlated for the 5-HT1F receptor. This was also observed when correlating the pEC50 
values obtained in our second messenger assays and the contractile potency of the compounds 
tested in the human coronary arteries (Suppl. Fig. 3).
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Fig. 6. Correlation between the pKi values obtained in our study and the contractile potency of lasmiditan, 
triptans (sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, frovatriptan, donitriptan, avitriptan) 
and other 5-HT receptors ligands (ergotamine, alniditan, 5 HT, 5-carboxamidotryptamine) in human isolated 
coronary arteries; N.S., non-significant; *P<0.05.
In vivo studies  
In anaesthetized dogs, a directly proportional relationship was observed between lasmiditan and 
sumatriptan cumulative i.v. doses and their plasma concentrations; these latter values were used 
for validating the concentrations used in the in vitro studies (data not shown). Moreover, as shown 
in Fig. 7, changes in carotid artery diameter were not statistically significant in the lasmiditan-
treated group as compared to the time-matched vehicle control group. In contrast, as expected, 
sumatriptan induced dose-dependent decreases in carotid artery diameter, although these effects 
were statistically significant only at the doses of 0.13 mg·kg-1 (clinically relevant) and 11.13 mg·kg-1 
(Fig. 7). In the LCX coronary artery, lasmiditan failed to induce any statistically significant change 
in diameter at any dose. Conversely, statistically significant decreases in the LCX coronary artery 
diameter were observed at all doses in sumatriptan-treated animals as compared to the time-
matched vehicle control animals, even at the lowest dose of 0.03 mg·kg-1, which already corresponds 
to a clinically relevant dose. 
 Carotid blood flow was not significantly different after vehicle or clinically relevant doses of 
lasmiditan (0.03-1.13 mg·kg-1). Lasmiditan decreased carotid blood flow significantly, but only after 
the supratherapeutic cumulative doses of 4.13 mg·kg-1 and 11.13 mg·kg-1. In contrast, sumatriptan 
elicited a statistically significant rapid, dose-dependent, decrease in carotid blood flow at all doses 
tested. Regarding coronary blood flow, the administration of vehicle, lasmiditan or sumatriptan did 
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not elicit any statistically significant changes (data not shown). Heart rate was stable over the course 
of the study and no significant changes were observed in the lasmiditan or vehicle groups. In the 
sumatriptan–treated group, cumulative doses of 4.13 and 11.13 mg·kg-1 elicited dose-dependent 
decreases in heart rate which were statistically significant, with a peak decrease at 90 min of 16.5±6 
bpm (data not shown). MAP, SAP and DAP showed no significant changes in either sumatriptan or 
lasmiditan-treated groups as compared to the time-matched vehicle group at cumulative doses 
of up to 4.13 mg·kg-1. At higher doses, both lasmiditan and sumatriptan-treated groups showed a 
dose-dependent trend to decrease MAP, SAP and DAP; however, these changes were not statistically 
significant (Fig. 7). 
Fig. 7. Changes in the left circumflex (LCX) coronary artery diameter (A), carotid artery diameter (B) and mean 
arterial blood pressure (C) after the continuous infusion of lasmiditan and sumatriptan (0.03-11.13 mg·kg-1 
each) or the corresponding infusion volumes of vehicle in female beagle dogs (n=6 each). *P<0.025 vehicle vs. 
sumatriptan post hoc analysis. 
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Discussion and conclusions 
The current study was designed to investigate the selectivity and vasoconstrictor profile of 
lasmiditan, which belongs to a novel class of acute antimigraine drugs, the ditans. According to 
its binding and functional activity, it was confirmed that lasmiditan is a highly selective agonist 
of the 5-HT1F receptor. Moreover, since lasmiditan was developed based on the premise that 
coronary vasoconstriction is a side effect of the triptans attributed to 5-HT1B receptors, we studied 
the vasoconstrictor potential of 5-HT1F agonism in two different vascular models and compared 
our in vitro and in vivo results to those obtained with sumatriptan, since it is the ‘gold standard’ 
triptan for acute antimigraine treatment. This allowed us to compare the results from the current 
study with results obtained earlier. In accordance with our previous work4, sumatriptan induced 
a concentration-dependent contraction in human isolated coronary arteries, which tended to be 
larger in distal than in proximal coronary artery segments. This contraction was apparent at clinically 
relevant concentrations, and is most likely due to activation of 5-HT1B receptors in vascular smooth 
muscle4. In contrast, lasmiditan did not induce a contraction at concentrations up to 100  µM (≥ 
100x the clinically relevant concentrations) in either proximal or distal coronary arteries. Although 
moderate to intense expression of mRNA encoding the 5-HT1F receptor in human coronary arteries 
has been described16, presence of mRNA does not necessarily mean protein expression, which 
may well be the case. Thus, the physiological role of this receptor in blood vessels remains to be 
determined. 
 Subsequently, we performed more in-depth experiments in the internal mammary artery, 
where we studied the influence of endothelial functional quality, and the effects of a precontraction 
induced by the thromboxane A2 analogue U46619, since such a precontraction is known to 
‘unmask’ or augment contractions to other ligands, such as sumatriptan20. As in the coronary artery, 
sumatriptan contracted the internal mammary artery, similarly in both segments with and without 
functionally active endothelium. In accordance with earlier observations20, the contractions to 
sumatriptan were augmented in the presence of U46619. In contrast, lasmiditan did not induce 
any contraction in the absence or presence of U46619 in either vessel segments with or without 
endothelium. Interestingly, in the rabbit saphenous vein, precontraction with PGF2α unmasked a 
contractile response to the 5-HT1F receptor agonists, LY334370 and LY344864, but only after high 
concentrations (>10 μM), and therefore likely due to activation of vascular 5-HT1B receptors
33. Hence, 
the absence of contractile responses with high concentrations of lasmiditan, even in precontracted 
vessels, is surprising, given the difference in affinity between sumatriptan and lasmiditan to the 
5-HT1B receptor. However, binding affinity does not always correlate with second messenger 
activation and biological response34. Therefore, while our radioligand studies (Table 1) showed 
a ~100-fold binding difference to the 5-HT1B receptor between sumatriptan (pIC50=7.81) and 
lasmiditan (pIC50=5.54), our cAMP assays (Table 2) showed that the functional potency (pEC50) of 
sumatriptan was 7.32 and lasmiditan was <5. As we could not determine the precise pEC50 value 
of lasmiditan, the potency difference between both compounds could be larger than 1000 fold 
and thus, explain the complete absence of vasoconstrictive responses even at supra-therapeutic 
concentrations such as 100 μM. This could represent a cardiovascular safety advantage over its 
triptan predecessors.
 Additionally, as contraction of the meningeal artery is thought to contribute to the antimigraine 
effects of the triptans35-37, but is not a class effect of all anti-migraine drugs (e.g. gepants), we 
investigated the contractions to sumatriptan and lasmiditan in human meningeal arteries. In 
accordance to the previously described craniovascular selectivity of the triptans22, 38, contractions to 
sumatriptan were larger in this dural artery than those in the proximal coronary artery. However, as 
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we have also previously shown, contractions to sumatriptan in distal coronary artery (and internal 
mammary artery) were not significantly different from those in meningeal artery4. In contrast, 
lasmiditan was devoid of vascular effects in this cranial vessel. Therefore, the efficacy of lasmiditan 
as acute migraine treatment may be due to inhibition of CGRP release from perivascular fibres or 
direct central (antinociceptive) modulation37.
 Our binding studies showed that, as mentioned previously, most of the triptans available in 
the market, namely, almotriptan, frovatriptan, naratriptan, sumatriptan and zolmitriptan are also 
agonists of the 5-HT1F receptor (Fig. 1). Furthermore, the correlation between binding and the 
contractile potency of the compounds tested revealed that the potency of the agonists to contract 
the HCA positively correlated to their potency to bind the 5-HT1B receptor, whereas it negatively 
correlated for the 5-HT1F receptor (Fig. 6) and this was also observed when correlating the contractile 
potency and second messenger activation (Suppl. Fig. 3). Moreover, when analyzing the correlation 
between second messenger activation by 5-HT1B vs. 5-HT1F receptors, also a negative correlation 
was observed (Supplementary Fig. 4). These results, together with our in vitro data suggest that, 
although the mRNA of both receptor subtypes has been described in human vasculature4,14-16,22,23,39, 
only activation of the 5-HT1B receptor will result in vasoconstriction of, at least, coronary, mammary 
and meningeal arteries, whereas activation of the 5- HT1F receptor will not. This could suggest 
that 5-HT1F receptors in human vasculature are not functional or, that 5-HT1F receptor mRNA is not 
translated to protein.
 When considering the acute hemodynamic effect of sumatriptan in humans, it is well-known 
that after subcutaneous administration, there are vasopressor responses in the systemic arterial 
circulation and coronary artery vasoconstriction40. Although we observed carotid and coronary 
vasoconstriction in anesthetized dogs, there were no significant increases in blood pressure, as 
previously reported in this animal model41. In fact, after high doses of sumatriptan a non-significant 
tendency to decrease blood pressure and significant decreases in heart rate were observed, most 
probably due to inhibition of vascular and cardiac sympathetic outflows via the stimulation of 
prejunctional 5-HT1B/1D receptors on perivascular
42 and cardiac43,44 sympathetic nerves. Lasmiditan 
only showed a trend to decrease blood pressure at the highest (supratherapeutic dose) which, based 
on the affinity of lasmiditan (see Table 1), could be due to a non-selective activation of prejunctional 
5-HT1D receptors and subsequent inhibition of sympathetic perivascular nerves
42. Admittedly, this 
has not been shown directly in dogs but in pithed Wistar rats and, in patients, no changes in blood 
pressure have been observed45,46. Further experiments, falling beyond the scope of the present 
study, would be required to shed more light on the mechanisms behind these responses, which are 
only observed at non clinically relevant doses.
 In summary, our in vitro and in vivo results indicate that lasmiditan is devoid of contractile 
properties in isolated human and anesthetized dog arteries, respectively. This might be of particular 
relevance in migraine patients who have a high risk of developing cardiovascular disease, such as 
subjects with hemiplegic migraine, prolonged migraine with aura, or with established cardiovascular 
disease. Clearly, further studies are needed to evaluate the safety of lasmiditan in these specific 
patient populations and its effectiveness compared with triptans. Finally, clinical trials have shown 
that lasmiditan is effective for migraine treatment10, suggesting a mechanism of action (partially) 
different to that of the triptans27.
 In conclusion, our data support our initial hypothesis that lasmiditan is a high-affinity and 
highly selective agonist for the human 5-HT1F receptor that is devoid of contractile properties in 
human isolated blood vessels and in anesthetized canines. 
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Suppl. Table 1. Reference tracers (concentration, nM), and reference competitors used for radioligand binding 
competition assays for the different receptors studied. *Historical pIC50 values obtained at Ogeda S.A. (now 
Epics Therapeutics S.A., Gosselies, Belgium). Values represent mean values±SEM of a stated number of averaged 
technical duplicates (n).
Receptor Reference tracer Assay concentration (nM)
Reference 
competitor
Historical* pIC50 
(reference competitor)
Estimated pIC50 
(reference competitor)
pKi (reference 
competitor)
5-HT1A [
3H]-8-OH-DPAT 0.39 5-HT hydrochloride 8.83±0.04 (23) 9.00±0.06 (2) 9.51±0.06 (2)
5-HT1B [
3H]-5-CT 0.60 5-HT hydrochloride 8.42±0.10 (8) 8.61±0.19 (2) 9.09±0.19 (2)
5-HT1D [
3H]-5-CT 0.50 5-HT hydrochloride 8.35±0.08 (7) 8.67±0.18 (2) 9.35±0.18 (2)
5-ht1E [
3H]-LSD 14.0 BRL-54443 8.49±0.09 (5) 8.44±0.07 (3) 8.74±0.07 (3)
5-HT1F [
3H]-LSD 8.00 BRL-54443 8.59±0.17 (5) 8.54±0.12 (3) 8.96±0.12 (3)
5-HT2A [
3H]-Ketanserin 1.48 Ketanserin 8.22±0.18 (6) 8.17±0.04 (2) 8.69±0.04 (2)
5-HT2B [
3H]-Mesulergin 1.00 5-HT hydrochloride 7.67±0.09 (8) 7.68±0.05 (3) 7.89±0.05 (3)
5-HT7 [
3H]-LSD 1.00 5-CT maleate 9.28±0.05 (13) 9.42±0.17 (3) 9.51±0.17 (3)
Suppl. Table 2. Reference agonists for second messenger activation assays of cAMP (5-HT1A/B/E/F and 5-HT7), 
GTPγS (5-HT1D) and IP (5-HT2A/B). *Historical pEC50 values obtained at Ogeda S.A. (now Epics Therapeutics S.A., 
Gosselies, Belgium). Values represent mean values±SEM of a stated number of averaged technical duplicates (n).
Receptor Reference agonist Historical* pEC50 cAMP/IP/ GTPγS
Estimated pEC50 cAMP/
IP/ GTPγS
5-HT1A 5-CT maleate 9.18±0.05 (35) 9.02±0.17 (4)
5-HT1B 5-CT maleate 8.78±0.07 (23) 8.80±0.01 (2)
5-HT1D 5-CT maleate 9.30±0.05 (21) 9.26±0.13 (3)
5-ht1E 5-HT hydrochloride 9.00±0.16 (2) 8.61±0.05 (3)
5-HT1F 5-HT hydrochloride 8.94±0.15 (7) 8.69±0.16 (3)
5-HT2A α-Me-5-HT 8.68±0.05 (31) 8.33±0.06 (2)
5-HT2B α-Me-5-HT 9.70±0.09 (28) 9.63±0.08 (2)
5-HT7 5-CT maleate 9.59±0.03 (45) 9.62±0.01 (3)
Supplementary Table 3. Summary of pEC50 values of vasoconstriction of the human coronary artery. These 
values represent the negative logarithm of the molar concentration of these compounds at which 50% of their 
maximal response was exerted. When a compound was devoid of vasoconstrictor activity, a pEC50 of 5 was set. 
Agonist pEC50 Reference
5-HT hydrochloride 6.50 (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998; Parsons et al., 1998)
5-CT maleate 6.44 (MaassenVanDenBrink, Reekers, Bax & Saxena, 2000)
Ergotamine tartrate 7.81  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998) 
Sumatriptan succinate 6.11  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998) 
Zolmitriptan 6.33  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998) 
Naratriptan hydrochloride 6.78  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998) 
Rizatriptan benzoate 6.36  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998) 
Eletriptan hydrobromide 5.54  (van den Broek et al., 2000)
Frovatriptan Racemate 7.86  (Parsons et al., 1998)
Donitriptan hydrochloride 8.25  (van den Broek et al., 2002)
Avitriptan fumarate 7.06  (MaassenVanDenBrink, Reekers, Bax, Ferrari & Saxena, 1998; Saxena et al., 1997)
Lasmiditan hemisuccinate 5.00
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Suppl. Fig. 2. Functional responses (cAMP assay) to 5-CT in CHO cells transfected with 5-HT1B receptor (upper) 
and in CHO cells transfected with an unrelated G protein-coupled receptor.
Suppl. Fig. 1. Correlation between the pKi values obtained from literature and the pKi values obtained in 
our study for lasmiditan, triptans (sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, 
frovatriptan, donitriptan, avitriptan) and other 5-HT receptors ligands (ergotamine, alniditan, 5 -HT, 
5-carboxamidotryptamine). For references see Suppl. Table 5.
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Suppl. Fig. 3. Correlation between second messenger activation (i.e. cAMP, IP) and the contractile potency of 
lasmiditan, triptans (sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, frovatriptan, 
donitriptan, avitriptan) and other 5-HT receptors ligands (ergotamine, 5 HT, 5-CT) in human isolated coronary 
arteries; N.S., non-significant; *P<0.05.
Suppl. Fig. 4. Correlation between the second messenger activation of 5-HT1B receptor vs 5-HT1F receptor by 
lasmiditan, triptans (sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, frovatriptan, 
donitriptan, avitriptan) and other 5-HT receptors ligands (ergotamine, 5 HT, 5-carboxamidotryptamine) in 
human isolated coronary arteries; *P<0.05.
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PART III:
Prophylactic treatment of migraine

Chapter VI.  
Blocking CGRP in migraine patients – 
a review of pros and cons
Based on: M Deen*, E Correnti*, K Kamm*, T Kelderman*, L Papetti*, E Rubio-Beltrán*, 
S  Vigneri*, L  Edvinsson*, A MaassenVanDenBrink*. On behalf of the European Headache 
Federation School of Advanced Studies (2017) Journal of Headache and Pain; 18:96.
*Authors contributed equally
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Abstract
Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic 
impact. Currently, preventative treatment options for migraine include drugs developed for 
diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, 
however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism 
for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks 
and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons 
of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have 
been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, 
targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy 
and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, 
especially with regards to the antibodies. In addition, the efficacy is in line with other currently used 
prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, 
which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is 
seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present 
in both the vasculature, and in the peripheral and central nervous system, and are involved in several 
physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities 
such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from 
animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic 
functions of the pituitary hormones or attenuate wound healing. However, these effects have so 
far not been reported in human studies. In conclusion, this review suggests that, based on current 
knowledge, the pros of blocking CGRP in migraine patients exceed the cons.
Introduction
Migraine is a highly prevalent and disabling disorder for which treatment options are still inadequate. 
The underlying pathophysiology is largely unknown, but calcitonin gene-related peptide (CGRP) 
most likely plays an important role. The first time CGRP was hypothesized to be involved in migraine 
was in 19851. This hypothesis was later supported by the finding of CGRP release during acute 
migraine attacks and the subsequent demonstration of normalization of CGRP levels in migraine 
patients after efficacious sumatriptan treatment2. In animal studies, triptans also inhibit the release 
of CGRP3. Evidence for a causative role of CGRP in migraine came from a study showing that 
intravenous provocation with CGRP induces migraine-like attacks in migraine patients4.  This led to 
focus on this peptide and its receptor as a possible target for new migraine therapies.
 CGRP and its receptor are expressed in both the peripheral and the central nervous system (CNS), 
including the trigeminovascular pathways. More than 30 years ago CGRP was demonstrated in 
trigeminal ganglion (TG) pseudounipolar neurons5. These neurons connect cranial structures to the 
central nervous system at the lower brainstem, caudal part of the trigeminal nucleus caudalis and 
upper spinal cord at C1-C26. In the peripheral trigeminovascular system, as well as in the TG, CGRP 
is located in about 50% of the neurons and in unmyelinated C fibers, whereas the CGRP receptor 
elements are expressed in about 40% of the TG neurons and in myelinated Aδ-fibers, which connect 
the PNS with the CNS7,8. In humans, CGRP is present in two isoforms, αCGRP and CGRP, where αCGRP 
is most abundantly found in primary spinal afferent from sensory ganglia, whereas βCGRP is mainly 
found in the enteric nervous system6. The CGRP receptor consists of three subunits: receptor activity-
modifying protein 1 (RAMP1), calcitonin-like receptor (CLR) and receptor component protein (RCP)9. 
As well as playing a role in cranial nociception10, CGRP is a potent general arterial vasodilator. At 
peripheral synapses, CGRP is released from trigeminal terminals results in vasodilation via CGRP 
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receptors on the smooth muscle cells of meningeal and cerebral blood vessels8,11. CGRP and its 
receptor are also located in the cardiovascular system where they are assumed to exert a protective 
role9,12.
 The first designer drug able to competitively block the effect of CGRP was olcegepant13. This 
nonpeptide CGRP-receptor antagonist showed high efficacy but had a low oral bioavailability14. This 
led, however, to the synthesis of several other small molecule CGRP receptor antagonists. This class 
was later called the gepants. Though promising with regards to efficacy, further development of 
some of the gepants was discontinued due to liver toxicity upon repeated exposure15. Encouraged 
by the efficacy of blocking CGRP for the treatment of migraine, monoclonal antibodies able to block 
either CGRP or its receptor were developed and tested in several preclinical modalities16,17.  The 
antibodies are designer drugs that are highly specific for the target but about 500 times the size of 
gepants or triptans6. They have been designed for prophylactic use in frequent episodic and chronic 
migraine. In this review, we will discuss the pros and cons of blocking CGRP in migraine patients. 
We will review the efficacy and safety of already tested drugs and compare it to the efficacy and 
safety of topiramate, a widely-used migraine prophylactic. Additionally, we will review the possible 
consequences of blocking CGRP based on findings from animal studies. Lastly, we will discuss other 
concerns such as long-term use and cost of the treatment. 
Efficacy of CGRP (receptor) blockade: Evidence from double-blind, placebo-controlled trials 
In 2004, a proof-of-concept study showed that intravenous olcegepant was effective in the acute 
treatment of migraine18. Since then, five other gepants have been tested for the acute treatment 
of migraine19-31. Fig. 1 provides an overview of the efficacy data for these agents. All gepants 
were significantly better than placebo at achieving their primary outcome at adequate doses: 
pain freedom or relief at 2 hours. Only one study,  a study on safety in coronary patients, could 
not demonstrate difference in pain freedom at 2 hours after telcagepant; however, only 165 of the 
planned 400 patients were included, reducing the statistical power of this study27. 
 Five of these studies also included a comparison to a triptan19,21,26,29,30. In one of these studies, 
telcagepant showed a numerically higher efficacy than rizatriptan with regards to sustained 
pain relief29.  In other trials, the efficacy of telcagepant, BI44370 and rimegepant showed no 
significant difference to that of  zolmitriptan (5 mg), eletriptan (40 mg) and sumatriptan (100 mg), 
respectively21,26,30.  In one large study, assessing the long-term safety of telcagepant, 19820 attacks 
were treated with telcagepant and 10981 attacks with rizatriptan. For two endpoints, pain freedom 
and pain relief at 2 hours, rizatriptan was superior compared to telcagepant (OR < 1 in favor of 
rizatriptan. OR (95% CI): 0.58 (0.45, 0.75) and 0.70 (0.55, 0.89), respectively). For all other pre-specified 
efficacy outcome measurements, no difference was found between the efficacy of telcagepant and 
rizatriptan at 2 hours19. 
 Telcagepant has also been tested as prophylactic treatment of episodic migraine25,28. The first 
of these studies was terminated early due to adverse events and the pre-specified analyses could 
not be performed. However, post-hoc analysis showed telcagepant to be effective at four weeks 
in reducing migraine days25. In the second study, in a population of patients with perimenstrual 
migraine, administration of telcagepant in the perimenstrual period did not result in a significant 
reduction in mean monthly headache days, which was the primary endpoint28. There was a reduction 
of mean monthly on-drug headache days, but the reliability of this analysis is questionable, since no 
correction for multiple comparisons was done.
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Fig. 1. Efficacy of gepants in the acute treatment of migraine. Bars indicated with * represents statistically 
significant values compared to placebo (p<0.05).
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  Antibodies against CGRP or the CGRP receptor have been tested as prophylactic treatment of 
episodic and chronic migraine. To date, four agents have been studied in six clinical studies32-37. 
Fig. 2 provides an overview of the efficacy data of the studies where reduction in migraine days was 
the primary endpoint. All monoclonal antibodies showed a significant reduction in their primary 
endpoint, either mean change from baseline in monthly migraine days (5 studies) or mean change 
in headache hours from baseline (1 study).  These agents had an additional reduction over placebo 
of between 1 and 2.8 migraine days per month. In the study in chronic migraine, where change in 
headache hours was the primary outcome (data not included in the Fig.), the additional reduction 
over placebo was 22.7 and 30.4 hours per month for the two doses tested37. Interestingly, in one study, 
11 of the 67 (16%) patients who had 5 to 14 migraine days per month at baseline, experienced no 
migraine days during the 12 week study period, versus no patients in the placebo group34. In another 
study, 31 of 98 (32%) patients reporting 4 to 15 migraine days at baseline had a 100% response 
(defined as a 28-day migraine free period over the 12-week treatment period). In the placebo group, 
only 18 of 104 (17%) of placebo patients had a 100% response35.  No other studies reported on the 
100% responder rate. Although these data seem interesting, they come from post-hoc analyses and 
so their significance remains unclear. The data from these 20 studies provides robust and consistent 
evidence for a crucial role of CGRP in migraine pathophysiology and a high efficacy of blocking CGRP 
as a prophylactic treatment.
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Fig. 2. Efficacy of monoclonal antibodies in the preventive treatment of migraine. Bars indicated 
with * represents statistically significant values compared to placebo (p < 0.05). (1) had change in mean monthly 
migraine days from baseline to weeks 5-8 as the primary endpoint. All other studies had change in monthly 
migraine days from baseline to weeks 9-12 of the 12-week double-blind treatment phase as the primary 
endpoint. In (1) the drug/placebo was administered intravenously. In all other studies, the drug/placebo were 
given subcutaneously. (2) is on chronic migraine patients. All other studies are on episodic migraine patients.
Is blocking CGRP as or more efficient than current preventative treatments? 
Current preventative treatment options for migraine include antihypertensive drugs, antidepressants 
and antiepileptic medication. In contrast to CGRP (receptor) blockers, these have all been developed 
for diseases other than migraine and it is estimated that less than 50% of patients on prophylactics 
experience a 50% reduction in their monthly attack frequency38.
 Topiramate was proven efficient as a preventative treatment of episodic migraine after 
positive results from three randomized, multi-center, placebo-controlled studies. Thus, topiramate 
is currently recommended as a level A medication for prevention of episodic migraine with 
established efficacy (≥ 2 Class I trials) in the 2012 AHS/AAN guidelines38. Here, we review so far 
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published data from Phase III studies of the monoclonal antibodies39-42 in relation to pivotal studies 
on topiramate43-47 in episodic and chronic migraine. In three phase III studies, including over 
1500 patients, topiramate 100 mg/d significantly reduced the number of monthly migraine days 
compared to placebo (reduction of monthly migraine days about -1.8 to -2.6 for topiramate vs. -1.0 
to -1.3 for placebo). The ≥50% responder rates were also significantly higher for topiramate (37-54% 
vs. 22-23%, respectively)44-46. In the so far available data from Phase III studies of CGRP (receptor) 
antibodies, blocking of CGRP showed a similar efficacy with a reduction of monthly migraine days 
from baseline of -2.9 (verum) vs. -1.8 (placebo) for erenumab (AMG 334)42; -4.3 (300mg)/-3.9(100mg) 
vs. -3.2 (placebo) for eptinezumab (ALD-403)40; -4.0 (120mg)/-3.8 (240mg) vs. -2.15 (placebo) for 
galcanezumab (LY2951742)39 and -3.7 (225mg monthly)/-3.4 (675mg quarterly) vs. -2.2 (placebo) for 
fremanezumab (TEV-48125)41. The ≥50% responder rates were also significantly higher than for 
placebo and similar, albeit a little higher, to those of topiramate, ranging from 56.3% to 62.3% (≥50% 
responder rates: eptinezumab: 56.3% (300mg)/49.8% (100mg) vs. 37.4% (placebo)40; galcanezumab: 
62.3% (120mg)/60.9% (120mg) vs. 38.6% (placebo)39).
 Topiramate has also proven efficacious in patients with chronic migraine47. In two randomized, 
placebo-controlled, double-blinded studies with 387 subjects with a daily dose of 100mg or 
50-200mg topiramate showed a significant reduction in monthly migraine days compared to 
placebo (-6.4±5.8 vs. -4.7±6.1 and -3.5±6.3 vs. 0.2±4.7). The ≥50% responder rate was also significantly 
higher for topiramate (22% vs. 0% for placebo)47. In line with this, blocking of CGRP significantly 
reduced the number of monthly headache migraine days in 1113 chronic migraine patients 
with an average of 19.4 headache days (-4.8(120mg)/-4.6(240mg) vs. -2.7(placebo)). Likewise, the 
≥50% responder rate was significantly higher for the active drug compared to placebo (27.6% 
(120mg)/27.5% (240mg vs. 15.4%)48.
 Another important aspect of medication is the incidence and severity of adverse events. 
Compared to topiramate, adverse events reported from CGRP trials were generally mild and less 
frequent. Upper respiratory tract infection/nasopharyngitis, and injection-site pain have so far been 
the most frequent reported adverse events39-42 (see below for more details). In contrast, reported 
adverse events of topiramate, such as taste disturbance, weight loss, anorexia, fatigue, memory 
problems and paresthesia were more common in the active groups than in the placebo groups. 
Safety issues regarding blocking of CGRP – are there any?
Evidence from clinical studies
Even though the knowledge of the presence and function of CGRP in the CNS is sparse, the function 
in both the peripheral and enteric nervous system is well established and CGRP is expressed widely 
throughout both systems. Thus, a wide variety of possible adverse events could be anticipated 
when blocking CGRP. However, reported adverse events after blocking of CGRP have in general 
been mild to moderate and the incidences have been low. 
 Among the first CGRP receptor antagonists under trial, intravenous olcegepant caused mild to 
moderate adverse events such as paresthesia, nausea, headache, dry mouth and unspecific vision 
disturbances in a minority of patients18. However, more serious adverse events were reported with 
telcagepant and MK-3207, which caused liver toxicity with transient increase of transaminases 
in a small group of included subjects (n=13 for telcagepant) upon repeated doses. This lead to 
discontinuation of the trial program for these molecules15,25. Other non-peptide CGRP receptor 
antagonists such as BI44370TA, BMS-927711, and, most recently, MK-1602 have also been tested. 
For all three molecules adverse events were mild to moderate and the incidence was low and similar 
to the placebo group21,30,31. No liver toxicity was reported for these drugs, and the gepant program 
is thus still ongoing.
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 More recently, great attention has been given to the development and testing of monoclonal 
antibodies (mABs) targeting circulating CGRP or its receptors. Most importantly, none of these drugs 
show liver toxicity. This is in line with the theoretical probability of mABs causing liver toxicity, which 
is very low, since metabolism of mABs do not result in production of toxic metabolites49. In addition, 
despite the potentially harmful inhibition of vasodilation due to CGRP inhibition, no cardiovascular 
concerns have been disclosed with any of these drugs50. In trials, eptinezumab, galcanezumab and 
fremanezumab, monoclonal antibodies which all target CGRP, showed variable percentages of 
adverse events, which in line with the gepants, were mild to moderate (e.g. upper respiratory or 
urinary tract infection, fatigue, back pain, arthralgia, nausea and vomiting). Erenumab, which binds 
to the CGRP receptor, was also safe and well tolerated in a phase 2 trial32. 
 In line with the poor chance of both the non-peptide CGRP receptor antagonists and the 
antibodies crossing the blood-brain barrier (BBB)51, no central side effects have been reported so 
far. Therefore, although crossing of the BBB is likely to occur to some extent, telcagepant has been 
detected in primates cerebrospinal fluid, suggesting its presence in the CNS52, a central effect, and 
side effect, of these drugs seems unlikely. 
Do preclinical studies give reason to be concerned about side effects?
CGRP is an ubiquitous peptide  that is not only involved in migraine, but also in several physiological 
processes12 and in homeostatic responses during pathophysiological conditions (Fig. 3)9,12. As such, 
it is vital to consider the possible side effects caused by the non-selective blockade of α and βCGRP 
with the CGRP (receptor)-antibodies. As discussed in the previous section, the adverse events of the 
Phase II trials were mild32-37, but it should be noted that the duration of these trials is not sufficient to 
see the long-term effects of continuingly blocking CGRP or its receptor. 
 In the cardiovascular system, CGRP is present in nerve fibers that innervate blood vessels53 and 
the heart54,55, and participates in the regulation of blood pressure12,55-57. Furthermore, it has also 
been described to have a role in the maintenance of (cardio)vascular homeostasis during ischemic 
events9 and in tissue remodeling in pulmonary hypertension58. This protective role raises a concern, 
since migraine patients present an increased cardiovascular risk59,60. This topic was recently reviewed 
elsewhere9. Hence, it is important to consider preexisting cardiovascular risk factors in patients (i.e. 
family history, tobacco exposure, obesity) to prevent a possible cardiovascular event.
 Although CGRP participates in inflammatory processes61-63, it has also been associated with 
facilitation of wound healing64. This is thought to be mediated through its ability to promote 
keratinocytes proliferation65, enhance revascularization66, reduce expression of TNF-α and attenuate 
macrophage infiltration67. A consequence of blocking CGRP could thus be alterations in wound 
healing and increased inflammatory responses in skin injuries at the site of injection for the 
antibodies. However, this is a theoretical risk which has so far not been observed in clinical trials. 
 The antibodies against CGRP are not selective for αCGRP but also block βCGRP. The 
gastrointestinal tract is highly innervated by βCGRPergic fibers from the enteric nervous system68,69. 
In fact, animal studies with antibodies against CGRP showed extensive mucosal damage70,71, 
suggesting a role of CGRP in maintaining the mucosal integrity of the gastrointestinal tract. 
Blocking this could thus contribute to inflammatory bowel disease. Gastrointestinal motility is also 
considered to be modulated by CGRP, and administration of this peptide induces a dose-dependent 
biphasic response72, which could lead to episodes of diarrhea or constipation. Furthermore, studies 
with CGRP KO mice have suggested CGRP agonists as a possible treatment for ulcer healing73; 
therefore, monitoring of gastrointestinal complications (i.e. ulcers, constipation) is recommended, 
even though 12 week studies have not reported these. 
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 Finally, since, as mentioned, it is unlikely that the antibodies cross the BBB, and that the BBB 
penetration is changed during migraine attacks74,75, it is important to consider the structures from 
CNS that are not protected by the BBB. Recent studies have demonstrated that the TG, together with 
the pituitary, are outside the BBB76. An effect on the TG could thus, partly, explain the therapeutic 
effect of the antibodies. However, CGRP and its receptor are also expressed in the anterior pituitary, 
suggesting a possible involvement in the regulation of hypothalamo-pituitary tract functions77. 
The exact involvement is still unknown, and further studies are needed to determine the long-term 
effects of blocking CGRP on the homeostatic functions of the pituitary hormones.
Fig. 3. Possible side effects after long-term exposure to CGRP (receptor)-antibodies. An overview of the 
organ systems where CGRP and the receptor are present and possible side effects that could be caused by the 
non-selective blockade of α- and β-CGRP with the CGRP (receptor)-antibodies
Other considerations
Even though blocking of CGRP seems to be an efficacious and safe preventative treatment of 
migraine, there are many other aspects to consider with regards to the pros and cons of blocking 
CGRP in migraine patients. 
 Firstly, the administration of the newly developed monoclonal antibodies is either intravenous 
or subcutaneous. This could potentially cause complications at the injection site, and common 
adverse events in those treated with fremanezumab, galcanezumab and erenumab were indeed 
mild injection-site pain, pruritus and erythema78.  A disadvantage of the intravenous administration 
route is the need of it being administered by a medical doctor. This not only increases the placebo 
response in clinical trials, but does also require for the patient to spend time visiting the clinic – 
increasing the risk of pathologization of the patient. However, the monthly administration, which is 
feasible due to the long half-lives of the medication, could improve adherence and compliance to 
medication, which is a common problem in treating migraine79,80. Additionally, the CGRP antibodies 
seem to show a low risk for drug-drug interactions and hepatotoxicity since they are metabolized 
by degradation into peptides and single amino acids81, which could be important for patients using 
multiple medications.
Chapter VI
 77
 Secondly, as mentioned, the long-term risks of blocking CGRP are still unknown. Even though 
the absence of liver toxicity or other abnormalities in routine blood testing is in support of no 
or low long-term risks78, studies testing the cardiovascular safety of the long-term blockade are 
warranted in order to answer the numerous questions on the possibility of higher risk in cardio- and 
cerebrovascular compromised patients. For example, it is unknown whether blocking CGRP could 
potentially transform transient mild cerebral ischemia into a full-blown brain infarct9 and whether 
these risks are higher in women9,82. To investigate these aspects, future studies should include 
patients with preexisting cardiovascular conditions. 
 Thirdly, the exact site of action of blocking CGRP is still partly unknown and CGRP could exert 
its effects on receptors distinct from the CGRP receptor9. Recently it was put forward that CGRP may 
act on the amylin receptor in TG83 as well as in human coronary arteries84. If this is the case, this could 
pose an additional – unknown – potential risk of wiping out CGRP. We can also only guess whether 
patients not benefitting from receptor blockade would benefit from blockage of the peptide itself. 
Future studies should investigate how to differentiate responders from non-responders.
 Lastly, a disadvantage when using antibodies is the risk of development of antibodies against 
the drug15. Indeed, antidrug antibodies were detected with all four antibodies78, but these did not 
seem to affect efficacy32. However, long-term studies are needed to investigate whether, at long 
term, neutralizing antidrug antibodies will pose a problem for efficacy and safety of blocking CGRP 
with monoclonal antibodies. Finally, it is well known that antibody treatment is costly and the price 
of the drugs has to be taken into consideration when deciding whether to use CGRP antibodies as a 
prophylactic treatment and which patient groups to treat.   
Conclusion
Here, we have reviewed the pros and cons of blocking CGRP in migraine patients. In favor of using 
blocking of CGRP as a treatment of migraine, is that, based on evidence from clinical trials, whether 
using small molecule receptor antagonists or antibodies, the treatment is efficacious. Additionally, 
the liver toxicity induced by some of the gepants is not present with the antibodies, which are well 
tolerated. Lastly, in contrast to current prophylactic treatments, the drugs are developed specifically 
for migraine, based on findings from human migraine studies. Thus, the drugs may exert a more 
direct effect on migraine specific pathways than previously used prophylactic drugs. In addition, this 
provides hope and encouragement for further research into the pathophysiological mechanisms of 
migraine and potentially the discovery of other migraine specific therapeutic targets. 
 Speaking against chronically blocking CGRP, the long-term effects, particularly regarding the 
cardiovascular risks, are still unknown as well as the exact mode of action of the antibodies. In 
addition, development of neutralizing antidrug antibodies may, with time, affect the efficacy of the 
antibodies. Lastly, as with all antibody therapies, CGRP antibodies have the problem of being costly. 
However, taking into consideration the enormous socioeconomically burden that migraine is85, the 
price may be well payed off. 
 In conclusion, based on current knowledge, we believe that the benefits of blocking CGRP, 
including the perspectives of improving the lives of those suffering from frequent headaches, 
seems to be greater than the disadvantages. 
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Chapter VII.  
Is CGRP receptor blockade cardiovascularly safe? 
Appropriate studies are needed
Based on: A Maassen van den Brink, E Rubio-Beltrán, D Duncker, CM Villalón (2018) Headache; 
58:11257-1258
With great interest, we read the publication by Depre and colleagues1 describing that inhibition of 
the canonical CGRP receptor does not seem to worsen myocardial ischemia contrary to theoretical 
concerns2. In a randomized, double‐blind, placebo‐controlled study the authors did not find 
evidence for an adverse effect of the CGRP receptor antibody erenumab on exercise time during 
a treadmill test in patients with stable angina. Although we certainly appreciate the endeavor to 
address this important issue, we are concerned that the study population, the study design, and the 
interpretation of the results do not allow for such a reassuring conclusion.
 While the authors rightly indicate that it is currently not clear to which extent CGRP is relevant 
in maintaining blood flow in case of myocardial and cerebral ischemia, we do not agree with their 
argument stating that “the concentrations of exogenous CGRP required to increase total exercise 
time or protect against myocardial ischemia far exceed the endogenous physiological levels of 
CGRP that are released during a response to ischemia”. This is because it is not the systemic plasma 
concentration that is relevant in this perspective, but the actual concentration of CGRP at the neuro‐
vascular junction, where CGRP is released. Obviously, the plasma concentration is likely to be several 
log units lower than the junctional concentration due to dilution and hydrolysis. Further, we feel that 
the argument that erenumab does not contract the human isolated coronary artery per se3 does not 
add to the introduction, since the question that should be answered here is whether inhibition of 
the actions of CGRP is potentially harmful in myocardial ischemia.
 More importantly, the patients included in this study suffered from stable angina pectoris, 
which often is caused by a stenosis of the epicardial conducting portions of the coronary artery. As 
we pointed out earlier2, the importance of CGRP in the proximal, epicardial portions of the coronary 
artery bed seems limited, while CGRP is a highly effective vasodilator in the intramyocardial, smaller 
(distal) sections of the coronary artery bed. Thus, it is unfortunate that a patient population with, most 
likely, mainly diseased proximal coronary arteries, was chosen for this study, despite the advantage 
of a clear‐cut definition of these patients. Although stable angina pectoris due to epicardial stenosis 
may occur in both men and women, this is typically considered a “male” form of cardiac pathology4, 
as illustrated by the fact that 78% of patients included in the current study were male. In contrast, 
in females, who are the majority of migraine sufferers and thus also the majority of the population 
likely to use erenumab or related drugs in future, coronary artery disease often presents as diffuse 
atherosclerosis, without an angiographically detectable stenosis4-7. These observations indicate 
that coronary microvascular dysfunction plays a more important role in angina pectoris in female 
patients and that blocking the effects of CGRP in female patients may have different effects than in 
male patients.
 An essential concern of this study is based on pharmacokinetic and pharmacodynamic 
considerations. The authors rightly indicate that plasma concentrations obtained 30 minutes after 
intravenous infusion of 140‐mg erenumab (the time interval until the start of the treadmill test) will 
provide “a substantial margin over concentrations achieved by subcutaneous administration of 140 
mg”. In contrast, their claim that “the use of 140 mg intravenous dose of erenumab ensured rapid 
and robust blockade of the CGRP receptor” is not substantiated by any evidence. It should be taken 
into account that, before a receptor blocking antibody can effectively occupy the receptor where it 
is binding to, the antibody should first have access to the receptor biophase. In this case, erenumab 
was infused intravenously and thus reached the blood vessel wall from the luminal side. The CGRP 
receptor is located in the smooth muscle wall5, thus it may take several hours before the receptor 
was reached by erenumab at sufficiently high concentrations to induce an effective blockade of the 
CGRP receptor, especially given the large molecular size (150 kDa) of erenumab. This is well beyond 
the time the treadmill test had finished. A way to verify whether blockade has been achieved (at 
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least in skin blood vessels) is by assessing blockade of capsaicin‐induced increases in dermal blood 
flow. The earliest time point for such measurements that has been published, to the best of our 
knowledge, for erenumab is 2 days after intravenous administration8, which is about 100‐fold longer 
than the period applied in the current study. Thus, we feel that evidence for significant blockade of 
the canonical CGRP receptor should have been provided to substantiate the statement that CGRP 
receptor blockade was reached during the treadmill study, since otherwise the interpretation of the 
current study is questionable.
 Taken together, we would politely urge the authors to provide evidence for the fact that vascular 
CGRP receptor blockade has been achieved 30 minutes after intravenous infusion of erenumab, 
since this is a crucial part of the study. Further, we plead for cardiovascular safety studies on patients 
and/or experimental animals with microvascular disease, as such a group may better represent the 
patients at cardiovascular risk after the use of erenumab. Even if the antibodies against CGRP or its 
receptor would not increase the risk for cardiovascular ischemia, there will be cases of patients with 
ischemic complaints, even without a causal relationship. Appropriate studies in relevant subjects 
may avoid sudden distress, such as happened with the triptans in the past.
References 
1. Depre C, Antalik L, Starling A, et al. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate 
the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache; 
2018;58:715-723.
2. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping Out CGRP: Potential Cardiovascular Risks. 
Trends Pharmacol Sci 2016;37:779-788.
3. Rubio-Beltran E, Labastida A, de Vries R, et al. Effects of AMG 334 on human isolated coronary artery. 
Cephalalgia; 2016: 41-41.
4. Humphries KH, Pu A, Gao M, Carere RG, Pilote L. Angina with “normal” coronary arteries: Sex differences in 
outcomes. American Heart Journal 2008;155:375-381.
5. Maas AHEM, Stam HCG, Eizema K, et al. Red alert for women's heart: the urgent need for more research and 
knowledge on cardiovascular disease in women: Proceedings of the Workshop held in Brussels on Gender 
Differences in Cardiovascular disease, 29 September 2010. European Heart Journal 2011;32:1362-1368.
6. Duncker DJ, Koller A, Merkus D, Canty JM. Regulation of Coronary Blood Flow in Health and Ischemic Heart 
Disease. Progress in Cardiovascular Diseases 2015;57:409-422.
7. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide 
receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther 
2010;334:746-752.
8. Vu T, Ma P, Chen JS, et al. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) 
and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharmaceutical Research 
2017;34:1784-1795.
 85
VII
Is CGRP receptor blockade cardiovascularly safe?

 87
Chapter VIII.  
Characterization of vasodilatory responses 
in the presence of the CGRP receptor antibody 
erenumab in human isolated arteries
Based on: E Rubio-Beltrán, A Labastida-Ramírez, KA Haanes, A vd Bogaerdt, AJJC  Bogers, 
C  Dirven, AHJ  Danser, C Xu, J Snellman and A  MaassenVanDenBrink (2019) Cephalalgia; 
In Press.
88
Abstract
Background: Migraine is associated with activation of the trigeminovascular system, release of 
calcitonin gene-related peptide (CGRP) and dilation of dural arteries. Novel treatments target CGRP 
or its receptor, which are present in all vascular beds, raising cardiovascular concerns. Erenumab is a 
human CGRP-receptor antibody approved for the prophylactic treatment of migraine. 
Methods: We characterized the relaxant responses to CGRP in the absence and presence of erenumab 
(1 μM) in isolated human middle meningeal (HMMA), internal mammary (HIMA) and (proximal 
and distal) coronary arteries (HCA). Furthermore, in HIMA from cardiovascularly-compromised 
patients, we assessed the pharmacological specificity of erenumab by investigating whether 
the vasodilatory responses to acetylcholine, sodium nitroprusside, pituitary adenylate cyclase 
activating polypeptide-38 (PACAP), vasoactive intestinal peptide (VIP) and nicardipine, along with 
the vasoconstrictor responses to dihydroergotamine, were modified by erenumab. 
Results: CGRP induced concentration-dependent vasodilatory responses in all vessels studied that 
were significantly antagonized by erenumab. In HIMA from cardiovascularly-compromised patients, 
the responses to acetylcholine, sodium nitroprusside, PACAP, VIP, nicardipine and dihydroergotamine 
were unaffected by erenumab. 
Conclusion: Erenumab inhibits CGRP-induced vasodilatory responses in HMMA, HIMA and HCA. 
Moreover, erenumab shows functional specificity as no interaction was observed with the relaxant 
responses to several vasodilators, nor the dihydroergotamine-dependent vasoconstrictor responses.
Introduction
Migraine is a highly disabling neurovascular disorder and its pathophysiology remains elusive. 
However, it has been associated with an activation of the trigeminovascular system, release of 
calcitonin gene-related peptide (CGRP) and increase in middle meningeal artery circumference 
specific to the head pain side1. Based on the involvement of CGRP in the pain signalling pathway 
of migraine, small molecule-CGRP receptor antagonists (gepants) were developed for the 
treatment of migraine. The first gepants did not reach the market, due to hepatotoxicity cases 
and pharmacokinetic problems2. Although novel gepants are currently being developed, with no 
reported toxicity so far3, the most recent approach for CGRP blockade consists of the antibodies 
against CGRP (eptinezumab, fremanezumab, galcanezumab) or its receptor (erenumab). They have 
all shown to be effective for the prophylactic treatment of migraine and are either approved or likely 
soon to be approved for commercialization4. 
 While the development of antibodies directed against the CGRP pathway (i.e., antibodies against 
CGRP or the CGRP receptor) represents a milestone in migraine treatment, it is important to also 
consider the implications of peripheral CGRP receptor blockade. To begin with, CGRP fibres innervate 
blood vessels, and are thought to contribute in the homeostatic responses to ischemic events5-7. 
This raises some concerns, especially as migraine patients present increased cardiovascular risk8,9. 
Indeed, all the antibodies have been reported to be well tolerated even in subjects exposed longer 
that one year, with no cardiovascular events reported in the clinical trials that were considered to 
be related to CGRP pathway blockade10. Moreover, a study explored the effect of erenumab on 
exercise time during a treadmill test in mainly male patients with stable angina, and no changes 
were observed11, although no evidence was provided for CGRP receptor blockade to be established 
already at the time of the treadmill test12. In addition, previous studies have also shown that the 
vasodilatory role of CGRP in the coronary arteries is more prominent in the distal portion when 
compared to the proximal portion13. While males are more prone than females to present ischemic 
events in the proximal portion of the coronary artery, females are more prone than men to present 
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myocardial ischemic events in the distal portion of the coronary artery14. As the vast majority of 
migraine patients are female, it is important to study the effects of erenumab in the distal portion 
of the coronary arteries. Also, for migraine patients with established cardiovascular disease, it is 
important to investigate whether blockade of the CGRP pathway could worsen their disease6. Thus, 
appropriate in vitro and in vivo studies are needed to assess the vascular safety of blocking the CGRP 
pathway. 
 The aim of this study was to investigate the inhibition of the vasodilatory responses to CGRP by 
erenumab in human isolated meningeal artery (HMMA), one of the proposed sites of therapeutic 
action. But also, in view of theoretical cardiovascular safety concerns, in human isolated proximal 
and distal coronary arteries (HCA), and in internal mammary arteries (HIMA) from cardiovascularly 
compromised patients undergoing coronary artery bypass grafting surgery. Furthermore, in 
HIMA, we studied the functional specificity of erenumab by comparing the relaxant responses to 
several vasodilators in the absence and presence of erenumab, namely: (i) acetylcholine, coupled 
to endothelium-dependent, nitric oxide-cGMP signalling; (ii) sodium nitroprusside, coupled 
to endothelium-independent, nitric oxide-cGMP signalling; (iii) pituitary adenylate cyclase 
activating peptide-38 (PACAP) and vasoactive intestinal peptide (VIP), peptides of interest for 
migraine pathophysiology that are coupled to an adenylate cyclase-cAMP signalling pathway; 
and (iv) nicardipine, a calcium channel blocker, prescribed for the treatment of hypertension that 
may also be used in migraine. Finally, as migraine patients under prophylactic treatment could still 
use acute antimigraine medication, the vasoconstrictor responses to dihydroergotamine (DHE) in 
absence and presence of erenumab were also analyzed, to discard a possible augmentation of the 
contractile responses due to the inhibition of the CGRP-mediated vasodilation.
Methods
Human isolated arteries collection
Middle meningeal arteries
Segments of HMMA (internal diameter 0.5–1.5 mm) were obtained from six patients (two male and 
four female, 49±8 years old) who underwent neurosurgical procedures requiring a trepanation of 
the skull. The HMMA, attached to the dura mater, was collected in a sterile organ-protecting solution 
and immediately transported to the laboratory to be dissected and subsequently placed in a cold, 
oxygenated Krebs solution of the following composition (mM): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 
1.2, KH2PO4 1.2, NaHCO2 25 and glucose 11.1; pH 7.4.
Coronary arteries
Coronary arteries were obtained from six “heart beating” organ donors (two male and four female; 
52±5 years old), who died of non-cardiac disorders. The hearts were provided by the Heart Valve 
Bank Beverwijk (at that time still located in Rotterdam) from Dutch post-mortem donors, after donor 
mediation by The Dutch Transplantation Foundation (Leiden, The Netherlands), following removal 
of the aortic and pulmonary valves for homograft valve transplantation. All donors gave permission 
for research. Immediately after circulatory arrest, the hearts were stored at 4°C in a sterile organ 
protecting solution and were brought to the laboratory within 24 hours of death. After arrival, the 
right proximal (internal diameter 3–5 mm) and distal (internal diameter 0.5–1 mm) portions of the 
HCA were dissected and placed in a cold, oxygenated with carbogen (95% O2/5% CO2) Krebs buffer 
solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 8.3; pH 7.4. The studies on coronary arteries were approved by the Scientific 
Advisory Board of the Rotterdam Heart Valve Bank.
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Internal mammary arteries
Segments of HIMA (internal diameter 2–3 mm) were obtained perioperatively from 10 male patients 
(72±2 years old) undergoing coronary artery bypass surgery. After completion of the coronary 
bypass procedure, the remaining segment of HIMA was immediately brought to the laboratory. 
Connective tissue was removed from the segment and the tissue was kept in cold Krebs solution 
(for composition see above), aerated with carbogen. All vessels were used on the same day or stored 
overnight and used the following day for functional experiments. The Medical Ethics Committee of 
the Erasmus Medical Centre, Rotterdam, approved the study protocols with regard to mammary 
arteries and middle meningeal arteries.
Isometric tension measurements
Proximal HCAs were cut into segments of 2–4 mm length, excluding macroscopically visible 
atherosclerotic lesions. Segments were mounted on stainless steel hooks in 15-mL organ baths filled 
with oxygenated Krebs buffer solution at 37°C. After 30 min of stabilization, the vessel segments 
were stretched to a tension of about 15 mN, as described earlier by our group13. Changes in tension 
were measured with an isometric force transducer (Harvard, South Natick, MA, U.S.A.) and recorded 
on a flatbed recorder (Servogor 124, Goerz, Neudorf, Austria).
 The HMMA, distal HCA and HIMA were cut into circular 1-2 mm long segments and mounted 
in Mulvany myographs (Danish Myo Technology, Aarhus, Denmark) between two parallel small 
stainless-steel wires (40 µm Ø). Baths were filled with oxygenated Krebs buffer (37°C) and their 
tension was normalized to 90% of l100 for all segments (the diameter when transmural pressure 
equals 100 mm Hg) as previously reported15. Data was recorded using a LabChart data acquisition 
system (AD Instruments Ltd, Oxford, UK).
Experimental protocols
A paired parallel set up (i.e. experiments with and without erenumab were performed in different 
segments obtained from the same artery) was used. Initially, all segments were exposed to 30 mM KCl 
to ‘prime’ the tissue for stable contractions. After washout, the tissue was exposed to 100 mM KCl 
to determine the reference contractile response. All segments were pre-contracted with 30 mM KCl 
after being incubated with vehicle or erenumab (1 µM)16 for 15 min. After 15 min of precontraction 
(i.e., after a total incubation time of 30 min for erenumab), a concentration response curve to human 
αCGRP (0.1 nM-1 µM, half logarithmic steps) was performed. 
 Additionally, in HIMA, after segments were pre-contracted (30 mM KCl) and incubated with 
vehicle or erenumab (1 μM), concentration response curves to acetylcholine (0.1 nM-3  µM, half 
logarithmic steps), sodium nitroprusside (1 nM-10 µM, half logarithmic steps), PACAP (0.1 nM-1 µM, 
whole logarithmic steps), VIP (0.1 nM-1 µM, whole logarithmic steps), or nicardipine (1 nM-30 µM, 
whole logarithmic steps) were performed. Also, in vessels incubated 30 min with vehicle or 
erenumab (1 μM), a concentration response curve to DHE (1 nM-100 µM, whole logarithmic steps) 
was performed. 
 Finally, at the end of each experiment, i.e., after construction of a concentration response curve, 
and washing out, the functional integrity of the endothelium was verified by observing relaxation 
to bradykinin (1 µM, HIMA) or substance P (10 nM, HMMA and HCA) after precontraction with the 
thromboxane A2 analogue U46619 (10 nM) in every individual vessel segment.
Statistical analysis
Vasodilatory responses were expressed as percentage of the precontraction induced by 30 mM KCl. 
For contractile responses, the values were expressed as percentage of the contraction induced by 
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100 mM KCl. Curves covering the full sigmoidal range were analyzed by means of a computerized 
curve fitting technique to obtain pEC50 (negative log of the molar concentration of an agonist needed 
to reach half of its maximal effect) and Emax (maximal response) values. If Emax was not reached, the 
contraction or relaxation obtained at the highest concentration of agonist was considered as Emax, 
except for CGRP in the presence of erenumab, where the respective control Emax (i.e., in the absence 
of erenumab) was used as Emax for fitting. The blocking potency of erenumab in each tissue was 
estimated by calculating EC50 ratios and plotting a Schild plot 
17 and constraining the slope to unity 
to obtain the apparent pKb values. All data are presented as mean±S.E.M. Significant differences 
in pEC50 and Emax between control and erenumab groups were examined with a paired t test. 
Differences between tissues were analyzed by a one-way analysis of variance (ANOVA), followed 
by Tukey’s post hoc analysis. P values of 0.05 or less were assumed to denote significant changes. 
Compounds used
Erenumab and vehicle were kindly provided by Amgen (Thousand Oaks, CA, U.S.A.). Acetylcholine 
chloride, sodium nitroprusside, nicardipine hydrochloride, dihydroergotamine mesylate and 
U46619 were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Human α-CGRP, PACAP and 
VIP were obtained from PolyPeptide (Strasbourg, France).
Results
Responses to 100 mM and 30 mM KCl resulted in a mean contraction of 19±4 mN and 17±3.1 mN, 
respectively. 
Effect of erenumab on the vasodilatory responses to CGRP in human isolated middle meningeal 
arteries
In HMMA (Fig. 1), the vasodilatory responses to CGRP were significantly shifted in the presence 
of 1 μM erenumab (control: pEC50 8.56±0.16 vs. erenumab: pEC50 6.51±0.19; n=6 each; t(5)=16.74, 
p<0.0001). The apparent pKb value was 8.05±0.12. No significant changes were observed in 
the maximal responses to CGRP (control: Emax 64±11% vs.  erenumab Emax:  56±10%; n=6 each; 
t(5)=2.11, p=0.088). Verification of endothelial function resulted in a mean dilation of 83±3% of the 
precontraction. 
Fig. 1. Relaxant responses to CGRP in the middle meningeal artery in the presence of erenumab (1 μM) or the 
vehicle. Data are expressed as mean±SEM, n=6. 
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Effect of erenumab on the vasodilatory responses to CGRP in human isolated coronary arteries
Relaxant responses to CGRP in the proximal HCA (pEC50<6.54; n=4), were inhibited in the presence of 
1 μM erenumab (pEC50<5.24; n=4), with no significant change in the response obtained at the highest 
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Fig. 2. Relaxant responses to CGRP in the proximal (left) and distal (right) coronary arteries in the presence of 
erenumab (1 μM) or the vehicle. Data are expressed as mean±SEM, n=4-6. 
Effect of erenumab on the vasodilatory responses to CGRP in human isolated internal mammary artery
In HIMA, the vasodilatory responses to CGRP were also significantly inhibited by erenumab (control: 
pEC50  7.83±0.34 vs. erenumab: pEC50 5.94±0.37; n=8 each; t(7)=4.18, p=0.004), with an apparent 
pKb value of 7.85±0.46, and no significant change in the maximal response was observed (control: 
Emax 32±12% vs. erenumab:  24±10%; n=8 each; t(7)=1.44, p=0.19; Fig. 3). Verification of endothelium 
function resulted in a dilation of 6±3% of the precontraction. Precontraction with 30 mM KCl was 
not modified by erenumab (control: 154±47% vs. erenumab 141±22% of the contraction to 100 mM 
KCl; t(7)=0.47, p=0.66; data not shown).
Fig. 3. Relaxant responses to CGRP in the human isolated internal mammary artery in the presence of 
erenumab (1 μM) or the vehicle. Data are expressed as mean±SEM, n=8. 
concentration (control: Emax 36±6% vs. erenumab: Emax 21±3%; t(3)=1.86, p=0.15). Due to the limited 
effect of CGRP on the proximal portion of the HCA, no apparent pKb value was calculated. In the distal 
HCA, a significant shift was observed in the vasodilatory responses to CGRP (control: pEC50 9.04±0.18 
vs. erenumab: pEC50 6.81±0.18; n=6 each; t(5)=13.46, p<0.0001), with no change in the maximal 
relaxation (control: Emax 85±5% vs. erenumab: Emax 83±6%; n=6 each; t(5)=0.88, p=0.42; Fig. 2) and 
an apparent pKb value of 8.22±0.17. A significant difference was observed between the maximal 
relaxation to CGRP in proximal and distal HCA (Emax proximal: 36±6% vs. Emax distal: 85±5%; t(8)=4.95, 
p=0.001). Endothelial function analysis resulted in a mean dilation of 12 ± 3% of the precontraction 
in proximal HCA and of 89 ± 4% in distal HCA.
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Effect of erenumab on non-CGRP induced vasodilatory responses in human isolated mammary 
artery
The relaxant responses to the different vasodilators studied were not modified in the presence of 
erenumab (Table 1, Fig. 4)
Fig. 4. Vasodilatory responses to acetylcholine, sodium nitroprusside, VIP, PACAP and nicardipine in the human 
isolated internal mammary artery in the presence of erenumab (1  μM) or the vehicle. Data are expressed as 
mean±SEM, n=7 each.
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Table 1. Vasodilatory responses to acetylcholine, sodium nitroprusside, VIP, PACAP and nicardipine in the HIMA 
in the absence and presence of erenumab; n=7 each. 
Agonist
pEC50 Emax (%)
Control Erenumab P value Control Erenumab P value
Acetylcholine 7.42±0.96 6.22±0.45 0.66 14±4 11±6 0.57
Sodium nitroprusside 6.31±0.29 6.44±0.44 0.98 50±13 50±14 0.97
VIP 6.83±0.11 7.05±0.45 0.29 25±10 21±3 0.69
PACAP 6.78±0.01 7.00±0.21 0.28 17±7 14±4 0.63
Nicardipine 5.77±0.24 5.49±0.06 0.23 72±9 68±11 0.49
Emax: maximal response; PACAP: pituitary adenylate cyclase activating polypeptide-38; pEC50: negative log of the 
molar concentration of an agonist needed to reach half of its maximal effect; VIP: vasoactive intestinal peptide
Effect of erenumab on the contractile responses to dihydroergotamine
Similar to above, contractile responses to DHE (pEC50 control: 6.78±0.40 vs. pEC50  erenumab: 
6.65±0.40, t(6)=0.41, p=0.72; Emax control: 11±6% vs. Emax erenumab: 17±12%, t(6)=0.66, p=0.53; n=7 
each) were unaffected by the presence of erenumab (Fig. 5).
Fig. 5. Contractile responses dihydroergotamine (DHE) in the human isolated internal mammary artery in the 
presence of erenumab (1 μM) or the vehicle. Data are expressed as mean±SEM, n=7 each.
Comparison of the responses to CGRP in human middle meningeal, coronary and mammary 
arteries
The vasodilatory responses to CGRP were more potent in the distal portion of the HCA when 
compared to the HIMA (pEC50 9.04±0.18 vs. pEC50 7.83±0.34, respectively; F(2,17)=5.471, 
papparent=0.01). No significant differences were observed in the potency between HMMA and HIMA 
(pEC50 8.56±0.16 vs. pEC50 7.83±0.34, respectively; F(2,17)=5.471, papparent=0.15), nor between HMMA 
and the distal portion of the HCA (pEC50: 8.56±0.16 vs. pEC50: 9.04±0.18, respectively; F(2,17)=5.471, 
papparent=0.47).
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 When comparing the Emax, the vasodilatory responses to CGRP were more pronounced in the 
distal portion of the HCA, when compared to the HIMA (Emax distal HCA: 85±5% vs. Emax HIMA: 32±12%; 
F(3,20)=6.302, papparent=0.004). No significant differences were observed between the maximal 
responses to CGRP in HMMA and HIMA (Emax HMMA: 64±11% vs. Emax HIMA: 32±12%; F(3,20)=6.302, 
papparent=0.112) nor HMMA and distal HCA (Emax HMMA: 64±11% vs. Emax distal HCA: 85±5%; 
F(3,20)=6.302, papparent=0.47). Also, no significant differences were observed between the maximal 
vasodilatory response to CGRP in proximal HCA and HIMA (Emax proximal HCA: 36±6%  vs. Emax HIMA: 
32±12%; F(3,20) = 6.302, papparent=0.991) nor proximal HCA and HMMA (Emax proximal HCA: 36±6% vs. 
Emax HMMA: 64±11%;  F(3,20)=6.302, papparent=0.311)
 Finally, no significant difference was observed in the potency of erenumab to antagonize the 
responses to CGRP amongst the tissues studied (p=0.73; pKb HMMA: 8.05±0.12 vs. pKb HCA: 8.22±0.17, 
F(2,17)=0.3106, papparent=0.94; pKb HMMA: 8.05±0.12 vs. pKb HIMA: 7.85±0.46, F(2,17)=0.3106, 
papparent=0.91; pKb HCA: 8.22±0.17 vs. pKb HIMA: 7.85±0.46, F(2,17)=0.3106, papparent=0.72).
Discussion
In this study the inhibition of the CGRP-vasodilatory responses by erenumab was examined in 
human isolated arteries.  We used a supratherapeutic concentration of erenumab (1 μM)16 to allow a 
clear analysis of its effects on CGRP as well as other vasoactive substances of interest.
 Firstly, we investigated the effect of erenumab on the vasorelaxant responses to CGRP in 
HMMA, with our results showing a significant shift of the concentration response curve to CGRP 
in the presence of erenumab. As antibodies are considered to have a BBB permeability of < 0.1%18 
and erenumab has been shown to be effective for the prophylactic treatment of migraine19,20, it is 
considered that the mechanisms of action of erenumab are peripheral, with one of them being 
possibly inhibition of the CGRP-mediated vasodilation of the dural arteries1. While erenumab has 
no vasoconstrictive properties per se21, its success as prophylactic treatment may well be (partly) 
by effectively preventing the vasodilatory responses to CGRP in the HMMA, associated with the 
onset of migraine attacks. In accordance with this, human provocation studies have shown dilation 
of the HMMA on the headache side at migraine onset, and headache relief after vasoconstriction 
of the HMMA by sumatriptan1,22. Certainly, these studies have been performed during exogenously 
provoked migraine-like attacks and a magnetic resonance angiography study of the intracranial 
and extracranial arteries in patients with spontaneous migraine attacks failed to show extracranial 
arterial dilatation23. However, as previously addressed by our group24, in the latter study authors 
could not exclude dilatation of dural branches of the HMMA, as those small branches could not be 
analyzed due to technical limitations. 
 Due to the theoretical cardiovascular concerns of blocking the actions of CGRP6,25, especially 
since migraine patients have an increased cardiovascular risk8,9, we further studied the effect of 
erenumab in proximal and distal HCA (Fig. 2). Although it has been shown that erenumab does 
not contract the HCA21, it is important to consider the risks of the blockade of the cardioprotective 
vasodilation by CGRP7. In our study, and in accordance with previous work13,26,27, the vasodilatory 
responses to CGRP in the distal portion of the HCA were significantly more pronounced than in 
the proximal portion of the HCA and HIMA. Moreover, in the presence of erenumab, a significant 
shift was observed in both portions of the HCA, that seemed to be more pronounced in the distal 
portion. This reinforces the importance of appropriate vascular safety studies in migraine patients, 
with especial emphasis in female patients that are more prone to present ischemic events in the 
distal portion of the coronary arterial bed, where the role of CGRP in cardioprotection seems to be 
more significant7,12,14. 
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 Furthermore, we analyzed the effect of erenumab on isolated arteries from cardiovascularly 
compromised patients. For this, we obtained HIMA peri-operatively from coronary artery bypass 
surgery patients, most of them suffering from atherosclerotic disease that is usually more prominent 
in the proximal HCA and more common in men as previously mentioned, thus all our experiments 
were performed in HIMAs obtained from male subjects.  However, while the responses to CGRP are 
more pronounced in the distal coronary artery (where women are more prone to present ischemic 
events), as previously mentioned, when a patient undergoes coronary bypass surgery, a portion 
of HIMA is grafted and thus gets incorporated in the proximal coronary arterial bed, making it a 
relevant tissue to study the characteristics of the CGRP-mediated vasodilatory responses and the 
effects of erenumab. Based on the limited relaxation to bradykinin that was analyzed in every 
individual HIMA segment, and in accordance with the small vasodilatory responses to acetylcholine 
(Fig. 4), functional endothelial quality was limited in these coronary artery bypass grafts, probably 
associated with the endothelial dysfunction associated with cardiovascular disease28. When 
analyzing the responses to CGRP, a concentration-dependent vasodilation was observed, which was 
significantly antagonized in the presence of erenumab, with no change in the maximal response. 
The Emax of CGRP in the HIMA was significantly lower when compared to the distal portion of the 
HCA and not significantly different when compared to the proximal HCA (Figs. 2-3), suggesting a 
similar role for CGRP in HIMA and proximal HCA. The vasodilatory peptides VIP and PACAP, currently 
considered possible therapeutic targets for migraine29, do not seem to play an important role in 
HIMA vasodilation as their maximal response was rather low. Most importantly, erenumab did not 
modify the responses to acetylcholine and sodium nitroprusside (nitric oxide-cGMP signalling), nor 
the vasorelaxant responses to PACAP and VIP (adenylate cyclase-cAMP signalling). Even though the 
cardiovascular safety concerns are theoretical and trials have not reported cardiovascular events 
that were considered to be related to inhibition of the CGRP pathway10, the vasodilatory responses 
to acetylcholine, VIP and PACAP in our study were limited. Therefore, further studies should address 
the vasodilatory pathways involved in ischemic conditions after long-term blockade of the CGRP 
pathway. Nonetheless, erenumab did not modify the vasodilatory responses to nicardipine, an 
antihypertensive given to cardiovascularly compromised patients (Fig. 4), and did not augment the 
vasoconstrictor responses to 30 mM KCl or DHE, an acute acting antimigraine drug that could be 
taken concomitantly with erenumab (Fig. 5). Similar results have previously been reported in HCA 
with sumatriptan21, which is of great importance for patients under ergot (or triptan) treatment. 
 Finally, as the efficacy and potency of the CGRP-dependent vasodilatory responses differ 
amongst arteries13, CGRP receptor blockade by erenumab could also present differential responses 
depending on the vessel studied; however, erenumab had a similar potency (pKb) across the distal 
HCA (8.22±0.17), HMMA (8.05±0.12) and HIMA (7.85±0.46). When comparing these results to the 
gepants, similar pKb values were obtained previously by our group for telcagepant in distal HCA and 
HMMA (8.43±0.24 and 8.03±0.16, respectively)13,26. Interestingly, olcegepant was more potent in 
HMMA (pKb: 10.59±0.54) than in the distal portion of the HCA, with pKb values ranging from 8.41±0.26 
to 9.29±0.34, depending on the concentration studied30,31. While we do not know the reason for this 
discrepancy, it may well be caused by an underlying heterogeneity in CGRP receptors that could 
be targeted by olcegepant30,32,33, whereas erenumab only acts at the canonical CGRP receptor34, 
thus, receptors other than the CGRP receptor to which CGRP may still bind (e.g. amylin 1 receptor), 
may compensate for blockade of the CGRP receptor. Conversely, in the case of the antibodies 
directed against CGRP, peptides other than CGRP that may also bind to the CGRP receptor, may 
exert compensatory effects. Further studies should address whether there are clinically relevant 
differences (i.e. in efficacy or cardiovascular safety), between the prophylactic treatment with the 
antibodies directed against CGRP and against the CGRP receptor.  
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 Our results, taken together, show a differential response profile to CGRP in human isolated 
arteries, being more potent in the distal portion of the HCA, when compared to the proximal portion 
and the HMMA and HIMA. Moreover, erenumab significantly inhibits CGRP-mediated vasodilation 
in vitro and does not interact with responses to other vasodilatory or contractile agents of interest.
Conclusion
In conclusion, erenumab is a potent inhibitor of the vasodilatory responses to CGRP in HMMA, 
HCA and HIMA. While the prominent role of CGRP in distal coronary artery warrants further safety 
studies, particularly in women, it is important to point out that erenumab does not interact with 
vasodilatory responses to other vasodilators, nor with the contractions to DHE.
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Abstract
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed 
neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. 
Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has 
not been fully elucidated.
 Migraine is a neurovascular disorder, recognized as the second most disabling disease. 
Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the 
only prophylactic treatment developed specifically for migraine. These antibodies have displayed 
positive results in clinical trials, but are not effective for all patients; therefore, new pharmacological 
targets need to be identified. 
 Due to the ability of PACAP38 to induce migraine-like attacks, its location in structures previously 
associated with migraine pathophysiology and the 100-fold selectivity for PAC1 receptor when 
compared to VIP, new attention has been drawn to this pathway and its potential role as a novel target 
for migraine treatment. In accordance with this, antibodies against PACAP38 (ALD 1910) and PAC1 
receptor (AMG 301) are being developed, with AMG 301 already in Phase II clinical trials. No results 
have been published so far, but in preclinical studies, AMG 301 has shown responses comparable to 
those observed with triptans. If these antibodies prove to be effective for the treatment of migraine, 
several considerations should be addressed, for instance, the potential side effects of long-term 
blocking of the PACAP (receptor) pathway. Moreover, it is important to investigate whether these 
antibodies will indeed represent a therapeutic advantage for the patients that do not respond the 
CGRP (receptor)-antibodies.
 In conclusion, the data presented in this review indicate that PACAP38 and PAC1 receptor 
blockade are promising migraine therapies, but results from clinical trials are needed in order to 
confirm their efficacy and side effect profile. 
Discovery of PACAP
The description of the pituitary adenylate cyclase activating polypeptide-38 (PACAP38) was made by 
Arimura and his team in 1989, following the extraction of the peptide from more than 4000 samples 
of ovine hypothalamus. After the isolation, its characterization showed that it was formed by 38 
amino acids, with a 68% homology with the vasoactive intestinal peptide (VIP), described almost 
twenty years earlier1. Subsequently, the peptide was synthesized and shown to activate adenylyl 
cyclase (AC) in cultures of rat pituitary cells, thereby obtaining its name as pituitary adenylate 
cyclase activating polypeptide. A year later, a fragment of PACAP38 with similar AC activation 
profile was isolated. This was formed by 27 amino acids and thus named PACAP272. That same year, 
cloning of cDNA from ovine PACAP38 revealed that the amino acid sequence of the mature human 
PACAP38 was identical to that of the ovine. In addition, later studies showed that it was identical in 
all mammals3, suggesting that it has been conserved during evolution.
 This review will give an overview of PACAP, its complex signaling pathway, the role PACAP 
and its receptors have in physiological conditions and their involvement in some disorders, with 
special focus on migraine. Moreover, the preclinical results of PACAP (receptor) blockade in migraine 
models, the side effects that could be expected in clinical trials, and the considerations that must be 
taken if PACAP (receptor)-antibodies are effective for migraine treatment will be discussed. 
Pharmacology
PACAP belongs to a wider group of peptides called the VIP/glucagon/growth hormone releasing 
factor/secretin superfamily. The ADCYAP1gene, located on chromosome 18, encodes PACAP; 
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initially, a proprotein is expressed, and later processed to form a 38 amino acid peptide (PACAP38) 
with a cleavage-amidation site that can generate a 27-residue-amidated fragment (PACAP27). In 
mammals, the most prevalent form is PACAP384, therefore, in this review PACAP38 will be referred 
as PACAP unless stated otherwise. 
 Three PACAP receptors have been described: VPAC1, VPAC2 and PAC1, all coupled to G-proteins 
(Fig. 1). VPAC1 and VPAC2 receptors present equal affinity for PACAP and VIP and their activation 
stimulates AC. On the other hand, PAC1 receptor is 100 times more selective for PACAP and presents 
a complex signaling pathway4. 
 Alternative splicing of the PAC1 receptor gene results in several isoforms. These receptor variants 
are characterized by shorter extracellular domains (PAC1short, PAC1veryshort), different inserts in 
an intracellular loop important for G-protein interaction (PAC1null, PAC1hip, PAC1hop1, PAC1hop2, 
PAC1hiphop1, PAC1hiphop2) and/or discrete sequences located in transmembrane domains II and 
IV (PAC1TM4)
5-8. Of relevance, in humans, twelve homologues have been reported7,9-11, and have 
been reviewed elsewhere12,13. For each splice variant, PACAP38 and PACAP27 present similar affinity 
and potency for AC and phospholipase C (PLC) stimulation, but different efficacy (i.e. maximal 
effect) of PLC responses14,15.  Although in several processes the activation of AC or PLC can result in 
similar “stimulatory” responses, in smooth muscle cells (e.g. blood vessels), activation of AC leads 
to vasodilation, whereas PLC activation results in vasoconstriction. This plays an important role in 
disorders such as migraine, where expression of a PAC1 receptor isoform with a lower PLC efficacy 
could favor AC stimulation, thus facilitating vasodilatory responses in cranial blood vessels16,17.
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Fig. 1.  PACAP receptors. Three receptors to PACAP have been described: VPAC1, VPAC2 and PAC1. VIP and PACAP 
show similar affinity for VPAC1 and VPAC2, whereas PACAP is 100-fold more selective for PAC1 receptor. The 
antibodies developed for prophylactic migraine treatment bind either to PACAP (PACAP38, ALD1910) or to the 
PAC1 receptor (AMG 301).
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 To study PAC1 receptor-mediated responses, selective agonists and antagonists are used. 
Currently, one selective agonist has been described, maxadilan18,19 and three antagonists M65, 
Max.d.4 and PACAP6-3820. However, no study has investigated whether such compounds are 
selective for one PAC1 receptor variant, or whether they bind to all isoforms. Moreover, PACAP6-38 
also binds to the VPAC2 receptor, and, together with M65, have been shown to behave as agonists of 
the PAC1 receptor in certain tissues
21,22. Hence, novel selective pharmacological tools are needed to 
characterize PAC1 receptor-mediated responses. Indeed, an antibody against PAC1 receptor, such as 
AMG 301, could be useful for characterization; however, it is yet not clear if this antibody is selective for 
one specific variant. If the antibody would be selective for one of the splice variants, this may affect its 
therapeutic potential, in particular if there are different splice variants expressed in different human 
populations. On the other hand, different splice variants might hypothetically offer the possibility 
of designing a drug that would selectively affect the PAC1 receptor in the trigeminovascular system, 
while not affecting PAC1 receptors at other sites in the body, thus reducing its potential side effects.
Physiological roles of PACAP and PAC1 receptor
Preclinical studies have shown that PACAP and PAC1 receptors are widely distributed, both 
centrally and peripherally. It is therefore not surprising that it is described as a (neuro)hormone, 
neurotransmitter, neuromodulator, neurotrophic factor and immunomodulator13. As the PAC1 
receptor is currently under investigation for migraine treatment, only the distribution of this receptor 
will be reviewed, while the distribution of VPAC1/2 receptors is reviewed extensively elsewhere
13,23,24.
PACAP/PAC1 receptor in the central nervous system
PACAP fibers and PAC1 receptors are widely expressed throughout the central nervous system (CNS) 
with the highest density of both in the hypothalamus and supraoptic nucleus25-31. In accordance 
with this, PAC1 receptor activation has been associated with release of vasopressin and regulation 
of drinking behavior32,33, decrease of food intake34-36, modulation of the sleep/wake cycle37,38, clock 
gene expression38, melatonin synthesis stimulation39, sexual maturation40,41, stress and sexual 
behavior41,42, learning43, pain processing44  and psychomotor responsiveness45 . 
 Of special interest for migraine, both PACAP fibers and the PAC1 receptor are present in the 
paraventricular nucleus of the hypothalamus, the ventrolateral periaqueductal gray, the locus 
coeruleus, the solitary nucleus, the trigeminal nucleus caudalis (TNC) and the trigeminal ganglion (TG). 
These structures have all been associated with nociception and/or migraine pathophysiology23,46-49. 
PACAP/PAC1 receptor in the periphery 
Peripherally, PACAP fibers and/or cell bodies have been described in acrosome caps of primary 
spermatocytes, mature spermatids, in the testis, epithelial cells from epididymal tubules, the ovaries, 
mammary glands, in stromal stem cells and terminal placental villi, and the amount of PACAP mRNA 
increases with the progression of pregnancy50-52. Similarly, PAC1 receptors have been described in 
spermatids, the penile corpus cavernosum, the ovaries, the chorionic vessels and in stromal and 
decidual cells of the placenta51,53-55.  Considering the presence of PACAP and PAC1 receptors also in 
hypothalamus and pituitary, an important role in modulation of the hypothalamo-pituitary-gonadal 
axis is suggested. 
 PACAP fibers and cell bodies are also found in the adrenal gland, pancreas, epithelium and 
smooth muscle cells of the urinary tract, the bladder, urethra, larynx, lungs, gastrointestinal 
smooth muscle cells, duodenal mucosa, thymus, spleen and innervating vascular smooth muscle 
cells23,26,56-67. PAC1 receptors have been described in the adrenal medulla, pancreas, liver, lungs, 
enterochromaffin-like cells, thymus and vascular smooth muscle cells47,56,62,67-70. 
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 Due to their vast distribution peripherally, PACAP and the PAC1 receptor are involved in 
a variety of physiological processes, such as regulation of adrenaline release71, stimulation of 
adipocyte thermogenesis72, lipid metabolism73, metabolic stress adaptation74, glucose and energy 
homeostasis75, renin production76,77 and inflammatory responses78. Furthermore, PACAP and the 
PAC1 receptor have a crucial role in the long-term maintenance of neurogenic vasodilation in the 
periphery and in the homeostatic responses to cerebral, retinal, cardiac, hepatic, intestinal and renal 
ischemic events79-88. This topic has been extensively reviewed elsewhere89.  
PACAP and PAC1 receptor in pathophysiological conditions
Besides being involved in several physiological processes, PACAP is thought to contribute to the 
pathophysiology of several conditions. 
 PACAP has been associated with regulation of inflammatory processes. In an arthritis model, 
PACAP-/- mice showed absence of arthritic hyperalgesia and reduction of joint swelling, vascular 
leakage and inflammatory cell accumulation. In the late phase of the disease, immune cell function 
and bone neoformation were increased90. In rheumatoid arthritis, the vasodilatory effects of 
PACAP through activation of the PAC1 receptor facilitated plasma leakage, edema formation, and 
leukocyte migration91,92. Furthermore, PACAP-/- mice developed more severe inflammation and 
tumors in a model of colitis78. In preclinical models, upregulation of PACAP and its receptors in 
micturition pathways contributed to the development of urinary bladder dysfunction, including 
symptoms of increased voiding frequency and pelvic pain58, suggesting a role in low urinary tract 
dysfunction. In the nervous system, studies demonstrated anxiogenic actions of PACAP and the 
possibility of blocking anxiety-related behaviors with PAC1 receptor antagonists
93-95. In patients 
with post-traumatic stress disorder (PTSD), blood levels of PACAP correlated with severity of stress-
related symptoms96, and in females, a single nucleotide polymorphism in the estrogen response 
element of the PAC1 receptor gene is predictive of PTSD diagnosis
97. 
 Furthermore, PACAP plays a complex role in pain transmission. At the peripheral sensory nerve 
terminals, pro- and anti-nociceptive effects are observed; while in CNS, central sensitization, increase 
of neuronal excitation and induction of chronic pain have been described98. In an acute somatic 
and visceral inflammatory model, PACAP decreased pain transmission; however, after application in 
the spinal cord, a transient induction of analgesia was followed by long-lasting algesia99. Moreover, 
injection of PACAP into the paraventricular nucleus of hypothalamus increased the activity of the 
TNC, an effect which was inhibited by the PAC1 receptor antagonist
48. Although it has been shown 
that PACAP is transported through the blood-brain barrier (BBB) actively, it is rapidly degraded or 
returned by efflux pumps100. Thus, a direct central action of peripheral PACAP is unlikely. 
 Although the role of PACAP in pain processing remains elusive, clinical data strongly suggest 
the involvement of PACAP in the pathophysiology of migraine and cluster headache (CH). Recent 
evidence of a correlation between a genetic variant of the PAC1 receptor gene (ADCYAP1R1) 
and susceptibility to CH was demonstrated103. Another study identified a relationship between 
altered PACAP levels in peripheral blood and different types of headache104. Further, two studies 
reported low interictal plasma levels of PACAP in migraine and CH when compared to controls105,106. 
Particularly, a detailed analysis of PACAP mRNA expression in peripheral blood mononuclear cells 
detected a significantly lower level of PACAP in migraine patients compared to healthy controls, 
with no significant differences revealed between the control group and tension-type headache, CH 
or medication overuse headache groups. Interestingly, PACAP increased ictally in jugular or cubital 
blood of migraine105,107,108 and CH patients93,106, and levels decreased as headache ameliorated after 
sumatriptan administration108. Finally, when administered to migraine patients, PACAP induced an 
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instant headache in 90% of patients, which was later followed by a delayed headache similar to 
a migraine-like attack in two thirds of the subjects109. This has led to study the role of PACAP in 
migraine pathophysiology as will be discussed in the next section.
PACAP in migraine pathophysiology
The use and development of experimental animal and human models of headache, migraine in 
particular, have provided invaluable insight into the pathophysiological mechanisms underlying 
headache disorders110,111. To investigate the molecular mechanisms behind the headache-inducing 
effects of PACAP, a number of animal studies have been conducted. Additionally, several human 
studies have been performed, some of these in combination with imaging techniques. In the 
following sections, both human and animal studies investigating the headache-related effects of 
PACAP will be reviewed.
Human studies
The headache-inducing effect of PACAP was first reported in a study on cerebral blood flow in 
healthy volunteers, where 10 out of 11 participants reported mild to moderate headache after PACAP 
infusion112.  A double-blind, randomized, placebo-controlled, crossover study later showed that 12 
out of 12 healthy subjects and 11 out of 12 migraine patients reported headache after intravenous 
infusion of PACAP, compared to two and three, respectively, after placebo109. Further, two healthy 
subjects and one migraine patient reported a migraine-like attack within 2 h after infusion, whereas 
six migraine patients reported a migraine-like attack within 6 h after infusion. This study also found 
dilation of middle cerebral artery (MCA) and the superficial temporal artery after PACAP infusion. 
 The role of vasodilation in PACAP induced headache was further explored in a magnetic 
resonance angiography (MRA) study in healthy volunteers113. Eight out of nine participants reported 
an immediate headache and 100% reported a delayed headache after PACAP infusion. Further, 
over a 5 h period PACAP induced a sustained dilation of the extracranial middle meningeal artery 
(MMA) but no change in intracerebral MCA. Collectively, these studies support the notion that 
PACAP induces headache via sustained vasodilation. In another MRA study, PACAP infusion induced 
headache in 91% of included migraine patients, and 73% reported migraine-like attacks compared 
to 82% and 18%, respectively, after VIP administration. Further, PACAP induced a long-lasting (>2 h) 
dilation of extracranial arteries, whereas the dilation caused by VIP normalized after 2 h. This further 
underlines prolonged vasodilation as the migraine inducing mechanism of PACAP114. Interestingly, 
in an in vitro study neither PACAP nor VIP were potent in inducing vasodilation of the human MMA115. 
 In a resting-state magnetic resonance study, infusion of PACAP affected connectivity in the 
salience, the default mode and the sensorimotor network during migraine attacks. VIP had no effect 
on these networks116. Another study in migraine patients reproduced the induction of migraine-like 
attacks in 72% of patients and showed that PACAP induced premonitory symptoms in 48% of 
patients compared to 9% after CGRP117, suggesting an effect on central PAC1 receptors. However, 
PACAP is rapidly degraded or transported back after actively crossing the BBB100; therefore, the 
premonitory symptoms could be mediated via activation of a central structure that is not protected 
by the BBB. Lastly, increased blood markers of hypothalamic activation, neuronal damage and 
peptide release from parasympathetic and sensory perivascular nerve fibers were found during 
PACAP-induced migraine-like attacks118. 
 The human studies point out PACAP as a key player in migraine pathophysiology102. As VIP 
does not induce migraine-like attacks, it is assumed that PACAP’s actions are mediated by PAC1 
receptor activation. However, it is still too early to rule out VPAC1/2 receptors as additional potential 
antimigraine targets, since no studies in humans have been performed with antagonists. Further, 
the short half-life of VIP (2 min119), could be the cause of its lack of migraine-inducing effects. 
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Animal studies
To characterize the exact receptor involved in PACAP-mediated actions, the vasodilatory effect of 
PACAP was elucidated in animal studies showing that both VIP, PACAP38 and PACAP27 induce 
vasodilation of the rat MMA in vivo120,121. Interestingly, this effect was blocked by VPAC1 antagonists 
in the former120 and VPAC2 antagonists in the latter
121. Both studies found no effect of PAC1 
antagonists on vasodilation. In contrast, an ex vivo study found that PAC1 antagonists reversed the 
PACAP-induced vasodilation in the rat MMA17. As mentioned previously, PAC1 receptor antagonists 
have shown agonistic behavior and affinity for VPAC2 receptors. This could explain the contradictory 
results observed in the rat MMA vasodilation studies. Therefore, different methods must be used, 
in order to elucidate the receptors involved in migraine pathophysiology. For example, in a in vivo 
model of chronic migraine, induced by recurrent chemical dural stimulation, PAC1 receptor mRNA 
was shown to be increased in the TG, but not in the TNC, and no significant differences were found 
in the expression of the VPAC1 and VPAC2 receptors
122. Moreover, in an in vivo rat model, intravenous 
administration of AMG 301, the PAC1 receptor antibody, inhibited evoked nociceptive activity in 
the trigemino-cervical complex, and the results were comparable to the inhibition observed with 
sumatriptan123. 
 In addition to sustained vasodilation, mast cell degranulation has also been suggested as 
one of the headache inducing mechanisms of PACAP. This hypothesis is based on findings from 
animal studies showing that PACAP degranulates mast cells from the rat dura mater124. Further, 
PACAP-induced delayed vasodilation of the rat MMA is attenuated in mast cell depleted rats125. 
Interestingly VIP did not result in mast cell release of histamine from the dura126.
 Collectively, the animal studies confirm that PACAP induces vasodilation and suggest that this 
effect might be mediated through degranulation of mast cells. Also, recent results show that these 
effects are most likely exerted through activation of the PAC1 receptor. Due to the contradictory 
results, further studies are warranted to confirm this. 
 
PACAP (receptor) blockade as a therapeutic target
As shown above, PACAP seems to play an important role in migraine pathophysiology. Although the 
exact receptor involved has not yet been elucidated, some studies indicate that the PAC1 receptor 
is the most important17,48,113,117,122,123. Therefore, both PACAP and PAC1 receptor have been suggested 
as novel targets for migraine treatment and possibly a new therapeutic option for patients who 
do not respond to CGRP (receptor) blocking drugs. Although both neuropeptides co-localize in 
the trigeminal ganglion49, and could share some biological cascades, the PACAP-induced migraine 
attacks indicate an independent role of PACAP in the genesis of migraine. 
 In this light, the interest from pharmaceutical companies for blocking the PACAP/PAC1 receptor 
pathway has increased. There are two therapeutic approaches to inhibit PACAP: (i) PAC1 receptor 
antagonists or antibodies directed against this receptor; or (ii) antibodies directed against the 
peptide PACAP102. Since PAC1 receptor antagonists have been reported to act as agonists depending 
on the tissue (see Pharmacology), the antibodies seem a better option for blocking this receptor.
 Currently, a phase 2a, randomized, double blind, placebo-controlled study is underway to 
evaluate the efficacy and safety of a PAC1 receptor antibody (AMG 301) in subjects with chronic 
or episodic migraine (Clinical trials identifier: NCT03238781). Unfortunately, no preliminary results 
have been published so far. Preclinical studies are also evaluating a monoclonal antibody (ALD1910) 
targeting PACAP38 for its potential in the treatment of migraine patients who have an inadequate 
response to therapeutics directed at CGRP or its receptor128. 
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Potential side effects of PACAP/PAC1 receptor blockade
Indeed, the possibility of a new therapeutic target for prophylactic migraine treatment is exciting; 
however, it is important to consider that PACAP and PAC1 receptor participate in numerous 
physiological processes (see Fig. 2). As antibodies are not likely to cross the BBB, only the possible 
side effects regarding peripheral blockade of PACAP and PAC1 receptor will be discussed.
 As PACAP and PAC1 receptor are expressed throughout the components of the 
hypothalamo-pituitary-gonadal axis50-52, and the pituitary gland is not protected by the BBB, a 
dysregulation of the functions of this axis could be a concern. Also, the immune system has been 
described to be regulated by activation of PAC1 receptor
61. This, together with its participation in 
the modulation of inflammatory processes, could result in alterations in the immune response and 
increased production of pro-inflammatory cytokines78,129. In accordance with this, in a mouse model 
of colitis, PACAP-deficient mice developed a more severe disease78.
 Blocking PACAP might also alter the response to metabolic stress. Studies with PACAP-deficient 
mice have shown a more profound and longer lasting insulin-induced hypoglycemia and a 
reduction in glucose-stimulated insulin secretion74,75. Moreover, PACAP-deficient mice had hepatic 
microvesicular steatosis, intracellular fat accumulation in muscle and skeletal muscle and depletion 
of subcutaneous white fat73.
 Furthermore, PACAP and PAC1 receptor participate in vasodilatory responses, renin release and 
regulation of cardiovascular function77,115,125. Although the density of VPAC1/2 and PAC1 receptors in 
coronary artery is less than that in cranial MMA115, arguing for a limited role in cardiac ischemia, a 
protective role in ischemic events has been described. Thus, considering the increased cardiovascular 
risk that migraine patients present130-133, careful monitoring of patients with preexisting cardiovascular 
risk factors is advised. However, similar concerns have been raised with the CGRP (receptor)-
antibodies134,135, with no cardiovascular adverse events reported in the clinical trials136. 
Fig. 2. Possible side effects after long-term exposure to PACAP (receptor)-antibodies. An overview of the 
organ systems where PACAP and PAC1 receptor are present and the possible side effects that could be observed.
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Further considerations
If the antibodies against the PAC1 receptor prove to be effective for the prophylactic treatment of 
migraine, some concerns should be addressed. Firstly, as previously discussed, it is important to 
consider the possible side effects of long-term blocking of PACAP/PAC1 receptor, with emphasis 
on the cardiovascular system, as migraine patients present a higher cardiovascular risk.  Therefore, 
safety studies in patients with cardiovascular disease are needed. Moreover, the administration route 
of the antibody against the PAC1 receptor is subcutaneous, thus erythema, pruritus and mild pain in 
the injection site could be expected, as it has been observed with the CGRP (receptor) – antibodies137. 
Nevertheless, the monthly administration represents an advantage for treatment adherence. 
 It will also be important to define if PAC1 receptor antibodies will really represent a therapeutic 
advantage for the patients that are not responding to the CGRP (receptor)-antibodies. Since studies 
have shown that PACAP and CGRP co-localize in structures relevant for migraine pathophysiology 
(e.g. trigeminal ganglion)49, PACAP blockade may only be effective for the same patients to whom 
CGRP blockade is already effective. If a distinction can be made between patient groups this 
would also shed light on the pathophysiology of migraine, as it could distinguish between CGRP-
associated or PACAP-associated migraine patients. Moreover, the PAC1 receptor sequence that is 
recognized by the antibody has not been disclosed, thus, the variants of the receptor to which the 
antibody binds are not known. If revealed, it would be interesting to study whether certain receptor 
isoforms predispose patients to present migraine, or whether the treatment will only be effective in 
patients with those isoforms. 
 Finally, as mentioned previously, it is still too early to rule out VPAC1/2 receptors as therapeutic 
targets for migraine treatment. Therefore, ALD1910, the antibody against PACAP38, currently 
undergoing preclinical studies128, broadens the therapeutic options for migraine treatment. 
However, further safety studies should be addressed, as blocking PACAP38 would inhibit the 
actions of three different receptors, increasing the possibilities of adverse side effects. 
Conclusion
The possible role of PACAP/PAC1 receptor blockade as migraine treatment has been reviewed. All 
three PACAP receptors have been described in TG, TNC and (dural) arteries, structures previously 
related to migraine pathophysiology47,49. Indeed, infusion of PACAP is able to induce migraine-like 
attacks109. Moreover, interictally, low plasma levels of PACAP have been described105, while during 
a migraine attack, PACAP increases in jugular and cubital blood105,108 and decreases as headache 
ameliorates after sumatriptan administration108.
 Clinical studies have shown that infusion of VIP does not induce migraine-like headaches114, 
therefore, it is considered that the possible receptor involved in PACAP actions is PAC1 receptor, as 
VIP has affinity for VPAC1 and VPAC2 receptors. Although this could be attributed to pharmacokinetic 
aspects (i.e. half-life), rather than pharmacodynamic. Pharmacological characterization in preclinical 
studies has given contradictory results, indicating a complex pharmacology of the PAC1 receptor
21,22. 
However, a recent in vivo study showed that intravenous infusion of PAC1 receptor antibody, 
inhibited evoked nociceptive activity in the trigemino-cervical complex in rats, and these results 
were comparable to the inhibition observed with sumatriptan123. These results have led to the 
development of antibodies against PACAP (ALD1910) and PAC1 receptor (AMG 301) for migraine 
treatment.
 In conclusion, the data presented in this review indicate that PACAP and PAC1 receptor blockade 
are promising migraine therapies but results from clinical trials are needed in order to confirm their 
efficacy and their side effects profile.
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Chapter XI.  
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produced by moxonidine and agmatine 
on the vasodepressor sensory CGRPergic 
outflow in pithed rats 
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Abstract
Calcitonin gene-related peptide (CGRP) plays a role in several (patho)physiological functions, and 
modulation of its release is considered a therapeutic target. In this respect, electrical spinal (T9 -T12) 
stimulation of the perivascular sensory outflow in pithed rats produces vasodepressor responses 
mediated by CGRP release. This study investigated the role of imidazoline I1 and I2 receptors in the 
inhibition by moxonidine and agmatine of these vasodepressor responses. Male Wistar pithed rats 
(pretreated i.v. with 25 mg/kg gallamine and 2 mg/kg.min hexamethonium) received i.v. continuous 
infusions of methoxamine (20 μg/kg.min) followed by physiological saline (0.02 ml/min), moxonidine 
(1, 3, 10 or 30 μg/kg.min) or agmatine (1000 or 3000 μg/kg.min). Under these conditions, electrical 
stimulation (0.56-5.6 Hz; 50  V; 2  ms) of the spinal cord (T9-T12) produced frequency-dependent 
vasodepressor responses which were: (i) unchanged during saline infusion; and (ii) inhibited during 
the above infusions of moxonidine or agmatine. Moreover, using i.v. administrations, the inhibition 
by 3 μg/kg.min moxonidine or 3000 μg/kg.min agmatine (which failed to inhibit the vasodepressor 
responses by αCGRP; 0.1-1  µg/kg) was: (i)  unaltered after saline (1 ml/kg), rauwolscine (300 μg/
kg; α2-adrenoceptor antagonist) or BU224 (300 μg/kg; imidazoline I2 receptor antagonist); and (ii) 
reversed after AGN 192403 (3000  μg/kg; imidazoline I1 receptor antagonist). This reversion was 
relatively more pronounced after AGN 192403 plus rauwolscine. These blocking doses of antagonists 
lacked any effects on the electrically-induced vasodepressor responses. Therefore, the inhibition of 
the vasodepressor sensory CGRPergic outflow by moxonidine and agmatine is mainly mediated by 
prejunctional imidazoline I1 receptors on perivascular sensory nerves.
Introduction
Blood pressure is determined by the interaction of neural, humoral and local mechanisms. The neural 
modulation of the vascular tone is mainly mediated by activation of sympathetic (noradrenergic) 
and sensory (non-adrenergic non-cholinergic) fibres1. In turn, perivascular sensory fibres may release 
(depending on the vascular bed) different neuromediators, including adenosine triphosphate, 
vasoactive intestinal peptide, neuropeptide Y, substance P, nitric oxide and calcitonin gene-related 
peptide (CGRP)2-5. Of these neuromediators, CGRP has been shown to play an important role in the 
modulation of vascular tone, as well as in the pathogenesis of several diseases/disorders, such as 
migraine, diabetes, arthritis and obesity6. 
 Due to the (patho)physiological importance of CGRP, it is crucial to elucidate the mechanisms 
associated with its release. For example, in the pithed rat model, electrical spinal (T9-T12) stimulation 
of the perivascular sensory outflow results in vasodepressor responses mainly mediated by CGRP 
release, as these responses are blocked by the CGRP receptor antagonists CGRP8-37
7or olcegepant8. 
This vasodepressor sensory CGRPergic outflow is modulated by activation of prejunctional 
α2A/2C-adrenoceptors
9, serotonin 5-HT1B/1D/1F/7
10,11, dopamine D2-like receptors
12 and histamine 
H3 receptors
13. Additional evidence suggests that imidazoline receptors can also modulate 
neurotransmitter release14,15. In the pithed rat model, Cobos-Puc et al.16 have demonstrated that 
activation of prejunctional imidazoline I1 receptors inhibits the sympathetic vasopressor outflow. 
Furthermore, Villalón et al.9 have shown that clonidine, an α2-adrenoceptor and imidazoline I1 receptor 
agonist, inhibits the vasodepressor sensory CGRPergic outflow by activation of α2A/2C-adrenoceptors; 
however, this study could not exclude the possible role of imidazoline receptors.
 On this basis, the present study was designed to investigate if moxonidine (imidazoline 
I1∕α2-adrenoceptor agonist) and agmatine (endogenous ligand of imidazoline receptors)  inhibit the 
vasodepressor sensory CGRPergic outflow, and the receptors involved in this inhibition by using 
selective antagonists (see Table 1).
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Table 1. Affinity constants (pKi) of the different drugs considered in this study. Receptor binding affinities 
(pKi) of the drugs considered in the present study at α2-adrenoceptors, imidazoline I1 and I2 receptors. Data taken 
from the following references: 1[Ernsberger and Haxhiu, 1997]; 2[Atlas, 1994] ; 3[Li et al., 1994] ; 4[Hieble and 
Ruffolo] ; 5[Munk et al., 1996]; 6 [Flamez et al., 1997] . N.D. stands for “not determined”.
Agonists α2 I1 I2
Moxonidine 7.11 8.61 5.01
Agmatine 5.42 6.153 6.03
Antagonists
Rauwolscine 8.04 4.01 N.D.
AGN 192403 4.65 7.45 N.D.
BU224 4.86 5.76 8.66
Materials and methods 
Ethical approval of the study protocol
The experimental protocol of this study was approved by our Institutional Ethics Committee (CICUAL 
Cinvestav; permission protocol number 507-12) and followed the regulations established by the 
Mexican Official Norm (NOM-062-ZOO-1999) in accordance with the guide for the Care and Use of 
Laboratory Animals in the U.S.A.23, the ARRIVE guidelines for reporting experiments in animals24 and 
the Legislation for the protection of animals used for scientific purposes Directive 2010/63/EU25.
General methods
Experiments were carried out in 135 male Wistar normotensive rats (300-350 g). The animals were 
maintained at a 12/12h light-dark cycle in a special room at a constant temperature (22±2°C) 
and humidity (50%), with food and water freely available in their home cages. After anaesthesia 
with sodium pentobarbital (60 mg/kg, i.p.) and cannulation of the trachea, the rats were pithed 
as reported earlier 9. This procedure consists in inserting a stainless steel rod through the orbit 
and foramen magnum and into the vertebral foramen to avoid the influence of the central 
nervous system. Immediately afterwards, the animals were artificially ventilated with room air 
using an Ugo Basile pump model 7025 (56 strokes/min; stroke volume: 20 ml∕kg). After bilateral 
cervical vagotomy, catheters were placed in: (i) the left and right femoral veins for the continuous 
infusions of methoxamine and the agonists (moxonidine, agmatine or vehicle), respectively; (ii) the 
left jugular vein for the continuous infusion of hexamethonium; and (iii) the right jugular vein, 
for the bolus injections of gallamine, αCGRP or the antagonists. Then, the left carotid artery was 
connected to a Grass pressure transducer (P23 XL), for the recording of blood pressure. Both heart 
rate (measured with a 7P4F tachograph) and blood pressure were recorded simultaneously by a 
model 7D Grass polygraph (Grass Instrument Co., Quincy, MA, U.S.A.).  At this point, the 135 rats were 
divided into two main sets to study the effects of i.v. infusions of either the vehicle (physiological 
saline), moxonidine or agmatine, on the vasodepressor responses induced by either: (i) electrical 
stimulation of the vasodepressor sensory CGRPergic outflow (set 1, n=115); or (ii) i.v. bolus of αCGRP 
(set 2, n=20). The dose-response curves (D–R curves) and vasodepressor stimulus-response curves 
(S–R curves) elicited by α-CGRP and electrical stimulation, respectively, were completed in about 
50 min, with no changes in resting blood pressure. The electrical stimuli (0.56, 1, 1.8, 3.1 and 5.6 Hz), 
as well as the i.v. doses of αCGRP (0.1, 0.18, 0.31, 0.56 and 1 μg/kg), were given using a sequential 
schedule at 5–10 min intervals as previously reported 9,16. The body temperature of each pithed rat 
was maintained at 37 °C by a lamp and monitored with a rectal thermometer.
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Experimental protocols
After the animals had been in a stable hemodynamic condition for at least 20 min, baseline values 
of diastolic blood pressure (a more accurate indicator of peripheral vascular resistance) and heart 
rate were determined. Subsequently, the following experimental protocols were applied.
Electrical stimulation of the vasodepressor sensory CGRPergic outflow
In the first set or rats (n=115), the pithing rod was replaced by an electrode enamelled except for 
1.5 cm length 9 cm from the tip, placing the uncovered segment at the thoracic segments T9–T12 of 
the spinal cord to allow selective stimulation of the vasodepressor sensory CGRPergic outflow7,9,16. 
Before electrical stimulation, the animals received (i.v.): (i) gallamine (25  mg/kg) to avoid the 
electrically-induced muscular twitching; (ii) 10 min later, a continuous infusion of hexamethonium 
(2 mg/kg.min) to block the vasopressor responses resulting from stimulation of the preganglionic 
sympathetic outflow; and (iii) 10 min later, a continuous infusion of methoxamine (20 µg/kg.min) 
to increase diastolic blood pressure at a value of, at least, 135 mm Hg9. Then, this set of rats was 
divided into 4 groups (n=40, 25, 25 and 25).
 The first group (n=40) was subdivided into four subgroups that received an i.v. continuous 
infusion of: (i) nothing (control; n=5); (ii) 0.02 ml/min physiological saline (n=5); (iii) moxonidine 
(1,  3, 10 or 30  µg/kg·min;  n=5 each); or (iv) agmatine (1000 or 3000  µg/kg·min;  n=5 each). 
Twenty min later, the perivascular sensory CGRPergic outflow was electrically stimulated during 
the above treatments to elicit vasodepressor responses by applying 10-s trains of monophasic 
rectangular pulses (2  ms, 50  V) at 0.56, 1, 1.8, 3.1 and 5.6  Hz. When diastolic blood pressure 
returned to baseline levels, the next frequency was applied. This procedure was performed until 
the S-R curve had been completed.
 The second group (n=25) received an i.v. continuous infusion of 0.02 ml/min saline and, 10 min 
later, it was subdivided into 5 subgroups (n=5 each) that were treated with i.v. bolus injections 
of: (i)  1  ml/kg saline; (ii) 300  µg/kg rauwolscine (α2-adrenoceptor antagonist); (iii)  3000  µg∕kg 
AGN 192403 (imidazoline I1 receptor antagonist); (iv) 300  µg/kg BU224 (imidazoline I2 receptor 
antagonist); and (v) 300 µg/kg rauwolscine+3000 µg/kg AGN 192403. Ten min later, a S-R curve was 
elicited as described above, to analyze the effect per se of each of these antagonists.
 The third group (n=25) received an i.v. continuous infusion of 3  µg/kg.min moxonidine; 
10  min later, it was subdivided into 5 subgroups (n=5 each) that received i.v. bolus injections 
of:  (i)  1  ml∕kg  saline; (ii) 300  µg/kg rauwolscine;  (iii) 3000  µg/kg  AGN 192403;  (iv)  300  µg∕kg 
BU224; and (v) 300 µg∕kg rauwolscine+3000 µg/kg AGN 192403. Ten min later, a S–R curve was 
elicited.
 The fourth group (n=25) received an i.v. continuous infusion of 3000  µg/kg·min agmatine. 
As previously, 10 min later, was subdivided into 5 subgroups (n=5 each) that were administered 
i.v. bolus injections of: (i) 1 ml/kg saline; (ii) 300 µg/kg rauwolscine; (iii) 3000 µg/kg AGN 192403; 
(iv) 300 µg/kg BU224; and (v) 300 µg/kg rauwolscine+3000 µg/kg AGN 192403. Ten min later, a S–R 
curve was elicited.
 The interval between the different frequencies of stimulation depended on the duration of 
the resulting vasodepressor responses (5–10 min), as we waited until diastolic blood pressure had 
returned to baseline values. It is important to highlight that tachyphylaxis of the vasodepressor 
responses was observed when eliciting a second S–R curve; as a result, only one S–R curve was 
performed per animal, as previously reported9,12.
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Administration of exogenous αCGRP
The second set of rats (n=20) was pithed as previously described, but the pithing rod was not 
replaced with an electrode since electrical stimuli were not applied. Consequently, the pithing rod 
was left throughout the experiment and the administration of both gallamine and hexamethonium 
was omitted9,12. Subsequently, an i.v. continuous infusion of 20  µg/kg.min methoxamine was 
administered. Ten min later (with diastolic blood pressure maintained at values of, at least, 
135 mmHg), this set was divided into four groups (n=5 each) that received i.v. continuous infusions 
of: (i) nothing (control group); (ii) 0.02 ml/min physiological saline; (iii) 3 µg�kg.min moxonidine; 
and (iv) 3000  µg/kg·min agmatine. Twenty min later, the vasodepressor responses by i.v. bolus 
injections of αCGRP (0.1, 0.18, 0.31, 0.56 and 1  µg/kg) were determined during the continuous 
infusion of the agonists.
Other procedures applied to the experimental protocols
Hexamethonium, methoxamine, moxonidine, agmatine and saline were infused at a rate of 0.02 ml/
min by a WPI model sp100i pump (World Precision Instruments Inc., Sarasota, FL, U.S.A.). The 
continuous infusion of methoxamine (20 µg/kg.min) increased diastolic blood pressure in all cases. 
The interval between the different frequencies of stimulation or doses of α-CGRP depended on the 
duration of the resulting vasodepressor responses (5-10 min), as we waited until diastolic blood 
pressure had returned to baseline values.
Compounds
The compounds used in this investigation were: gallamine triethiodide, hexamethonium 
chloride, methoxamine hydrochloride, rat α-CGRP, moxonidine hydrochloride, agmatine sulphate, 
rauwolscine hydrochloride (Sigma Chemical Co., St. Louis, MO, U.S.A.); (+/-)-2-endo-Amino-3-exo-
isopropylbicyclo[2.2.1]heptane hydrochloride (AGN  192403), 2-(4,5-Dihydroimidazol-2-yl)
quinoline hydrochloride (BU224 hydrochloride; purchased from Tocris Bioscience, Ellisville, MO, 
U.S.A.). All compounds were dissolved in physiological saline. The doses of the above compounds 
refer to the free base of substances, except in the case of gallamine and hexamethonium, where 
they refer to the corresponding salts.
Data presentation and statistical evaluation
All data in the text and Fig.s are presented as mean±S.E.M. The changes in baseline values of 
diastolic blood pressure before and during the continuous i.v. infusion of saline, moxonidine or 
agmatine were compared with a paired Student’s  t-test. Furthermore, the changes in diastolic 
blood pressure produced by i.v. bolus of αCGRP or electrical stimulation during saline, moxonidine 
and agmatine-infused animals were determined and expressed as percentage of change from 
baseline at the steady state effect of methoxamine. The difference between the changes in 
diastolic blood pressure induced by electrical stimulation or exogenous α-CGRP within the 
different subgroups of animals was compared with a two-way analysis of variance. Such analysis 
was followed, if applicable, by the Student-Newman-Keul’s post hoc test. Statistical significance 
was accepted at P<0.05.
Results 
Systemic haemodynamic variables
The baseline values of diastolic blood pressure and heart rate in the 135 rats were 55±4 mm Hg 
and 237±8 beats/min, respectively. These values did not change (P>0.05) after gallamine or 
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hexamethonium in the rats receiving electrical stimulation (n=115; data not shown). Twenty min 
after starting the infusion of methoxamine, diastolic blood pressure was significantly increased in all 
cases (179±8 mm Hg; n=115). The values of diastolic blood pressure and heart rate in the different 
subgroups before, immediately after and 10 min after i.v. saline or antagonists during methoxamine 
infusion were not significantly different (data not shown). 
Vasodepressor responses elicited by electrical stimulation of the sensory CGRPergic outflow or 
exogenous α-CGRP 
During the continuous infusion of methoxamine, the responses to electrical stimulation or to i.v. 
bolus of α-CGRP were immediate and resulted in frequency- or dose- dependent decreases in 
diastolic blood pressure as previously reported 9,10. In all cases, the vasodepressor responses were 
considered to be due to selective vasodepressor stimulation (Fig. 1), as only minor and inconsistent 
effects in heart rate were observed, as previously shown by Villalón et al.9.
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Fig. 1. Effect of continuous i.v. infusions of moxonidine (1, 3, 10 or 30 μg/kg∙min) or agmatine (1000 or 3000 μg/
kg∙min) on the vasodepressor responses induced by electrical stimulation of the sensory CGRPergic outflow. 
Full symbols represent significant differences vs control (P<0.05); *P<0.05 comparing 30 μg/kg∙min moxonidine 
vs 3 μg/kg∙min moxonidine and vs 10μg/kg∙min moxonidine; #P<0.05 comparing 3000 μg/kg∙min agmatine vs 
1000 μg/kg∙min agmatine. Note that there was no significant difference between the inhibition produced by 3 
and 10 μg/kg∙min moxonidine.
Effect of i.v. continuous infusions of moxonidine or agmatine on the vasodepressor responses 
induced by electrical stimulation of the sensory CGRPergic outflow 
Fig. 1A shows the inhibition of the vasodepressor responses induced by electrical stimulation 
of the sensory CGRPergic outflow during i.v. continuous infusions of  moxonidine (1, 3, 10 and 
30  µg∕kg·min). This inhibition, significant as from 3 μg/kg∙min moxonidine, was dose-dependent 
at 10 and 30μg/kg∙min moxonidine. On the basis of these results, and considering its selectivity 
(see Table 1), the dose of 3 µg/kg.min moxonidine was chosen for further pharmacological analysis. 
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Moreover, the i.v. continuous infusions of agmatine (1000 and 3000 µg/kg.min) dose-dependently 
inhibited the electrically-induced vasodepressor responses (Fig. 1B). This inhibition was significant 
at 1.8, 3.1 and 5.6 Hz in all cases (P<0.05).
Effects of compounds per se on the electrically-induced vasodepressor responses
Fig. 2 illustrates that i.v. bolus injections of 1 ml/kg saline (vehicle; Fig. 2A), 300 µg/kg rauwolscine 
(Fig. 2B), 3000 µg/kg AGN 192403 (Fig. 2C), the combination of  300 µg/kg rauwolscine+3000 µg/kg 
AGN 192403 (Fig. 2D) or 300 µg/kg BU224 (Fig. 2E) produced  no significant effects (P>0.05) on the 
electrically-induced vasodepressor responses.
Fig. 2. Effect of i.v. bolus injections of 1 ml/kg saline, 300 µg/kg rauwolscine, 3000 µg/kg AGN192403, 3000 g/kg 
AGN 192403+300 µg/kg rauwolscine or 300 µg/kg BU224 on the electrically-induced vasodepressor responses. 
Empty symbols represent no significant difference vs control (P>0.05).
Effect of vehicle or antagonists on the electrically-induced vasodepressor responses during the 
i.v. continuous infusions of moxonidine
The inhibition by the continuous infusion of 3 µg/kg.min moxonidine on the vasodepressor sensory 
CGRPergic outflow: (i) was not significantly modified (P>0.05) by the i.v. administration of 1 ml/kg 
saline (Fig. 3A), 300 µg/kg rauwolscine (Fig. 3B) or 300 µg/kg BU224 (Fig. 3E); and (ii) was significantly 
(P<0.05) attenuated by the i.v. administration of 3000 µg/kg AGN 192403 (Fig. 3C) or 3000 µg/kg 
AGN 192403+300 µg/kg rauwolscine (Fig. 3D). 
Effect of vehicle or antagonists on the electrically-induced vasodepressor responses during the 
i.v. continuous infusions of agmatine
The inhibition produced by 3000 µg/kg.min agmatine: (i) was not significantly modified (P>0.05) 
after the i.v. bolus administration of 1 ml/kg saline (Fig. 3F), 300 µg/kg rauwolscine (Fig. 3G) or 300 
µg/kg BU224 (Fig. 3J); and (ii) was reversed by the i.v. administration of 3000 µg�kg AGN 192403 or 
the combination of 3000 µg/kg AGN 192403+300 μg/kg rauwolscine (Fig. 3H and 3I; P<0.05).
Effect of i.v. continuous infusions of moxonidine or agmatine on the vasodepressor responses 
induced by i.v. bolus injections of αCGRP
The continuous infusion of: (i) 0.02 ml/min saline (Fig. 4A); (ii) 3 µg/kg.min moxonidine (Fig. 4B); or 
(iii) 3000 µg/kg.min agmatine (Fig. 4C) did not modify the vasodepressor responses induced by i.v. 
bolus of αCGRP (P>0.05).
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Fig. 3. Effect of i.v. injections of 1 m
l/kg saline, 300 µg/kg rauw
olscine, 3000 µg/kg AG
N
 192403, 3000 µg/kg AG
N
 192403+300 µg/kg rauw
olscine or 300 µg/kg BU
224 
on the inhibition by 3 µg/kg.m
in m
oxonidine (upper panel) or 3000 µg/kg.m
in agm
atine (low
er panel). Full sym
bols represent significant differences vs control (P<0.05); 
*P<0.05 com
paring 3 µg/kg.m
in m
oxonidine vs 3000 µg/kg AG
N
 192403+m
oxonidine and vs 3000 µg�kg AG
N
 192403+300 µg/kg rauw
olscine+m
oxonidine; #P<0.05 
com
paring 3000 µg/kg.m
in agm
atine vs 3000 µg/kg AG
N
 192403+agm
atine and vs 3000 µg/kg AG
N
 192403+300 µg/kg rauw
olscine+agm
atine.
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Fig. 4. Effect of i.v. continuous infusions of 0.02 ml/min saline (vehicle), 3 µg/kg.min moxonidine or 3000 µg/
kg.min agmatine on the vasodepressor responses induced by i.v. bolus injections of αCGRP. Empty symbols 
represent no significant differences vs control (P>0.05).
Discussion
General
The pithed rat is an experimental model useful for determining the cardiovascular effects of 
different drugs at the peripheral nervous system (sympathetic and sensory). The nature of this 
model allows us to discard the influence of the central nervous system, as previously established9,16. 
It is worth mentioning that, although we did not measure sensory nerve activity directly, 
the electrically-induced neurotransmitter release (i.e. CGRP) was estimated indirectly by the 
measurement of the evoked vasodepressor responses9. Our study shows that the vasodepressor 
sensory CGRPergic outflow was inhibited by the continuous infusion of moxonidine and agmatine 
(Fig. 1). These inhibitory responses are mainly mediated by imidazoline I1 receptors in view that 
they were: (i) significantly blocked by the imidazoline I1 receptor antagonist AGN 192403 (Fig. 3); 
and (ii) resistant to blockade by the α2-adrenoceptor antagonist rauwolscine or the imidazoline I2 
receptor antagonist BU224, which display very low affinity for imidazoline I1 receptors (see Table 1). 
Moreover, the responses to moxonidine and agmatine are considered sensory-inhibitory, since they 
inhibited the vasodepressor responses to electrical sensory stimulation without affecting those to 
i.v. bolus injections of exogenous α-CGRP (Fig. 4). 
Haemodynamic changes
Our group has previously shown that, in order to observe vasodepressor responses in pithed rats, 
diastolic blood pressure has to be initially raised and maintained above 135 mm Hg by a continuous 
i.v. infusion of the α1-adrenoceptor agonist, methoxamine
9. Moreover, α2-adrenoceptors, as well as 
the imidazoline I1 and I2 receptors, do not seem to play a physiological role in the modulation of 
the vasodepressor sensory CGRPergic outflow as the electrically-induced vasodepressor responses 
were not significantly affected by i.v. administration of rauwolscine, AGN 192403 or BU224 at doses 
previously shown to block their respective receptors in the pithed rat model9,16.
Role of imidazoline I1 receptors in the inhibition of the vasodepressor sensory CGRPergic outflow 
by moxonidine and agmatine
Imidazoline I1 receptors have been shown to inhibit the cardioaccelerator sympathetic outflow
16, 
but no studies have thus far analyzed whether these receptors also modulate the vasodepressor 
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sensory CGRPergic outflow. Our experimental approach in pithed rats shows that moxonidine and 
agmatine inhibited the vasodepressor responses induced by electrical stimulation (Fig. 1) without 
affecting those by exogenous CGRP (Fig. 4). This finding implies a prejunctional inhibition of the 
vasodepressor sensory CGRPergic outflow, particularly at the higher stimulation frequencies (1.8, 
3.1 and 5.6 Hz). Moreover, considering the binding selectivity of the compounds used (see Table 1), 
our results suggest a predominant role of the imidazoline I1 receptors since the inhibitory responses 
to moxonidine and agmatine were markedly (but not completely) reversed by blocking doses of 
AGN 192403 (Fig. 3C and 3H). 
Pharmacological evidence for the exclusion of the role of α2-adrenoceptors and imidazoline I2 
receptors
Our findings additionally allow us to exclude the role of α2-adrenoceptors and imidazoline I2 
receptors. In this respect, since the inhibitory responses to moxonidine and agmatine were resistant 
to blockade by rauwolscine (Figs. 3B and 3G), an α2-adrenoceptor antagonist with very low affinity 
for imidazoline I1 receptors (see Table 1), the role of α2-adrenoceptors can be excluded. Nevertheless, 
in view that moxonidine displays affinity for α2-adrenoceptors and imidazoline I1 receptors (Table 
1), it was reasonable to assume that the small (though significant) inhibition remaining after AGN 
192403 could involve α2-adrenoceptors. If this were the case, then the combination AGN 192403 
plus rauwolscine should have abolished this remaining inhibition. However, the blockade of this 
response by the above combination (Figs. 3D and 3I) was practically identical to that produced 
by AGN 192403 alone (Fig. 3C and 3H). Accordingly, the inhibition remaining after AGN 192403 is 
most likely mediated by novel receptors (probably coupled to Gi/o) that warrant further experiments 
falling beyond the scope of the present study.
 Finally, the fact that the inhibitory responses to moxonidine and agmatine were resistant to 
blockade by BU224 (Figs. 3E and 3J), an imidazoline I2 receptor antagonist with very low affinity 
for α2-adrenoceptors and imidazoline I1 receptors (Table 1), rules out imidazoline I2 receptors, as 
previously shown in other experimental models26. 
Potential clinical relevance
As a final point of reflexion, it is important to highlight the potential clinical relevance of the 
present findings. Indeed, the pharmacological modulation of perivascular CGRP release is of most 
interest due to the established antimigraine efficacy of the novel CGRP receptor antagonists (i.e. the 
gepants), with the downside of hepatotoxic side effects and pharmacokinetic limitations6,27, as well 
as the potential for cardiovascular side effects28. For example, the antimigraine drug olcegepant (a 
potent CGRP receptor antagonist29),  has recently been shown to block the vasodepressor sensory 
CGRPergic outflow and to potentiate the vasopressor sympathetic outflow8, an effect that might 
result in an increased vascular resistance and, consequently, in a prohypertensive action. Moreover, 
the triptans (acute antimigraine 5-HT1B/1D receptor agonists) are capable of inhibiting the trigeminal 
release of CGRP30 and also the vasodepressor sensory CGRPergic outflow10. On this basis, it is not 
unreasonable to postulate imidazoline I1 receptors as a therapeutic target for the development 
of novel antimigraine drugs with no prohypertensive action. For this purpose, moxonidine (an 
established central antihypertensive agents31), could be explored in other models predictive of 
antimigraine action, such as the inhibition of neurogenic dural vasodilatation induced by periarterial 
electrical stimulation in rats, using intravital microscopy32. Furthermore, there are other pathologies 
such as arthritis, obesity and diabetes where the role of CGRP is less clear6, but its modulation by 
imidazoline receptors could also be a possible therapeutic target.
Chapter XI
 141
Conclusion
Our results suggest that the inhibition of the vasodepressor sensory CGRPergic outflow by 
3  µg/kg.min moxonidine and 3000  µg/kg.min agmatine in pithed rats is mainly mediated by a 
prejunctional activation of imidazoline I1 receptors on perivascular sensory nerves.
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...and ends with reason.  
There is nothing higher than reason.”
Migraine is a highly prevalent and complex neurovascular disorder1. It has been shown that during 
migraine, (dysfunctional) activation of the trigeminovascular system leads to cranial vasodilation 
mediated by the release of calcitonin gene-related peptide (CGRP)2. Despite the high prevalence 
of migraine, current treatment options are not effective for all patients. Therefore, a need for novel 
acute and prophylactic antimigraine drugs exists.  
 In Chapter III we reviewed a new class of acutely acting antimigraine drugs, “ditans”, and 
compared them to the current gold standard for the acute treatment, the triptans. Triptans are 
5-HT1B/1D/(1F) receptor agonists that in the past already have been shown to inhibit the release of CGRP 
from trigeminal fibers via 5-HT1D receptor activation and to constrict cranial and coronary arteries 
via 5-HT1B receptor activation
3-6. Due to the coronary vasoconstriction, they are contraindicated in 
patients with cardiovascular disease7; however, it is important to also consider that migraineurs have 
an increased cardiovascular risk8,9, therefore it is important to develop antimigraine drugs devoid of 
vascular effects. On the other hand, lasmiditan was developed as a selective 5-HT1F receptor agonist, 
which has been shown to be effective for the acute treatment of migraine and with no reported 
vasoconstrictive properties, suggesting no vascular (side) effects. To corroborate the specificity and 
vascular profile of lasmiditan, in Chapter IV, we set out to investigate its pharmacological properties, 
in particular, to assess the selectivity, second messenger activity and its potential to induce 
vasoconstriction in vitro (in human isolated coronary, internal mammary and middle meningeal 
arteries) and in vivo (carotid and coronary artery diameters in anesthetized dogs). We compared 
our results to the responses obtained with sumatriptan, the most commonly prescribed triptan. Our 
results showed that lasmiditan is a selective agonist of the human 5-HT1F receptor  that is devoid of 
contractile properties in vitro and in vivo. The latter may represent a cardiovascular safety advantage 
when compared to the triptans.
 Due to the important role of CGRP in migraine pathophysiology small-molecule antagonists 
against the CGRP receptor (gepants) were developed. Unfortunately, due to pharmacokinetic 
issues and hepatotoxicity reports10, their development was temporarily halted. In the recent 
years, novel gepants have been developed and have been shown to be effective for the acute 
(ubrogepant) and prophylactic (atogepant) treatment of migraine11. In Chapter V, we analyzed 
the effects of ubrogepant and atogepant on the relaxations induced by CGRP in human isolated 
middle meningeal, cerebral and coronary arteries, as well as their antagonistic profile. As triptans 
are contraindicated in patients with cardiovascular disease due to their contractile properties, we 
also studied the effects per se in proximal and distal coronary arteries and compared them to the 
responses elicited by zolmitriptan. Our results showed that both gepants antagonized the CGRP-
induced relaxations in all vessels studied, being more potent in the cranial arteries when compared 
to the inhibition observed in human coronary arteries. This property may be of clinical relevance 
and an advantage for these antagonists, since they seem to be less potent where the antagonism 
of CGRP-induced vasodilation is not desired. Moreover, atogepant was shown to be more potent 
in inhibiting the CGRP-mediated vasodilatory responses in all vessels tested. The analysis of the 
antagonistic profile in human coronary arteries showed that ubrogepant presents a competitive 
profile and, interestingly, atogepant a non-competitive one. Furthermore, while zolmitriptan elicited 
concentration-dependent contractions, neither of the gepants had significant vasoconstrictor 
responses in human coronary arteries. 
 As the initial trials with gepants (namely, telcagepant)10 for the acute and prophylactic treatment 
of migraine were halted due to hepatotoxicity reports, a new class of prophylactic antimigraine 
drugs was developed: the antibodies against CGRP (eptinezumab, fremanezumab, galcanezumab) 
or its receptor (erenumab). This represents a milestone in prophylactic treatment, as previous 
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preventive treatments were not originally developed for migraine but were only later shown to 
be effective in this disorder. Nevertheless, the antibodies against CGRP (receptor) raise a concern, 
as CGRP is an ubiquitous peptide, not only involved in migraine pathophysiology, but also in 
physiological/homeostatic processes12. In light of this, in Chapter VI, we discussed the pros and 
cons of long-term CGRP blockade in migraine patients. In support of this therapeutic approach, 
clinical trials have shown that this treatment is efficacious, with results that seem comparable to the 
currently used prophylactic drugs. Furthermore, no major adverse effects related to CGRP (receptor) 
blockade have been reported. Additionally, the liver toxicity induced by some of the gepants is not 
present with the antibodies, which are well tolerated. On the other hand, as previously mentioned, 
there are concerns about the long-term effects, as CGRP and its receptor are abundantly present in 
both the vasculature, and in the peripheral and central nervous system, and are involved in several 
physiological processes and in the homeostatic response to ischemic events. Therefore, blocking 
CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, 
evidence from animal studies suggests that CGRP blockade may induce constipation, affect 
the homeostatic functions of the pituitary hormones and/or attenuate wound healing, though, 
none of these effects have so far been reported in clinical trials. Taking into consideration the 
abovementioned aspects, the pros of blocking CGRP in migraine patients seem to exceed the cons, 
but adequate (cardiovascular) safety studies are required. 
 In line with the cardiovascular concerns, Depre et al.13, recently addressed this matter by 
evaluating the effect of erenumab (CGRP receptor antibody) on exercise time during a treadmill 
test in patients with stable angina, concluding that the inhibition of the canonical CGRP receptor 
does not seem to worsen myocardial ischemia, contrary to theoretical concerns. Nevertheless, in 
Chapter VII, we commented on this study, as we considered that the design, the chosen patient 
population and the interpretation of the results do not entirely support such conclusions. To 
begin with, the authors of the study stated that the concentrations of exogenous CGRP required 
to increase total exercise time or protect against myocardial ischemia far exceed the endogenous 
physiological levels of CGRP that are released during a response to ischemia. This is not completely 
correct, as it is not the systemic plasma concentration that is relevant, but the concentration of CGRP 
at the neuro‐vascular junction, where CGRP is released. Furthermore, the authors quoted the lack of 
vasoconstrictive properties of erenumab14 as supporting argument of their conclusion, when the 
main concern is whether inhibition of the (vasodilatory) actions of CGRP is detrimental during an 
ischemic event. Regarding the study population, the patients included (78% male) suffered from 
stable angina pectoris, a typically considered “male” form of cardiac pathology15, often caused by 
stenosis of the epicardial conducting portions of the coronary artery, where the importance of CGRP 
is limited. In contrast, in females, coronary artery disease often presents without an angiographically 
detectable stenosis but as diffuse atherosclerosis in the intramyocardial, smaller (distal) sections 
of the coronary artery bed15-18 where the role of CGRP vasodilation seems more pronounced. As 
the majority of migraine sufferers are females, and therefore represent the main patient population 
under treatment with the CGRP (receptor) antibodies, the study failed to represent a relevant 
population. Moreover, the pharmacokinetic and pharmacodynamic considerations of this study 
were not adequate, since the plasma concentrations obtained 30 minutes after intravenous 
infusion could not ensure blockade of the CGRP receptor because it may well have taken several 
hours before the drug reached sufficiently high levels at the level of the receptor (located in the 
smooth muscle wall16), able to induce an effective blockade. Unfortunately, the authors did not 
confirm the blockade of the CGRP receptor and in previous studies the earliest time point shown 
for such blockade is 2 days after intravenous administration19. Overall, the study lacked to provide 
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evidence of effective CGRP receptor blockade and did not represent the patients that will benefit 
the most from the use of erenumab (i.e. females with microvascular disease) and might potentially 
be at the highest risk. As migraine patients have an increased cardiovascular risk, there will be cases 
of patients with ischemic complaints, even without a causal relationship. In fact, in the most recent 
interim analysis of the open-label extension study of erenumab, a patient died of what researchers 
called an “arteriosclerosis event”20. Therefore, appropriate studies in relevant study populations are 
needed to avoid sudden distress, such as happened with the triptans in the past.
 Considering the abovementioned concerns, in Chapter VIII we characterized the relaxant 
responses to CGRP in vitro, in the absence and presence of erenumab, the human CGRP-receptor 
antibody approved for the prophylactic treatment of migraine, in isolated human middle meningeal, 
internal mammary of cardiovascularly compromised patients undergoing bypass surgery and 
(proximal and distal) coronary arteries. Furthermore, in mammary arteries, we also assessed 
whether the vasodilatory responses to acetylcholine, sodium nitroprusside, pituitary adenylate 
cyclase activating polypeptide-38 (PACAP), vasoactive intestinal peptide (VIP) and nicardipine, as 
well as the vasoconstrictor responses to dihydroergotamine (DHE), were modified by erenumab. 
Our results showed that the CGRP-mediated vasodilatory responses were significantly antagonized 
in the presence of erenumab with no significant difference in potency among tissues, contrary to 
what we observed with the gepants in Chapter V. Moreover, in mammary arteries, erenumab did 
not affect the responses to the other vasoactive compounds, suggesting functional specificity. 
 Even though the development of the antibodies against CGRP or its receptor for the prophylactic 
treatment of migraine are a major breakthrough, for the past decades the preventive treatment 
has consisted of drugs initially developed for other diseases, such as hypertension, epilepsy and 
depression. Although these drugs have been proven to be effective21, their exact mechanism of 
action has not been described. As the trigeminovascular system is currently the main target for 
migraine treatment, in Chapter IX, we set out to investigate whether propranolol, one of the most 
widely prescribed drugs for the prophylactic treatment of migraine, modulates the activation of the 
trigeminovascular system. For this purpose, we investigated the effect of propranolol on the rise 
of dermal blood flow (DBF) of the forehead skin (innervated by the trigeminal nerve) by capsaicin 
application and electrical stimulation before and after placebo and propranolol in a randomized, 
double-blind, cross-over study, including healthy females on contraceptives and males. Additionally, 
we correlated our results with data from a Dutch prescription database by analyzing the change in 
triptan use after propranolol prescription in a population similar to our DBF study subjects. Our 
results showed that the DBF responses to capsaicin were attenuated after propranolol, but not after 
placebo. Interestingly, when we stratified by sex, no changes in the DBF responses to capsaicin were 
observed in females after propranolol, whereas a significant decrease remained present in males. 
DBF responses to electrical stimulation were not modified in any of the cases. Furthermore, when 
comparing the change in triptan use after propranolol, a more pronounced decrease was observed 
in male patients than in female patients on contraceptives. Our results suggest that propranolol 
modulates the trigeminovascular system activation in a sex-dependent manner, as in female 
subjects, that unfortunately represent the great majority of migraine patients, no significant DBF 
inhibition was observed after propranolol (80 mg) and in our retrospective study, a seemingly lower 
decrease in triptan use was observed in female patients.
 As the understanding of migraine pathophysiology increases, novel therapeutic targets are 
proposed. In Chapter X, we reviewed one of the most recently proposed targets: the pituitary 
adenylate cyclase activating polypeptide-38 (PACAP) and one of its receptors, the PAC1 receptor. 
PACAP is a neuropeptide described to be involved in neuroprotection, neurodevelopment, 
XIII
Summarizing discussion and future perspective
166
nociception and inflammation. Interestingly, PACAP and its receptors are present in the different 
components of the trigeminovascular system, and intravenous infusion of PACAP induces 
migraine-like attacks. This led to the development of antibodies against PACAP (ALD 1910) and 
also against the receptor considered to be the most likely involved in the pathophysiology of 
migraine, the PAC1 receptor (AMG 301), with the latter drug already being in Phase II clinical trials. 
No results have been published so far, but preclinical studies with AMG 301 have shown positive 
results comparable to those observed with triptans. However, as previously discussed with the 
CGRP (receptor)-antibodies, if these antibodies prove to be effective for the treatment of migraine, 
several considerations must be addressed, such as the potential side effects of long-term blocking 
of the PACAP (receptor) pathway and whether these antibodies will really represent a therapeutic 
advantage for the patients that do not respond to the CGRP (receptor)-antibodies. 
 Since inhibition of CGRP release is one of the proposed mechanisms of action of triptans22 and 
imidazoline receptors have been described to inhibit neurotransmitter release23,24, in Chapter XI 
we investigated whether moxonidine, an imidazoline I1/α2-adrenoceptor agonist, and agmatine, 
the endogenous ligand of the imidazoline receptors, inhibit the vasodepressor sensory CGRPergic 
outflow in pithed rats, and we further characterized the receptors involved. Our results showed 
that the infusion of moxonidine or agmatine inhibited the vasodepressor responses induced by 
stimulation of the sensory CGRPergic outflow, but not the responses to i.v. bolus of CGRP. Moreover, 
the inhibition of the vasodepressor responses was reversed after administration of the imidazoline 
I1 receptor antagonist, and relatively more pronounced after administration of the combination of 
the imidazoline I1 receptor antagonist plus the α2adrenoceptor antagonist. Therefore, the inhibition 
of the vasodepressor sensory CGRPergic outflow by moxonidine and agmatine is mainly mediated 
by prejunctional imidazoline I1 receptors on perivascular sensory nerves and could represent a 
therapeutic target for migraine treatment. 
 Despite the major therapeutic advances in the last decades with the triptans and, more recently, 
with the novel ditans, gepants and the antibodies against CGRP or its receptor, not all migraine 
patients respond to treatment, and thus, new therapeutic targets are needed. For this, we need 
to understand migraine pathophysiology, as it still remains largely unknown. Animal models have 
contributed greatly to our current knowledge, but only represent certain features of this rather 
complex disorder. There are, however, monogenic diseases such as Autosomal dominant Retinal 
Vasculopathy with Cerebral Leukodystrophy (RVCL, a vasculopathy caused by a mutation in the 
TREX1 gene that presents migraine as the earliest manifestation), that provide an opportunity to 
study the genetic and vascular mechanisms involved in migraine pathophysiology. In Chapter XII, 
we assessed whether a new mouse model of RVCL (RVCL-KI), has features in line with the pathology 
seen in patients, such as a reduced life expectancy and a vascular phenotype (as assessed by 
functional vascular measurements and induction of experimental stroke). Our results showed that, 
in line with the phenotype in patients, mutant mice showed  increased mortality, signs of abnormal 
vascular function and increased sensitivity to experimental stroke, suggesting that this transgenic 
mouse model can be instrumental to study the mechanisms underlying RVCL, as well as to further 
understand the pathophysiology of migraine. 
Future perspectives
In Chapter IV, we demonstrated that lasmiditan is a selective agonist of the human 5-HT1F receptor, 
devoid of contractile properties in vitro and in vivo. Currently, the exact mechanism(s) of action 
of lasmiditan remains elusive. As the therapeutic efficacy of triptans for the acute treatment of 
migraine is believed to be mediated via vasoconstriction of the trigeminal-innervated vasculature 
Chapter XIII
 167
and inhibition of CGRP release from the trigeminal fibers22, future studies should now assess whether 
lasmiditan modulates the activation of the trigeminovascular system. For this, our human model of 
trigeminal nerve-mediated vasodilation is an excellent option, as the results could be compared to 
the results obtained previously by our group in healthy volunteers with sumatriptan25. Furthermore, 
the response to lasmiditan could also be studied in migraine patients, to analyze whether in their 
case, modulation of the trigeminovascular system is altered. 
 As mentioned above, our human model of trigeminal nerve-mediated vasodilation is an 
excellent option to study modulation of the trigeminovascular system in vivo. In Chapter XI we 
showed that moxonidine inhibits the CGRPergic outflow in pithed rats by activation of prejunctional 
(imidazoline  I1) receptors; therefore, it would be of great interest to further confirm our results 
by analyzing the effect of moxonidine in our human model of trigeminovascular activation. This 
could reinforce moxonidine (and the I1 imidazoline receptors), as a therapeutic option for migraine 
treatment. Moreover, in this thesis, we characterized the inhibition of the CGRP-induced relaxations 
in human cranial and coronary arteries by ubrogepant, atogepant (Chapter V) and erenumab (Chapter 
VIII). Further studies could evaluate in our human model the modulation of the trigeminovascular 
system by both gepants and erenumab and assess whether the responses differ depending on 
the type of drug (gepants vs. antibodies), the intended type of treatment (acute vs. prophylactic) 
or whether there are no differences at all. Especially as at the moment, the only rationale behind 
choosing atogepant and erenumab for the prophylactic and ubrogepant for the acute treatment of 
migraine seems to be their half-life. 
 Besides investigating the mechanisms underlying the therapeutic efficacy of ubrogepant, 
atogepant and erenumab, future well-designed studies should evaluate the cardiovascular safety of 
these drugs. In the case of the gepants, experiments can be performed in a porcine in vivo model of 
ischemia-reperfusion, where one might assess cardiac function and infarct size in the absence and 
presence of cumulative doses of ubrogepant and, more importantly, atogepant (developed for the 
prophylactic treatment). In the case of erenumab, studies cannot be performed in animal models as 
it is a selective antibody against the human CGRP receptor, unless an antibody with affinity for the 
porcine (or rat/mice) receptor is developed. Alternatively, we could evaluate the effect of erenumab 
in a human model of microvascular function. Our group has previously assessed microvascular 
function with local thermal hyperemia (LTH) of the skin, measured with a laser Doppler flow 
imager26 in healthy volunteers. Prospective studies should assess microvascular function before and 
after erenumab in a population representative of migraine patients, taking into consideration the 
pharmacokinetics of erenumab. 
 Our group has previously evaluated the vasodilatory responses to PACAP in human meningeal 
and coronary arteries27, however, due to the complex pharmacology of the VPAC1/2 and PAC1 
receptors28, the exact receptor mediating the vasodilatory responses remained unclear. As 
discussed in Chapter X, if clinical trials show that the novel antibody against the PAC1 receptor (AMG 
301) is effective for the prophylactic treatment of migraine, this would suggest a peripheral site of 
action. Therefore, studies should evaluate whether the observed vasodilatory responses to PACAP 
in human meningeal and coronary arteries are inhibited in the presence of AMG 301. Otherwise, 
it would mean that the most likely site of action of the antibodies against the PAC1 receptor is the 
trigeminal ganglion rather than the dural vasculature. 
 Finally, CGRP does not only bind to the canonical CGRP receptor, but also to the adrenomedullin 
(AM1, AM2) and amylin (AMY1, AMY3) receptors. Similarly, adrenomedullin and amylin can bind to the 
canonical CGRP receptor29. In migraine patients under erenumab treatment, CGRP may stimulate 
the amylin receptors described in the trigeminovascular system30, reducing its efficacy. Conversely, 
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the amylin receptor has been proposed as the ‘second’ CGRP receptor previously reported by our 
group in the human coronary artery31,32, which may represent a cardiovascular safety benefit for 
erenumab. Future studies should evaluate the vasodilatory responses to adrenomedullin and amylin 
in human isolated meningeal and coronary arteries in the presence of erenumab and whether these 
responses differ between meningeal and coronary arteries.
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Migraine is een complexe neurovasculaire aandoening met een hoge prevalentie1. Het is aangetoond 
dat, tijdens een migraine aanval, (dysfunctionele) activatie van het trigeminovasculaire systeem tot 
craniale vasodilatatie leidt, opgewekt door de afgifte van calcitonin gene-related peptide (CGRP)2. 
Ondanks de hoge prevalentie van migraine zijn de huidige behandelopties niet bij alle patiënten 
effectief. Daarom bestaat er een behoefte aan de ontwikkeling van nieuwe acute en profylactische 
antimigraine middelen.  
 In hoofdstuk III geven we een overzicht van een nieuwe klasse acuut-werkende antimigraine 
middelen, “ditanen”, en vergeleken deze met de huidige gouden standaard voor de acute behandeling, 
de triptanen. Triptanen zijn 5-HT1B/1D/(1F) receptor agonisten waarvan in het verleden al aangetoond 
is dat ze de afgifte van CGRP in trigeminale vezels remmen door middel van 5-HT1D receptor 
activatie en craniële en coronaire arteriënvernauwen door middel van 5-HT1B receptor activatie
3-6. 
Vanwege de coronaire vasoconstrictie worden deze middelen gecontra-indiceerd bij patiënten 
met cardiovasculaire aandoeningen7. Het is belangrijk om ook rekening te houden met het feit dat 
migraineurs een verhoogd risico op cardiovasculaire aandoeningen hebben8, 9. Om deze reden is het 
belangrijk dat antimigraine middelen zonder vasculaire effecten ontwikkeld worden. Lasmiditan 
is ontwikkeld als een selectieve 5-HT1F receptor agonist, hetgeen aangetoond effectief was bij de 
acute behandeling van migraine en zonder vermelde vasoconstrictieve eigenschappen, wat erop 
wijst dat lasmiditan geen vasculaire (bij)werkingen heeft. Om de specificiteit en het vasculair profiel 
van lasmiditan te onderzoeken, hebben we in hoofdstuk IV de farmacologische eigenschappen van 
dit middel onderzocht.  We hebben de selectiviteit en second messenger activiteit bestudeerd, net 
als de potentie om in vitro vasoconstrictie te induceren (in de humane geïsoleerde coronair arterie, 
de a. mammaria interna en de a. meningea media), net als in vivo (diameters van de a. carotis en 
de coronair arterie in honden onder anesthesie). We vergeleken onze resultaten met die verkregen 
met sumatriptan, de triptaan die het vaakst voorgeschreven wordt. Onze resultaten toonden aan 
dat lasmiditan een selectieve agonist van de humane 5-HT1F receptor is, die zowel in vitro als in 
vivo geen vaatvernauwende eigenschappen heeft. Dit laatste vormt mogelijk een cardiovasculair 
veiligheidsvoordeel ten opzichte van de triptanen.
 Gezien de belangrijke rol van CGRP in de pathofysiologie van migraine zijn kleine molecuul 
antagonisten tegen de CGRP receptor (gepanten) ontwikkeld. Helaas is hun ontwikkeling 
tijdelijk stopgezet wegens farmacokinetische en hepatotoxische tekortkomingen10. Recent zijn 
nieuwe gepanten ontwikkeld en deze zijn aangetoond effectief voor de acute (ubrogepant) en 
profylactische (atogepant) behandeling van migraine11. In hoofdstuk V analyseerden we de effecten 
van ubrogepant en atogepant op de door CGRP veroorzaakte relaxaties in de humane geïsoleerde 
a. meningea media, cerebrale en coronaire arteriën, evenals hun antagonistische profiel. Aangezien 
triptanen gecontraïndiceerd zijn bij patiënten met hart- en vaatziekten vanwege hun contractiele 
eigenschappen hebben we ook de effecten per se bestudeerd in proximale en distale coronair arteriën 
en deze vergeleken met de contractiele effecten van zolmitriptan. Onze resultaten lieten zien dat 
beide gepanten de CGRP-geïnduceerde relaxaties in alle bestudeerde bloedvaten remden, waarbij 
de remming potenter was in de craniële arteriën in vergelijking met die in humane kransslagaders. 
Deze eigenschap is mogelijk klinisch relevant , aangezien een voordeel van deze antagonisten is dat 
deze minder sterk werkzaam lijken te zijn op plaatsen waar de remming van CGRP-geïnduceerde 
vasodilatatie niet wenselijk is. Bovendien toonde atogepant zich meer potent in het remmen van 
de CGRP-gemedieerde vasodilatoire response in alle geteste bloedvaten. De analyse van het 
antagonistische profiel in humane kransslagaders laat zien dat ubrogepant zich profileert als een 
competitieve antagonist, terwijl atogepant opmerkelijk genoeg een non-competitieve antagonist 
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lijkt. Terwijl zolmitriptan dosis-afhankelijke contracties teweeg bracht, gaf geen van de gepanten na 
toediening een significant vaatvernauwende respons in humane kransslagaders. 
 Aangezien de eerste studies met gepanten (namelijk telcagepant)10 voor de acute en 
profylactische behandeling van migraine stopgezet waren wegens gerapporteerde hepatotoxicitet, 
werd een nieuwe klasse profylactische antimigrainemiddelen ontwikkeld: de antlichamen tegen 
CGRP (eptinezumab, fremanezumab, galcanezumab) of de CGRP receptor (erenumab). Dit is 
een mijlpaal in de profylactische behandeling van migraine, aangezien eerdere preventieve 
behandelingen niet specifiek voor migraine ontwikkeld waren, maar later pas effectief bleken te 
zijn voor de behandeling van deze aandoening. Desondanks zijn er zorgen over de antilichamen 
tegen de CGRP (receptor), omdat CGRP een alom aanwezig peptide is dat niet alleen betrokken 
is bij de pathofysiologie migraine, maar ook bij fysiologische/homeostatische processen12. In het 
licht hiervan bespreken we in hoofdstuk VI de voor- en nadelen van lange-termijn CGRP remming 
bij migraine patiënten. In het voordeel van deze therapeutische aanpak spreken  klinische studies 
waarin werd aangetoond dat deze behandeling effectief is, met resultaten die vergelijkbaar lijken 
te zijn met de profylactische middelen die op dit moment gebruikt worden. Bovendien zijn er 
geen grote schadelijk effecten rondom CGRP (receptor) remming gevonden. Daarnaast induceren 
de antilichamen niet de levertoxiciteit die bij sommige gepanten optreedt. Aan de andere kant 
zijn er, zoals eerder genoemd, zorgen over de lange-termijn effecten, gezien het feit dat CGRP 
en de CGRP receptor in overvloed aanwezig zijn in zowel de vasculatuur als in het perifere en 
centrale zenuwstelsel, en dit peptide betrokken is bij meerdere fysiologische processen en in de 
homeostatische respons op ischemische gebeurtenissen. Om deze reden kan de remming van CGRP 
een risico vormen bij patiënten met comorbiditeiten zoals cardiovasculaire ziekten. Bovendien 
wijzen dierstudies uit dat CGRP remming kan leiden tot constipatie, een negatieve invloed heeft 
op de homeostatische functies van de hypofyse hormonen en/of wondheling afzwakt, alhoewel 
geen van deze effecten tot dusver gevonden worden bij klinische studies. De voorgenoemde 
zaken in ogenschouw nemend, lijken er meer voordelen aan aan CGRP remming bij migraine 
patiënten verbonden te zijn dan nadelen, maar adequate (cardiovasculaire) veiligheidsstudies zijn 
noodzakelijk. 
 In lijn met de cardiovasculaire bezwaren, zijn Depre et al.13 recentelijk  op deze kwestie ingegaan 
met een evaluatie van het effect van erenumab (CGRP receptor antilichaam) op de trainingstijd 
tijdens een inspanningstest bij patiënten met stabiele angina pectoris. Hieruit kwam naar voren 
dat de remming van de canonieke CGRP receptor de myocard ischemie niet lijkt te verergeren, 
in tegenstelling tot de theoretische bezwaren. Desalniettemin geven wij in hoofdstuk VII 
commentaar op deze studie, aangezien wij vinden dat de opzet, de gekozen patiëntenpopulatie en 
de interpretatie van de resultaten dit soort conclusies niet geheel ondersteunen. Om te beginnen 
beweren de auteurs van de studie dat de concentraties van exogeen CGRP die nodig zijn om de 
totale trainingstijd te verhogen of om te beschermen tegen myocard ischeme veel hoger zijn dan 
de endogene fysiologische CGRP spiegels die afgegeven worden tijdens een respons op ischemie. 
Dit is niet geheel juist, aangezien het niet de systemische plasma concentratie is die relevant is, maar 
de concentratie van CGRP bij de neurovasculaire verbinding, waarbij CGRP vrijkomt. Voorts halen de 
auteurs het gebrek aan vasoconstrictieve eigenschappen van erenumab14 aan als ondersteunend 
bewijs voor hun conclusie, terwijl het belangrijkste probleem is of remming van de (vasodilatoire) 
werking van CGRP tijdens een ischemische gebeurtenis nadelig is. Wat de studiepopulatie betreft: 
er waren patiënten geïncludeerd (78% mannelijk) die leden aan stabiele angina pectoris, wat als een 
typisch “mannelijke” vorm van cardiale pathologie15 beschouwd wordt, welke veelal veroorzaakt 
wordt door stenose in de epicardiale, geleidende delen van de kransslagader, waar het belang van 
XIII
Nederlandse samenvatting
172
CGRP beperkt is. In tegenstelling tot mannen openbaren coronaire hartziekten zich bij vrouwen vaak 
zonder een angiografisch meetbare stenose, maar als diffuse atherosclerose in de intra-myocardiale, 
kleinere (distale) secties van het coronaire vaatbed15-18 waar de rol van CGRP vasodilatatie veel 
groter lijkt te zijn. Gezien het feit dat de meerderheid van de patiënten die aan migraine ljiden 
vrouw is, en daarom de belangrijkste patiëntenpopulatie is die onder behandeling zal staan van 
de CGRP (receptor) antilichamen, werd in de bovengenoemde studie niet de relevante populatie 
onderzocht. Daarnaast waren de farmacokinetische en farmacodynamische redeneringen in deze 
studie niet adequaat, aangezien de plasma concentraties, die 30 minuten na intraveneuze infusie 
verkregen zijn, geen remming van de CGRP receptor kunnen garanderen omdat het een paar uur 
kan duren voordat het middel een voldoende hoge concentratie bereikt heeft op het niveau van 
de receptor  (die zich in de gladde spiercel wand16 bevindt), om zo een effectieve remming teweeg 
te brengen. Helaas hebben de auteurs de remming van de CGRP receptor niet bevestigd, en in 
eerdere studies werd een dergelijke remming op zijn vroegst 2 dagen na intraveneuze toediening 
vastgesteld19. Samengevatwerd in de studie geen bewijs voor effectieve CGRP receptor remming 
geleverd en omvatte de studie niet de groep patiënten die het meeste baat zouden hebben bij 
het gebruik van erenumab (d.w.z. vrouwen, veelal met microvasculaire aandoeningen) en wellicht 
het grootste risico lopen bij gebruik van het middel. Aangezien migraine patiënten een verhoogd 
risico op hart- en vaatziekten hebben, zullen er gevallen van patiënten met ischemische klachten 
zijn, zelfs zonder een causaal verband. Er is zelfs in de meest recente interim-analyse van de open-
label extensiestudie van erenumab een patiënt overleden aan wat onderzoekers een “manifestatie 
van arteriosclerose” noemden20. Daarom zijn passende studies in relevante studiepopulaties 
noodzakelijk om plotselinge problemen, zoals in het verleden met triptanen, te voorkomen.
 De voorgenoemde bedenkingen in ogenschouw nemend, typeren we in hoofdstuk VIII de 
relaxerende respons op CGRP in vitro, in de aan- en afwezigheid van erenumab, het humane CGRP-
receptor antilichaam geregistreerd voor de profylactische behandeling van migraine. We hebben 
de studie uitgevoerd in de humanegeïsoleerde a. meningea media, a. mammaria interna van 
cardiovasculair gecompromitteerde patiënten die een bypass operatie ondergingen en (proximale 
en distale) coronair arteriën. Bovendien hebben we in de a. mammaria interna onderzocht of de 
vaatverwijdende respons op acetylcholine, natrium nitroprusside, pituitary adenylate cyclase 
activating polypeptide-38 (PACAP), vasoactive intestinal peptide (VIP) en nicardipine, evenals de 
vaatvernauwende respons op dihydroergotamine (DHE), beïnvloed werden door erenumab. Onze 
resultaten lieten zien dat de CGRP-gemedieerde vaatverwijdende responsen significant afnemen in 
de aanwezigheid van erenumab, waarbij geen significant verschil in werkzaamheid is opgemerkt 
tussen de verschillende weefsels, in tegenstelling tot wat we bij de gepanten zagen in hoofdstuk V. 
In de a. mammaria interna liet erenumab bovendien geen effect zien op de responsen op de andere 
vasoactieve stoffen, wat wijst op een functionele specificiteit. 
 Waar de ontwikkeling van de antilichamen tegen CGRP of de CGRP receptor voor de profylactische 
behandeling van migraine een enorme doorbraak markeren, bestond de preventieve behandeling 
in de afgelopen decennia voornamelijk uit middelen die in eerste instantie ontwikkeld waren 
voor andere ziekten, zoals hypertensie, epilepsie en depressie. Ofschoon deze middelen bewezen 
effectief zijn21, is hun exacte werkingswijze nog niet bekend. Aangezien het trigeminovasculaire 
systeem op dit moment het voornaamste doelwit is bij de behandeling van migraine, onderzoeken 
we in hoofdstuk IX of propranolol, één van de meest voorgeschreven middelen voor de profylactische 
behandeling van migraine, de activatie van het trigeminovasculaire systeem reguleert. Voor 
dit doel onderzochten we het effect van propranolol op de verhoging van de doorbloeding 
van de huid (dermal blood flow, DBF) in het voorhoofd (geprikkeld door de n. trigeminus) door 
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de toediening van capsaïcine en electrische stimulatie voor en na toediening van placebo en 
propranolol in een gerandomiseerde dubbelblinde cross-over studie bij gezonde vrouwen die 
contraceptie gebruiken en bij mannen. Daarnaast correleerden we onze resultaten met data uit een 
Nederlandse doktersreceptendatabase door de verandering in triptaangebruik na voorschrijven 
van propranolol te analyseren in een populatie overeenkomstig met onze DBF proefpersonen. Onze 
resultaten toonden aan dat de DBF respons op capsaïcine na toediening van de propranolol werd 
afgezwakt, maar niet na toediening van de placebo. Interessant genoeg zagen we dat, wanneer we 
de proefpersonen op sekse indeelden, er bij vrouwen geen veranderingen in de DBF respons op 
capsaïcine was na toediening van propranolol, terwijl bij mannen een significante afname aanwezig 
bleef. In geen van de gevallen trad een verandering in DBF respons op bij electrische stimulatie. Bij 
een vergelijking van de verandering in triptaangebruik na propranolol zagen we bovendien een 
sterkere afname bij mannelijke patiënten dan bij vrouwelijke patiënten die contraceptie gebruiken. 
Onze resultaten wijzen erop dat propranolol de trigeminovasculaire systeem activatie op een sekse-
afhankelijke wijze reguleert, aangezien bij vrouwelijke proefpersonen, die het overgrote deel van de 
migraine patiënten vertegenwoordigen, geen significante DBF remming werd gezien na toediening 
van propranolol (80 mg). In onze retrospectieve studie werd een ogenschijnlijk lagere afname van 
triptaangebruik gevonden bij vrouwelijke patiënten.
 Met het toenemen van het begrip van de pathofysiologie van migraine worden nieuwe 
therapeutische aangrijpingspunten gepostuleerd. In hoofdstuk X beoordelen we één van de meest 
recentelijk voorgestelde doelen: pituitary adenylaat cyclase activerend polypeptide-38 (PACAP) en 
één van de receptoren, de PAC1 receptor. PACAP is een neuropeptide waarvan de literatuur stelt dat dit 
betrokken is bij neuroprotectie, neuro-ontwikkeling, nociceptie en ontstekingen. Het is interessant 
dat PACAP en de bijbehorende receptoren aanwezig zijn in de verschillende componenten van het 
trigeminovasculaire systeem, en dat intraveneuze infusie van PACAP migraine-achtige aanvallen 
teweegbrengt. Dit leidde tot de ontwikkeling van antilichamen tegen PACAP (ALD 1910) en ook 
tegen de receptor die het meest verdacht wordt van betrokkenheid bij de pathofysiologie van 
migraine, de PAC1 receptor (AMG 301). AMG 301 bevindt zich reeds in Fase II klinische studies. Er zijn 
tot dusver nog geen resultaten van de klinische studies gepubliceerd, maar pre-klinische studies 
met AMG 301 hebben positieve resultaten laten zien die vergelijkbaar zijn met de resultaten met 
triptanen. Echter, zoals eerder opgemerkt in het kader van de CGRP (receptor)-antilichamen, zijn er 
ook voor de remming van PACAP verschillende zaken die eerst in overweging genomen moeten 
worden, zoals de mogelijke bijwerkingen bij langdurige remming van de PACAP (receptor) route 
en of deze antilichamen daadwerkelijk therapeutische voordelen bieden bij de groep patiënten die 
niet reageert op de CGRP (receptor)-antilichamen. 
 Aangezien remming van de CGRP afgifte één van de voorgestelde werkingsmechanismen is 
van de triptanen22 en imidazoline receptoren volgens de literatuur afgifte van neurotransmitters 
remmen23,24, hebben we in hoofdstuk XI onderzocht of moxonidine, een imidazoline I1/α2-adrenoceptor 
agonist, en agmatine, de endogene liganden van de imidazoline receptoren, de vasodepressor 
sensorische CGRP uitstroom in verdoofde ratten onderdrukken. Voorts hebben we de betrokken 
receptoren gekarakteriseerd. Uit onze resultaten blijkt dat de infusie van moxonidine of agmatine 
de vasodepressor responsen, opgewekt door stimulatie van de sensorische CGRP uitstroom, 
onderdrukten, maar niet de respons op een intraveneus toegediende bolus met CGRP. Daarnaast 
werd de onderdrukking van de vasodepressor responsen ongedaan gemaakt na toediening van een 
imidazoline I1 receptor antagonist, en werd deze relatief verhoogd na toediening van de combinatie 
van de imidazoline I1 receptor antagonist plus de α2-adrenoceptor antagonist. We concluderen dat 
de onderdrukking van de vasodepressor sensorische CGRP uitstroom door moxonidine en agmatine 
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hoofdzakelijk gemedieerd wordt door prejunctionele  imidazoline I1 receptoren op perivasculaire 
sensorische zenuwen, dit zou een therapeutisch doel voor de behandeling van migraine kunnen zijn. 
 Ondanks de grote therapeutische vooruitgang in de afgelopen decennia met de triptanen en, 
meer recentelijk, met de nieuwe ditanen, gepanten en de antilichamen tegen CGRP of de CGRP 
receptor, reageren niet alle migraine patiënten op de behandeling en zijn nieuwe therapeutische 
doelen nodig. Hiervoor is een beter begrip van de pathofysiologie van migraine noodzakelijk, 
aangezien deze nog steeds grotendeels onbekend is. Diermodellen hebben veel bijgedragen aan 
onze huidige kennis, maar vertegenwoordigen slechts bepaalde kenmerken van deze redelijk 
complexe ziekte. Er bestaan echter monogenische ziekten zoals Autosomaal dominante Retinale 
Vasculopathie met Cerebrale Leukodystrophie (RVCL, een vasculopathie veroorzaakt door een 
mutatie in het TREX1 gen, waarbij migraine één van de vroegste manifestaties is), die mogelijkheden 
bieden om de genetische en vasculaire mechanismen die betrokken zijn bij de pathofysiologie van 
migraine nader te onderzoeken. In hoofdstuk XII bekeken we of een nieuw muismodel van RVCL 
(RVCL-KI) kenmerken heeft die parallellen vertonen met de pathologie die bij patiënten gezien 
wordt, zoals een verkorte levensverwachting en een vasculair fenotype (beoordeeld door middel 
van functionele vasculaire metingen en het induceren van een experimenteel herseninfarct). 
Onze resultaten toonden aan dat, overeenkomstig het fenotype in patiënten, mutante muizen 
een verhoogd sterftecijfer hadden, tekenen van abnormale vasculaire functie vertoonden en een 
verhoogde gevoeligheid hadden voor een experimenteel herseninfarct, wat erop wijst dat dit 
transgene muismodel kan bijdragen aan de bestudering van de onderliggende mechanismen bij 
RVCL, alsook voor het beter doorgronden van de pathofysiologie van migraine. 
Toekomstperspectief
In hoofdstuk IV toonden we aan dat lasmiditan een selectieve agonist van de humane 5-HT1F 
receptor is, zonder vaatvernauwende eigenschappen in vitro en in vivo. Momenteel is het precieze 
werkingsmechanisme van lasmiditan nog onbekend. Aangezien de therapeutische effictiviteit van 
triptanen voor de acute behandeling van migraine lijkt te worden gemedieerd door vasoconstrictie 
in de trigeminale-geïnnerveerde vasculatuur en remming van de CGRP afgifte vanuit de trigeminale 
vezels22, zouden toekomstige studies moeten uitwijzen of lasmiditan de activatie van het 
trigeminovasculaire systeem reguleert. Hiervoor is ons humane model voor trigeminale zenuw-
gemedieerde vasodilatatie een zeer geschikte optie, daar in dat geval de resultaten vergeleken 
kunnen worden met de eerdere resultaten bij onze groep gezonde vrijwilligers met sumatriptan25. 
Bovendien kan  de respons op lasmiditan ook bestudeerd worden bij migraine patiënten, om te 
analyseren of in hun geval regulatie van het trigeminovasculaire systeem verandert. 
 Zoals eerder genoemd, is ons humane model van trigeminale zenuw-gemedieerde vasodilatatie 
een zeer geschikte manier om de regulatie van het trigeminovasculaire systeem in vivo te 
onderzoeken. In hoofdstuk XI lieten we zien dat moxonidine de CGRP-uitstroom remt in verdoofde 
ratten door activatie van prejunctionele (imidazoline I1) receptoren. Om deze reden zou het erg 
interessant zijn onze resultaten verder te bevestigen door middel van een analyse van het effect 
van moxonidine in ons humane model voor trigeminovasculaire activatie. Dit versterkt mogelijk 
de positie van moxonidine (en de I1 imidazoline receptoren) als een therapeutische optie voor de 
behandeling van migraine. Bovendien hebben wij in dit proefschrift de remming van de CGRP-
geïnduceerde relaxaties in humane craniële arteriën en kransslagaders met ubrogepant, atogepant 
(hoofdstuk V) en erenumab (hoofdstuk VIII) getypeerd. Nader onderzoek in ons humane model is 
nodig om de regulatie van het trigeminovasculaire systeem door zowel gepanten als erenumab 
te evalueren en om vast te stellen of de responsen anders zijn afhankelijk van het type middel 
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(gepanten vs. antilichamen), het bedoelde behandeltype (acuut vs. profylactisch) of dat er wellicht 
helemaal geen verschillen optreden. Dit is zeker interessent omdat op dit moment de halfwaardetijd 
de enige gedachte achter de keuze tussen atogepant en erenumab voor de prophylactische en 
ubrogepant voor de acute behandeling van migraine lijkt te zijn. 
 Naast het onderzoek naar de onderliggende mechanismen van de therapeutische effectiviteit 
van ubrogepant, atogepant en erenumab, zouden toekomstige, goed opgezette studies dienen te 
bepalen wat de cardiovasculaire veiligheid van deze middelen is. In het geval van de gepanten, 
kunnen experimenten gedaan worden in een varkens in vivo model van ischemie en reperfusie, 
waarin gekeken kan worden naar de hartfunctie en infarctgrootte in de aan- en afwezigheid van 
cumulatieve doses ubrogepant en, nog belangrijker, atogepant (ontwikkeld voor de profylactische 
behandeling). In het geval van erenumab, kunnen studies niet in diermodellen worden uitgevoerd 
omdat het een selectief antilichaam tegen de humane CGRP receptor betreft, tenzij een antilichaam 
met affiniteit voor het varkens- (of rat-/muis-) receptor ontwikkeld wordt. Als alternatief zou 
gekeken kunnen worden naar het effect van erenumab in een human model voor microvasculaire 
functie. Onze groep heeft eerder de microvasculaire functie onderzocht met lokale thermale 
hyperemie (LTH) van de huid, gemeten met een laser Doppler flow imager26 in gezonde vrijwilligers. 
Toekomstige studies zouden de microvasculaire functie voor en na toediening van erenumab 
dienen te onderzoeken in een populatie die representatief is voor migraine patiënten, rekening 
houdend met de farmacokinetische eigenschappen van erenumab. 
 Onze groep heeft eerder onderzoek gedaan naar de vaatverwijdende responsen op PACAP in 
humane meningeale en coronaire arteriën27, maar door de complexe farmacologie van de VPAC1/2 
en PAC1 receptoren
28 blijft het onduidelijk welke receptor precies verantwoordelijk is voor het 
opwekken van de vaatverwijdende respons. Zoals besproken in hoofdstuk X zou, indien kllinische 
studies aantonen dat het nieuwe antilichaam tegen de PAC1 receptor (AMG 301) effectief is voor de 
profylactische behandeling van migraine, dit wijzen op een perifere plaats van werking. Daarom 
dienen nadere studies na te gaan of de geobserveerde vaatverwijdende responses op PACAP in 
humane meningeale en coronaire arteriën geremd worden in de aanwezigheid van AMG  301. 
Anders zou dit betekenen dat de meest waarschijnlijke plaats van werking van de antilichamen 
tegen de PAC1 receptor de trigeminale ganglion is in plaats van de durale vasculatuur. 
 Tot slot bindt CGRP zich niet alleen aan de canonieke CGRP receptor, maar ook aan de 
adrenomedulline (AM1, AM2) en amyline (AMY1, AMY3) receptoren. Evenzo kunnen adrenomedulline 
en amyline zich binden aan de canonieke CGRP receptor29. Bij migraine patiënten die behandeld 
worden met erenumab kan CGRP de amyline receptoren stimuleren, zoals beschreven in het 
trigeminovasculaire systeem30, hetgeeen de effectiviteit vermindert. Daartegenover wordt de 
amyline receptor voorgesteld als de ‘tweede’ CGRP receptor die eerder werd gerapporteerd door 
onze groep in de humane coronair arterie31, 32, hetgeen kan betekenen dat er een cardiovasculair 
veiligheidsvoordeel bestaat voor erenumab. Toekomstige studies dienen de vaatverwijdende 
responses op adrenomedulline en amyline in humane geïsolateerde meningeale en coronaire 
arteriën in de aanwezigheid van erenumab nader te onderzoeken en vast te stellen of er verschillen 
zijn in de respons tussen meningeale en coronaire arteriën.
 175
XIII
Nederlandse samenvatting

Eloísa Rubio-Beltrán was born on February 1st, 1989 in Santiago de Querétaro, México. 
 In 2007 she started her studies in Chemical Pharmaceutical Biology at the Autonomous University 
of Querétaro. In 2011 she initated her Bachelor internship at the Department of Pain and Epilepsy 
of the National Institute of Neurobiology under the supervision of Prof.  dr.  Miguel Condés-Lara. 
After completing her Bachelor, she joined the Master degree program in Neuropharmacology 
and Experimental Therapeutics in the Center for Research and Advanced Studies of the National 
Polytechnic Institute (CINVESTAV) in Mexico City, under the supervision of Prof. dr. Carlos M. Villalón. 
In 2015 she started her PhD training at the Department of Internal Medicine, Division of Vascular 
Medicine and Pharmacology of Erasmus MC under the supervision of dr. Antoinette Maassen van 
den Brink. 
 181
About the author

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJJC, 
Zanelli  E, Meeus  L, Danser AHJ, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, 
MaassenVanDenBrink A. Characterization of binding, functional activity and contractile responses of 
the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019; In press.
Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJJC, Dirven C, 
Danser AHJ, Xu C, Snellman J, MaassenVanDenBrink A. Characterisation of vasodilatory responses in 
the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia. 2019; 
In press.
Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AHJ, Edvinsson L, 
MaassenVanDenBrink A. Exploration of purinergic receptors as potential anti-migraine targets using 
established pre-clinical migraine models. Cephalalgia. 2019; In press.
Bussiere JL, Davies R, Dean C, Xu C, Kim KY, Vargas HM, Chellman GJ, Balasubramanian G, 
Rubio-Beltran E, MaassenVanDenBrink A, Monticello TM. Nonclinical safety evaluation of erenumab, 
a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmaco. 2019;106:224-238.
Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, de Vries R, Dammers R, Bogers AJJC, 
van  den  Bogaerdt A, Daugherty BL, Danser AHJ, Villalón CM, MaassenVanDenBrink A. Effects of 
two isometheptene enantiomers in isolated human blood vessels and rat middle meningeal artery – 
potential antimigraine efficacy. J Headache Pain. 2019; 19:47.
Rubio-Beltrán E, MaassenVanDenBrink A. Understanding CGRP and Cardiovascular Risk. In: 
Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg. 2019.
Rubio-Beltrán E, Labastida-Ramírez A. Sex Hormones and CGRP. In: Maassen van den Brink A., 
MacGregor E. (eds) Gender and Migraine. Headache. Springer, Cham. 2019.
MaassenVanDenBrink A, Rubio-Beltrán E, Duncker D, Villalón CM. Is CGRP Receptor Blockade 
Cardiovascularly Safe? Appropriate Studies Are Needed. Headache. 2018; 58:1257-1258.
Rubio-Beltrán E, Correnti E, Deen M, Kamm K, Kelderman T, Papetti L, Vigneri S, MaassenVanDenBrink 
A, Edvinsson L; European Headache Federation School of Advanced Studies (EHF-SAS). PACAP38 and 
PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018; 19:64.
Reglodi D, Vaczy A, Rubio-Beltrán E, MaassenVanDenBrink A. Protective effects of PACAP in ischemia. 
J Headache Pain. 2018; 19:19. 
Rubio-Beltrán E*, Labastida-Ramírez A*, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F 
receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 
2018; 186:88-97.
Condés-Lara M, Martínez-Lorenzana G, Rojas-Piloni G, Tello-García IA, Manzano-García A, 
Rubio-Beltran E, González-Hernández A. Axons of individual dorsal horn neurons bifurcate to project 
in both the anterolateral and the postsynaptic dorsal column systems. Neuroscience. 2018; 371:178-190. 
Labastida-Ramírez A*, Rubio-Beltrán E*, Villalón CM, MaassenVanDenBrink A. Gender aspects of 
CGRP in migraine. Cephalalgia. 2019; 39:435-444. 
 183
List of publications
Deen M*, Correnti E*, Kamm K*, Kelderman T*, Papetti L*, Rubio-Beltrán E*, Vigneri S*, Edvinsson L*, 
Maassen Van Den Brink A*; European Headache Federation School of Advanced Studies (EHF-SAS). 
Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017; 18:96. 
Rubio-Beltrán E, Labastida-Ramírez A, Hernández-Abreu O, MaassenVanDenBrink A, Villalón CM. 
Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor 
sensory CGRPergic outflow in pithed rats. Eur J Pharmacol. 2017; 812:97-103.
Labastida-Ramírez A, Rubio-Beltrán E, Hernández-Abreu O, Daugherty BL, MaassenVanDenBrink 
A, Villalón CM. Pharmacological analysis of the increases in heart rate and diastolic blood pressure 
produced by (S)-isometheptene and (R)-isometheptene in pithed rats. J Headache Pain. 2017; 18:52. 
Condés-Lara M, Martínez-Lorenzana G, Rubio-Beltrán E, Rodríguez-Jiménez J, Rojas-Piloni G, 
González-Hernández A. Hypothalamic paraventricular nucleus stimulation enhances c-Fos expression 
in spinal and supraspinal structures related to pain modulation. Neurosci Res. 2015; 98:59-63. 
184
amada_rb@hotmail.com
PhD Portfolio
Name PhD Student: Amada Eloísa Rubio-Beltrán
PhD period: 2015-2019
Erasmus MC Department: Department of Internal Medicine,                        
Division of Vascular Medicine and Pharmacology
Promotor: Prof. dr. A. H. J. Danser
Supervisor: Dr. A. Maassen van den Brink
Research School:  Cardiovascular Research School Erasmus University 
Rotterdam (COEUR)
In-depth Courses (13.7 ECTS)
2018 Homeostatic regulation and migraine, a view from the bench, London, England
 iHead Meeting, The International Headache Society, London, England
 Experimental Neurophysiology: Theory and Practice, Amsterdam, The Netherlands
2017 Headache research for young scientists, Vancouver, Canada
 1st School of Advanced Studies of the European Headache Federation, Rome, Italy
2016 Laboratory animal science, Erasmus MC, Rotterdam, The Netherlands
2015-2019 COEUR Courses and Research Seminars, Erasmus MC, Rotterdam, The Netherlands
Teaching activities (6 ECTS)
2015-2019 Pharmacology practical courses, scientific internship of Junior Med School students, 
Autonomic Nervous system practicum
2018 Supervising Master’s thesis of a Biomedical Science’s student
 Supervising Master’s thesis of a NIHES student
2016-2017 Supervising Bachelor’s thesis of Psychobiology students 
Presentations (5.7 ECTS)
2019 19th Congress of the International Headache Society, Dublin, Ireland. Characterization 
of the effects of the CGRP receptor antagonists, atogepant and ubrogepant, on isolated 
human coronary, cerebral, and middle meningeal arteries (E-poster).
 185
PhD Portfolio
 61th Annual Scientific Meeting of the American Headache Society, Philadelphia, United 
States. Characterization of the effects of the CGRP receptor antagonists, atogepant and 
ubrogepant, on isolated human coronary, cerebral, and middle meningeal arteries (Oral 
presentation).
 13th European Headache Federation Congress, Athens, Greece. Characterization of 
the effects of the CGRP receptor antagonists, atogepant and ubrogepant, on isolated 
human coronary, cerebral, and middle meningeal arteries (Oral presentation).
2018 12th European Headache Federation Congress, Florence, Italy. Effect of propranolol in 
a non-invasive human model of trigeminovascular activation (Poster presentation).
 12th European Headache Federation Congress, Florence, Italy. PACAP38 and PAC1 
receptor blockade: a new target for headache? (Oral presentation). 
 17th Biennial Migraine Trust International Symposium, London, England. 
Pharmacological selectivity of inhibition of CGRP-induced relaxations by erenumab 
studied in human isolated internal mammary artery (E- poster presentation).
 4th School of Advanced Studies of the European Headache Federation. Blocking CGRP 
in migraine patients, pros and cons (Oral presentation).
 28th ADMA Annual Meeting, Zwolle, The Netherlands. Effect of propranolol in a non-
invasive human model of trigeminovascular activation (Oral presentation).
 NVF Spring Meeting, Utrecht, The Netherlands. Functional activity of antimigraine 
drugs at 5-HT receptors. Coronary artery contraction correlation (Poster presentation). 
 Wetenschapsdagen Interne Geneeskunde, Antwerpen, Belgium. Lasmiditan and 
Sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro 
contraction of human arteries (Oral presentation).
 Wetenschapsdagen Interne Geneeskunde, Antwerpen, Belgium. Disturbed 
Prelamin-A processing in VSMC causes aortic root dilation and aging-resembling 
macrovascular motor dysfunction (Poster presentation).
2017 11th European Headache Federation Congress, Rome, Italy. Blocking CGRP in migraine 
patients, pros and cons (Oral presentation).
 18th Congress of the International Headache Society, Vancouver, Canada. In vitro 
characterization of agonist binding and functional activity at a panel of serotonin 
receptor subtypes for lasmiditan, triptans and other 5-HT receptor ligands and activity 
relationships for contraction of human isolated coronary artery (Poster presentation).
 18th Congress of the International Headache Society, Vancouver, Canada. 
Pharmacological analysis of the inhibitory effects produced by moxonidine and 
agmatine on the sensory vasodepressor CGRPergic outflow in pithed rats (Poster 
presentation).
 27th ADMA Annual Meeting, Norwich, England. Lasmiditan and Sumatriptan: 
comparison of in vivo vascular constriction in the dog and in vitro contraction of human 
arteries (Oral presentation).
186
 FIGON Dutch Medicine Days 2017, Ede, The Netherlands. Lasmiditan and Sumatriptan: 
comparison of in vivo vascular constriction in the dog and in vitro contraction of human 
arteries (Poster presentation).
 Wetenschapsdagen Interne Geneeskunde, Antwerpen, Belgium. Lasmiditan and 
Sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro 
contraction of human arteries (Poster presentation).
2016 FIGON Dutch Medicine Days 2016, Ede, The Netherlands. Effects of AMG 334 on 
human isolated coronary artery (Poster presentation).
 5th European Headache and Migraine Trust International Congress – EHMTIC, 
Glasgow, Scotland. Lasmiditan and Sumatriptan: comparison of in vivo vascular 
constriction in the dog and in vitro contraction of human arteries (Poster presentation).
 5th European Headache and Migraine Trust International Congress – EHMTIC, 
Glasgow, Scotland. Effects of AMG 334 on human isolated coronary artery (Poster 
presentation).
 NVF Spring Meeting, Groningen, The Netherlands. Pharmacological analysis of the 
inhibitory effects produced by moxonidine and agmatine on the sensory vasodepressor 
CGRPergic outflow in pithed rats (Poster presentation). 
 Wetenschapsdagen Interne Geneeskunde, Antwerpen, Belgium. Pharmacological 
analysis of the inhibitory effects produced by moxonidine and agmatine on the sensory 
vasodepressor CGRPergic outflow in pithed rats (Poster presentation). 
2015 FIGON Dutch Medicine Days 2016, Ede, The Netherlands. Pharmacological analysis 
of the inhibitory effects produced by moxonidine and agmatine on the sensory 
vasodepressor CGRPergic outflow in pithed rats (Poster presentation). 
International conferences (8.1 ECTS)
2019 19th Congress of the International Headache Society, Dublin, Ireland.
 61th Annual Scientific Meeting of the American Headache Society, Philadelphia, 
United States.
 13th European Headache Federation Congress, Athens, Greece.
2018 12th European Headache Federation Congress, Florence, Italy.
 17th Biennial Migraine Trust International Symposium, London, England.
 28th ADMA Annual Meeting, Zwolle, The Netherlands.
2017 11th European Headache Federation Congress, Rome, Italy. 
 18th Congress of the International Headache Society, Vancouver, Canada.
 27th ADMA Annual Meeting, Norwich, England.
 187
PhD Portfolio
2016 5th European Headache and Migraine Trust International Congress – EHMTIC, 
Glasgow, Scotland.
 26th ADMA Annual Meeting, Dordrecht, The Netherlands.
Grants & awards
 Fellowship of the International Headache Society for the International Headache 
Academy (iHEAD) 2019 (Dublin, 2-4 September).
 Fellowship of the International Headache Society for the International Headache 
Academy (iHEAD) 2018 (London, 3-5 September).
 Travel grant for the 28th ADMA Annual Meeting 2017 (Zwolle, 8-10 June).
 IHS travel grant to attend the IHC 2017 (Vancouver, 7-10 September).
 Travel grant for the 27th ADMA Annual Meeting 2017 (Norwich, 25-27 May).
 Fellowship of the European Headache Federation for the 1st School of Advanced 
Studies 2017 (Rome, 7-9 April).
 1st prize Poster competition with the poster “Lasmiditan and Sumatriptan: comparison 
of in vivo vascular constriction in the dog and in vitro contraction of human arteries” 
Wetenschapsdagen Interne Geneeskunde 2017 (Antwerpen, 12-13 January).
188
 189
Abbreviations
5-CT 5-carboxamidotryptamine
5-HT 5-hydroxytryptamine
AC adenylyl cyclase
AMY1 amylin type 1 receptor
ANCOVA analysis of covariance
ANOVA analysis of variance
BBB blood brain barrier
CGRP  calcitonin gene-related peptide
CH cluster headache
CLR calcitonin-like receptor
CNS central nervous system
DAP diastolic arterial pressure
DBF dermal blood flow
DHSC dorsal horn of the spinal cord
Emax maximal response 
HCA human coronary artery
HCxA human cerebral artery
HMMA  human middle meningeal artery
LCX left circumflex coronary artery
logDpH7.4 distribution coefficient at physiological pH
mABs monoclonal antibodies
MAP mean arterial pressure
MCA middle cerebral artery
MMA middle meningeal artery
MRA magnetic resonance angiography
ND not defined
NTS nucleus tractus solitarius
PACAP27 pituitary adenylate cyclase activating polypeptide-27
PACAP38 pituitary adenylate cyclase activating polypeptide-38
PAG periaqueductal grey area
pEC50 negative logarithm of the half maximal effective concentration
PLC phospholipase C
PTSD post-traumatic stress disorder 
PVN hypothalamic pararaventricular nucleus
RAMP1 receptor activity-modifying protein 1
RANCOVA repeated measure analysis of covariance
RCP receptor component protein
SAP systolic arterial pressure
TG trigeminal ganglion
TNC trigeminal nucleus caudalis
VIP vasoactive intestinal peptide
List of abbreviations
“All our knowledge begins with the senses, 
proceeds then to the understanding, 
and ends with reason.  
There is nothing higher than reason.”
Immanuel Kant
Critique of Pure Reason
